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A b s t r a c t
A major limitation to cancer chemotherapy is the non-selectivity of the drug. One such 
drug that is used extensively to combat cancer is the pyrimidine derivative 5- 
fluorouracil (5-FU). However, its associated high toxicity and side effects has limited 
its clinical use. This in turn has challenged chemists to explore 5-FU prodrug 
derivatives in order to find a selective, non-toxic form. Although libraries of 5-FU 
prodrugs have been reported, selectivity still remains a problem and needs 
improvement. It was therefore our goal to try and improve 5-FU selectivity by 
designing a 5-FU prodrug that could be selectively delivered to the cancerous tissue 
where it could be activated. To achieve this we designed a 5-FU produg based on the 
general tumour activated prodrug (TAP) model concept i.e. triggers, linker and effector.
It is known that nitro-aromatic moieties can be reduced by the hypoxic conditions 
associated with tumour cells hence, we can use these moieties as triggers to activate the 
5-FU prodrug. Seven such compounds were synthesised and incubated with 4T1 cancer 
cell lines for 72 hrs, however only two of the synthesised compounds (52) and (53) 
showed significant increase in cytotoxicity under hypoxic conditions, thus indicating 
that activation by endogenous one-electron reductases was occurring.
Photosensitisers used in photodynamic therapy (PDT) have been found to selectively 
accumulate in the cellular organelles of cancerous tissue. By exploiting this phenomena 
we coupled 5-FURD and the four synthesised nitro-5-FURD prodrugs to the 
photosensitiser dihydroxysilicon phthalocyanine. This in turn generated the five novel 
Bis(5-fluorouridine) phthalocyaninosilicon derivatives, thus allowing the 
photosensitiser to selectively carry the nitro-aromatic-5-FURD prodrug to the cancerous 
tissue, where the 5-FURD prodrug is activated thus releasing the 5-FU. However, this 
not only allows for the selective delivery of the 5-FU prodrug but generates a third 
generation photosensitiser that can be used in PDT application. However, the tumour 
reduction conditions may not be suitable for optimal activation of our nitro-aromatic 
prodrugs via the nitroreductase enzymes in the “dark”, we therefore propose two 
alternative possibilities for activation via (1) the action of gene directed enzyme prodrug 
therapy (GDEPT) and E.coli or (2) activation through the consequence of oxidative 
stress on the cell via the release of excess cellular reductase.
It was found that of eleven 5-FU prodrugs tested on the SW480 and 4T1 cancer cell 
lines two (59) and (58) gave similar IC50 values as that for the 5-FU drug and that three 
of the prodrugs (53), (59) and (69) gave lower anti-invasion activity then the 5-FU drug.
We report the synthesis of a novel prodrug 2’,3’-isopropylidene-5,-0-((-4” S,5” R)-N- 
acetyl-2’ ’ ,2” -dimethyl-4 ’ ’ -phenyl-1 ” ,3 ” -oxazolidine-5 ’ ’ -carboxylate)-fluorouridine 
102). This design incorporates a lipophillic handle coupled to 5-fluorouridine. This 
compound was tested on SW480 and 4T1 cancer cell lines, however no cell death was 
observed at the concentrations used, instead growth inducement behaviour was 
exhibited. Following a SAR study this was attributed to (1) 5-fluorouridine being in the 
protected form of 2,3-isoprpoylidene-5-fluorouridine, thus preventing the formation of 
5-fluorouracil metabolites and (2) the presence of the lipophillic ester slowing down its 
activation.
xiv
We also report that during our synthesis of prodrug (102) we discovered a novel 
isopropylidene deprotection procedure for the deprotection of 2,3 -isopropylidene-5 - 
fluorouridine and 2,3-isopropylideneuridine nuclosides to their parent nucleosides. This 
procedure also allowed for selective cleavage of trityl group in the presence of the 
isopropylidene moiety. The following optimised reaction conditions allow for reaction 
completion; 30% hydrogen peroxide 200|^1, a 1:1:1 stoichiometry of acetonide, benzyl 
chloroformate in the presence or absence of base, in DMSO at 85°C. Yields ranging 
between 42-58% were obtained.
xv
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I. Cancer
What is cancer? Cancer is the name given to a family of diseases that vary in rate of 
growth, state of cellular differentiation, diagnostic detectability, invasiveness, metastatic 
potential and response to treatment and prognosis.1 Cancer occurs when cells become 
abnormal and keep dividing, forming new cells without any control or order. All organs 
of the body are made up of cells. Normally, cells divide to form new cells only when 
the body needs them. When cells divide uncontrollably a mass of excess tissue is 
formed called a tumour. Tumours can be non-cancerous (benign) or cancerous 
(malignant). If cells are malignant they can invade and damage neighboring tissue and 
organs. These malignant cells can also travel into the blood stream to form new 
tumours in other parts of the body, this process is known as metastasis.
Cancer is the world’s biggest killer. It is a disease that can occur at any time and is 
impartial of age and sex. However, through better diagnostic techniques and improved 
treatment millions of people have been treated and cured.
1.0.1. Causes of cancer
In many cases, the causes of cancer are not clear, both external and internal factors play 
a role. Cigarette smoking is a major casual factor of lung cancer. Diet, genetic 
mutation, infection, sexual behaviour, exposure to ultraviolet light and carcinogenic 
chemicals have also been implicated in other forms of cancer. However, a hereditary 
link may be involved with cancers such as those which affect the breast.
1.0.2. Cancer prevention
The best way to reduce deaths from cancer is to prevent it. Doctors generally agree that 
about one third of all human cancers are directly related to cigarette smoking.1 For
1
smokers, the risk of cancer is much higher than that of a nonsmoker. Excluding the 
ultraviolet rays of sun light that cause skin cancer, the next most common cited cancer- 
causing factor is diet. The National Cancer Institute and the American Cancer Society 
recommended a diet low in fat, high in fiber, and rich in fruits and vegetables. 
Chemoprevention on the other hand is simply prevention with drugs. The word “ 
drugs” is used to include dietary supplements, hormones, and vitamins etc., as well as 
real drugs, synthetic and natural agents used for therapeutic purposes. The number of 
chemoprevention agents is increasing.2
1.0.3. Cancer Treatments
Surgery is still the oldest and most common treatment method for the removal of 
malignant tumours. Radiation therapy is another method used to treat cancer . It 
involves the irradiation of cancerous tissue with high energy X-rays, which damage the 
cancer cells, and stops them from growing and spreading. It can be used to shrink a 
tumour before surgery, however this treatment is often used after surgery. Like surgery 
it is a localised treatment affecting cells only in the area to be treated.
1.0.4. Cancer chemotherapy
Chemotherapy is the use of drugs to kill cancer cells. Unlike surgery and radiation 
therapy it is systemic; it works through the body. A single drug or a combination of 
drugs may be used. It is often used after surgery to kill any hidden cancer cells that may 
remain in the body. It works by interfering with the cells ability to replicated DMA thus 
preventing cells from multiplying. However most common cancers e.g. breast, lung, 
colorectal and prostrate cancer are not curable by chemotherapy alone, and often require 
a combination of surgery and radiation treatment.
2
In order for an effective chemotherapy drug to be developed its mechanism of action 
needs to be known as well as knowledge on normal cell division in comparison to 
cancerous “ abnormal” cells. Both of these features in conjunction with the ongoing 
advances in molecular and cellular biology should help in development of an effective 
chemotherapy drug.
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1.0. Chapter 1. The development of Cancer chemotherapy drugs
Throughout history, mankind has been interested in the properties of naturally occurring 
compounds. Simple extraction of these compounds from flowers and plants has 
allowed their properties to be used for various purposes, e.g. dyes, flavourings and 
perfumes.1 However, it has been the medicinal properties of these compounds that have 
received the most attention. Classic examples of medicinal natural product extracts 
used in modern medicine are viscristine, teniposide, camptotheca and paclitaxel. 
Viscristine (Oncovin®)(FiGURE 1) is isolated from periwinkle (catharaanthus roseus) 
and is an antimiotic agent that is used in combination with other agents for the treatment 
of a wide range of cancers, including leukemia, bladder cancer, testicular cancer and 
lymphomas such as Hodgkin’s diseases.2,3 Teniposide (Vumon©) (Figure  2) a 
chemical analog of the natural product podophyllotoxin shows activity against 
Hodgkin’s diseases, malignant lymphomas, paediatric refactory neuroblastoma, and 
brain tumors in adults.4,3,6,7 The alkaloid camptothecin was first isolated from the tree 
camptotheca acuminata. It has good activity against various cancers in the laboratory; 
but is too insoluble for clincial use.8, ,l0,u However, various water-soluble analogs of 
camptothecin (Figure  3) have been developed, and have found significant clinical use. 
Perhaps the most important member of the clinically useful natural anticancer agents is 
paclitaxel (Taxol®) (F ig ure  4) that was discovered in the bark of the western yew 
(Taxus brevifolia). The United States Food and Drug Administration (FDA) approved 
Taxol, for refractory ovarian cancer in December 1992 and refractory breast cancer in 
April 1 9 9 4 .12,13
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F ig ure  1. V in c ristine F igure  2. Tenipo side
F ig u r e  3. Ca m pto th ecin
Ph
F igure  4. P ac lita x el
A drug can be defined as a chemical used for the treatment/curing or prevention of 
disease in human beings or in animals.14 Unfortunately, many conventional drugs 
suffer from various drawbacks as outlined in Ta b l e  1. However, many of these 
drawbacks have been eradicated with the development of prodrugs.15
T a b l e  1. C o n v en tio n a l  d r u g  d r a w b a c k s  .
Ph a r m a c eu tic a l Pharmacokinetic
Unpleasant smell Poor bio-availability
Pain on injection Short duration
Poor solubility High first-pass metabolism
Instability Toxicity/side effects
Slow dissolution rate Non-specificity
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1.1. The Prodrug Concept
Prodrugs were defined in the 1950’s by professor Adrien Albert, an Australian 
medicinal chemist, as pharmacologically inactive chemical derivatives that could be 
used to alter the physicochemical properties of drugs, in a temporary manner, to 
increase their usefulness and/or to decrease associated toxicity. Subsequently, such 
drug-derivatives have also been referred to as ‘latentiated drugs’, ‘bio reversible 
derivatives’ and ‘congeners’, however, ‘prodrug’ is now the most commonly accepted 
term.16
Prodrugs can be defined as agents that are transformed after administration, either by 
metabolism or by spontaneous chemical breakdown, to form a pharmacologically active 
species. Ideally, the prodrug is converted to the original drug as soon as it reaches the 
site of action (F igure  5), followed by the rapid elimination of the released carrier 
without causing side effects in the process.17
enzym e/chem ical transformation
Drug + Carrier® Prodrug Drug Carrier
(Synthesis in the laboratory) (Released at the site of action)
F ig u r e  5. En zy m a t ic / ch em ical  t r a n sfo r m a t io n  of a  pr o d r u g  to  active  d r u g
A N D  C A R R I E R
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A lthough  a number o f  prodrugs have been designed and developed  to eradicate 
problem s associated  w ith  drug utilisation (see; Ta b l e  1.), three com m on attributes are 
associated  to all prodrugs:
1) A prodrug must be readily transported to the site of action.
2) A prodrug must be converted to the active drug.
3) Once the prodrug is generated at the site of action, the tissue must retain the 
active drug without further degradation.
Fortunately, there is a complement between bodily conditions and prodrug activation 
mechanisms, and it is this feature that has been instrumental in the design and 
development of prodrugs. This in turn has lead to the design of two types of prodrugs:
1) Prodrug design based on site-specific conditions, which utilises site-specific 
body conditions such as pH and oxygen content. This class of prodrug is 
commonly refered to as a carrier linked prodrug.
2) Prodrug design based on tissue/enzyme specific conditions. This class of
17prodrug is commonly refered to as a bioprecursor prodrug.
1.1.1. Carrier linked prodrug
As the name indicates a carrier-linked prodrug consists of an active drug linked to an 
easily removed non-toxic and bio-inactive carrier. The linkage between the two must be 
a labile functional group, which can be cleaved to release the active drug. Examples of 
such a linkage are esters, which can be readily cleaved by either enzymatic or 
hydrolysis conditions. Carrier-linked prodrugs can be further subdivided into bipartate 
and tripartate prodrugs. Where a bipartate prodrug consists of a carrier to drug 
conjugate, while a tripartate prodrug consists of a carrier conjugated via a linker to the 
drug (F ig ure  6).
7
Fig ure  6. B ipartate  a n d  trip a r t  ate  p r o d r u g  d e sig n
1.1.2. Bioprecursor prodrug
This type of prodrug design relies on the concept that a biologically inactive molecule 
can be metabolised into an active drug in-vivo (Figure  7).
Fig u r e  7. B io pr ec u r so r  pr o d r u g  d e sig n
Various prodrug strategies in cancer therapy have utilised both of the above designs, 
with success.18
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1.2. Prodrug Strategies in Cancer Therapy
It is known that the majority of clinically used anticancer drugs are cytotoxins, that 
preferentially kill dividing cells, primarily by attacking DNA at some level (synthesis, 
replication or processing). 17,22 However, these drugs are not truly selective for cancer 
cells as they may also damage normal proliferating cells and hence their use is limited. 
This has lead to the development of prodrugs that are selectively activated in tumour 
tissue, and are often referred to as "tumour activated prodrugs"(TAP). These prodrugs 
are selectively activated by tumour tissue by utilising the subtle metabolic and
20 23physiological properties unique to tumour tissue. ’
1.2.1. Prodrug activation via enzyme expression selective to tumour cells
Because certain enzymes are expressed in elevated levels (eg. carbonyl reductase, 
amidases and DT-diaphorase) within tumour tissue many produgs have been designed 
to incorporate a functional group that can be selectively metabolised by these enzymes. 
Examples of such prodrugs are 5-aziridinyl-2,4-dinitrobenzamide CB1954 1 and 
aziridoquinone E09 2 (Figure  8). Both were designed to take advantage of the high 
levels of DT-diaphorase expressed by tumours, but unfortunately they had limited 
success.
1 2
F igure  8. 5 -a z ir id in y l -2 ,4 -d in itr o b en za m id e  CB19 5 4 1  a n d  a zir id o q u in o n e
E 092
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Conjugated peptide drug designs have also been developed to take advantage of this 
phenomenon. In this case activation is via the selective cleavage of the peptide bond by 
enzymes that are secreted by tumour cells, (e.g. prostate-specific antigens (PSA) from 
protase tumour), to release the active drug at the tumour site.24'33
1.2.2. Prodrug activation via tumour hypoxia
Hypoxia in cancer tissue is a result of the blood vessels in the tumour tissue lacking 
regularity and systematic connectivity, which results in unvascularised areas in the 
tumour as a result of inadequate blood flow. Cells that do not have a sufficient supply 
of blood die as a consequence of oxygen deficiency. This, and the high and variable 
interstitial pressures caused by the growing tumour lead to the presence of a variable but 
high proportion of hypoxia cells. Hypoxia can be classified into two broad groups:
1) Chronic or diffusion hypoxia. This type of hypoxia keeps cells sufficiently 
distant from the nearest blood capillary hypoxia for long periods.
2) Transient or perfusion hypoxia. This type of hypoxia results from the temporary 
shut down of blood vessels, therefore placing sections of the tissue under 
hypoxia for short periods of time. 34’35=36
Hypoxia appears to be a common and unique property of solid tumours, and has 
therefore been a target for cancer prodrug development. Consequently, prodrug 
activation via hypoxic conditions has been a widely studied and used mechanism to 
generate the effector from hypoxia-selective TAP’s. Tai-Shun Lin et at. (1986) 
hypothesised that reactive electrophiles could be generated by prodrugs requiring 
reductive activation. They called this class of drugs bioreductive alkylating agents. 
This concept was first reported for the quinone antibiotic mitomycin C 3 that may be 
considered a prototype bioreductive-alkylating agent (F igure  9 ) . l7;25;37"39
10
3F igure  9. M ito m y c in  C
Once under hypoxic cellular or chemically reducing (Na2S020 4 or H2/Pt02) conditions 
it undergoes a cascade of transformations, which unmask its highly electrophilic 
reactivity that facilitates DNA alkylation.40 Its mode of action is believed to involve 
bioreduction to the hydroquinone 4 which is followed by the elimination of methanol 
and aziridine ring opening thus generating the vinologous quinone methide 5, which 
reacts exclusively with the N2 of guanine in DNA. The carbamate can be easily 
eliminated at this stage generating the conjugated iminium ion 6 situated near the 
guanine residue on opposing or separate strands, which trap the electrophile to form 
inter and intrastrand crosslinks 7 (F ig u r e  10).41,42,25
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F ig u r e  10. A c tiv a tio n  m e c h a n ism  fo r  M ito m y c in  C
Nitroaromatic heterocycles have also shown toxicity to hypoxic cells. The toxicity is a 
result of the complete enzymatic reduction activation of the nitro heterocyclic 
compounds. The Sartorelli A.C group demonstrated this by synthesising a number of 
nitroreductase-catalysed bioreductive alkylating agents that incorporated both 
nitrobenzyl and nitrobenzylcarbamate moieties. They hypothesised that their toxicity to 
EMT6 tumour cells was due to the formation of a reactive methide species following 
the bioreduction by a nitroreductase enzyme system.43 It has been postulated that the 
nitroreductase activity may involve the following enzymes: NADPH-cytochrome P-450 
reductase, xanthine oxidase, DT-diaphorase cytochrome P-450 or carbonyl reductase.
The nitro moiety of nitroaromatic prodrugs has been used to trigger these types of 
TAP’s.44'47
1.2.3. Bioreduction via nitroreductase.
Although naturally occurring nitro-aromatic compounds are rare, most classes of 
organisms, including bacteria, fungi, protozoa, plants and mammals can metabolise 
them using nitroreductase enzymes to reduce the nitro-group (Figure 12). This is 
because the reductive metabolism is carried out by widely distributed constitutive flavo- 
enzymes that are able to use nitro-aromatic compounds as alternative electron 
acceptors.48 Three of the cellular components in mammalian cells selectively produce a 
varity of nitroreductase enzymes. These cellular organelles consist of the cytoplasm, 
mitochondria and microsomes. The enzymes that are produced from these organelles 
include the following: aldehyde oxidase, DT-diaphorase and xanthine oxidase in the 
cytoplasm, NADPH-cytochrome reductase and cytochrome P-450 in the microsomes 
and the enzymes dihydrolipoamide dehydrogenase, cytochrome b5 reductase, NADH- 
dehydrogenase and succinate dehydrogenase in the mitochondria (Ta bl e  2.).49"53
Ta b l e  2. N it r o r e d u c ta ses  selective  fo r  the c y t o p l a sm , m icrosom es a n d
m it o c h o n d r ia l .
Cvtoplasm Microsomes Mitochondrial
aldehyde oxidase NADPH-cytochrome reductase dihydrolipoamide dehydrogenase
DT-diaphorase cytochrome P-450 cytochrome b5 reductase
xanthine oxidase NADH-dehydrogenase
succinate dehydrogenase
carbonyl reductase
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Although an exact bioreductive activation pathway still remains elusive, the nitro group 
of nitro-aromatic compounds would seem to undergo reduction by one of the 
endogenous enzymes listed above to their cytotoxic moieties in both aerobic and 
hypoxic cells. However, these drugs are only cytotoxic under hypoxia conditions as a 
result of their back oxidation in the presence of oxygen (F igure  11). Either a one two 
or a combined one two enzyme reducing cycle can achieve the bioreductive drug 
activation of nitro-aromatic moieties via the endogenous enzymes listed above. For 
example the enzymes cytochrome P450s, cytochrome P450 reductase, xanthine oxidase 
and cytochrome bs reductase occur via a one electron reducing enzymatic pathway. 
While, DT-diaphorase occurs via a two-electron reducing enzymatic pathway, and the 
carbonyl reductase by a one and two electron reducing enzymatic pathway. Studies 
have shown that activity levels of carbonyl reductase and DT-diaphorase can be 
significantly elevated within human tumours (biopsies), whereas cytochrome P450 
reductase and cytochrome b5 reductase levels were equivalent to those in normal
B a c k  o x i d a t i o n
R -N  0 2 R -N  0 2-
H y p o x i a
F igure  11. B a c k  o x id a t io n  to  p r o d r u g  u n d e r  aer o bic  co nditio ns
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F igure  12. B io r edu c tiv e  m e t a b o l ism  of a  n it r o - m o iety
Of the different nitroaromatic prodrugs studied, it has been found that the presence of an 
electron withdrawing group (i.e. amides, acids and esters) facilitates the reduction of the 
nitro group.57 These types of bioreductive agents have therefore received the most 
attention as TAP triggers.58 An example of one such nitroaromatic prodrug are the 
nitrobenzyl carbamates (F igure  13) which undergoes a multi electron reduction to 
generate an electron donating hydroxylamine or amine species. It is the release of 
electrons to the 71-system that stabilises the developing positive charge on the benzylic 
carbon that allows the hydroxylamine to readily fragment and release the amine.59 This 
prodrug design exemplifies well the trigger-linker-effector concept for TAP (section
1.4.).
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F igure  13. C a r b a m a t e  f r a g m en t a t io n
However, it has been reported that a reduction potential of approximately -500 mV is 
necessary for the nitro trigger to be reduced. This requirement has lead to many 
potential nitroaromatic prodrugs falling short of the required potential to be reduced by 
the cellular nitroreductase listed in T a b le  2 60
The discovery of an E. coli B nitroreductase enzyme (NTR) has however generated 
renewed interest into these bioreductive agents. It was found that when the NTR 
enzyme was used in conjunction with NADH or NADPH, the low reduction potential of 
typical nitrobenzyl carbamates (ca.-490mV), could be reached and undergo reduction to 
the corresponding unstable hydroxylamine.61'64
1.2.4. Radiation activited prodrugs
When the water in cells is exposed to ionising radiation the reduced species generated 
can be used to activate prodrugs (Fig ure  14).19
reductants spontaneous
from water or further
radiolysis metabolism
Prodrug 0ne electron Diffusable
adduct cytotoxin
0 2" 0 2
F ig ure  14. M ec h a n ism  of pr o d r u g  a c tiv a tio n  b y  th erapeutic  ra d ia tio n
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Radiation activated prodrugs are selective since they are activated in the hypoxia 
regions within the radiation field. The advantage of this approach is that prodrug 
activation can occur without the presence of enzymes, therefore allowing activation to 
occur in all the hypoxia regions of the tumour. However, as a consequence of small 
amounts of reducing equivalent been delivered via a dose amount of radiation 
considerable demand is placed on the prodrug design. Despite this shortfall radiation 
activated prodrugs are commonly used in cancer therapy. The quaternary ammonium 
salts of mechlorethane 8 and 9 have been reported as potential radiation-activated 
prodrugs (F igure  1 5 ) .65’66’19
F ig u r e  15. M ech lo reth ane  d er iv a tiv es  u se d  a s  r a d ia t io n -a c tiv a ted  pr o d ru g s
1.2.5. Tumour specific antigens (“armed antibody” approach')
Many tumour cell surfaces possess characteristic tumour associated antigens. It is 
possible to take advantage of this and attach prodrugs to “targeting” antibodies. Once 
the antibody binds to the tumour cell the prodrug would then be converted to the active 
drug.67 An adaption of this concept is Antibody directed enzyme prodrug therapy 
(ADEPT). In ADEPT, a prodrug is cleaved by a specific non-human enzyme; this 
enzyme, which can activate the prodrug, is attached to the targeting antibody, instead of 
the prodrug. The idea behind this is to localise the prodrug-activating enzyme at the
Cl ci
8 9
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tumour, the prodrug is then administered and will only be activated by the enzymes that 
have been targeted to the tumour.68 At this point the activated prodrug may diffuse 
from the cell where it is generated to enter and kill surrounding tumour cells. The 
efficacy of this approach depends on a number of factors related to choice of antibody, 
enzyme and prodrug.69'75
1.2.6. Gene directed enzyme prodrug therapy
This type of prodrug offers an alternative to ADEPT; where the enzyme is targeted to 
tumour cells by integrating the gene that produces it into the genome of the tumour 
cells. This therapy retains the advantages of ADEPT in terms of selectivity and access 
of the drug to tumour cells; it also increases the class of enzymes available to those that
A / '  7-Q 1 Q
require endogenous (human) cofactors. " 1
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1.3. Tumour-Activa ted Prodrug Design
In order for a tumour-activated prodrug (TAP) to be successful there are a number of 
factors that need to be incorporated into its design including the following:
* to have efficient distribution to remote hypoxia regions in the tumour tissue.
* to undergo selective cellular metabolism in tumour tissue to generate a cytotoxin 
capable of diffusing a limited distance to kill surrounding tumour cells that may 
lack the ability to activate the prodrug. 19
It is thought that in order to fulfil these criteria that the TAP design can be considered to 
encompass three separate units: trigger, linker and effector [tripartate design](Figure  
16).20,21 The role of the trigger unit is to undergo efficient metabolism by one of the 
above tumour specific mechanisms. The role of the linker is to deactivate the prodrug 
until the trigger undergoes metabolism thus rapidly transmitting the change to the 
effector in such a way as to cause rapid and significant activation. Consequently, the 
role of the effector is to kill the tumour cells rapidly, and be able to diffuse a sufficient 
distance to cause a substantial by-stander effect.
T rigger---------------------------------------------------- Linker--- Effector
(selective metabolism) (deactivate effector) (potent and diffusible cytoxin)
F igure  16. Tr igger-l in k er -effec to r  c o n c ept  for  tripartate  TAP d esig n
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1.4. 5-Fluorouracil
Because there is such a vast quantity of available anti-cancer drugs, it would have
proved a mammoth task to try and decide the most suitable cytotxoxin for our study.
For this reason, we decided to work on one of the most extensively studied and
commonly used drugs in cancer therapy, 5-fluorouracil. In 1959 5-fluorouracil (5-FU) 
10 (F ig u r e  17) was synthesised by Duschinsky and co. workers 79 while Heildelberger 
and co. workers 80 demonstrated its anti-tumor activity. Since then the fluorinated 
pyrimidine has been used as a chemotherapeutic agent in the treatment of a large 
number of malignant tumours. Some of these include colon, rectal, breast, stomach, 
pancreatic, ovarian, cervical and bladder cancers. The 5-FU can follow three pathways 
to induce cell death: 1) thymidylate synthase inhibition, 2) formation of 5-FU-RNA 
complexes and 3) 5-FU-DNA complexes. Once in-vivo, the 5-fluorouracil is converted 
into 2'-deoxy-5-fluorouridine-5'-monophosphate (5-FdUMP) 11 (F ig u r e  17).81 This 
acts as a powerful inhibitor of thymidylate synthase (TS), thus depleting the intra 
cellular stores of 2'-deoxythymidine-5'-monophosphate (dTMP) 12 (F ig u r e  17) 
inhibiting DNA production and cell division81. Therefore, if a cell cannot make 
thymidine, it cannot synthesise DNA. Alternatively, 5-FU may be anabolised to 5- 
fluorouridine monophosphate, which is further metabolised to 5-fluorouridine 
triphosphate (5-FUTP). The latter can be incorporated into RNA or converted into the 
5-FdUMP. Finally, the 5-FdUMP may subsequently be phosphorlyated to 5-fluoro-2'- 
deoxyuridine-5'-triphosphate (5-FdUTP), which is incorporated into DNA.82,83
20
H10 11
F ig u r e  17. 5-FU 10, FdUMP 11 and DTMP 12
12
1.4.1. Mechanism of Action
In order to understand the mechanism for inhibition of 5-fluorouracil thyimdylate 
synthase, we need to first look at its parent base uracil 15 (F ig u r e  18). As can be seen 
from T a b le  3 , one difference between DNA and RNA is that RNA contains the 
heterocyclic base uracil while DNA contains the heterocyclic base thymine 16 (F ig u re  
18). The thymine used in the biosynthesis of DNA is synthesised by thymidylate 
synthase, an enzyme that requires N5, N 10-methylene-tetrahydrofolate as a coenzyme.
Ta b l e  3. S h o w in g  the  differ en t  b a se s  a sso c ia t e d  w ith  RNA a n d  DNA.
RNA B a se s DNA Bases
Adenine Adenine
Guanine Guanine
Cytosine Cytosine
Uracil Thymine
21
14
0
A n h
H
uracil
15
O
Y V
N ^ C
H
thymine
16
NH„
N
X o
cytosine
17
Figure 18. Str u c tu r es  o r  R N A  a n d  D N A  ba ses
Outlined in (F igure 19). is the reaction mechanism involved in the conversion of uracil 
to thymine by thymidylate synthase. When the reaction is complete the dihyrofolate 
must be converted back to N \ N ll,-methylene-tetrahydrofolate so that the coenzyme can 
undergo another catalytic cycle.
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Step 2.
O -P (O H ),
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O
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F igure 19. M ech anism  for th e  g en e r a t io n  of  th y m in e  from  u r a c il  by  
t h y m id y la te  sy n t h a se s
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Although uracil and 5-fluorouracil react with thymidylate synthase in the same way, 
they differ only in their susceptibility to methylation at C-5 as outlined in (Figure  20). 
Since, the fluorine cannot be removed, the reaction stops at this point, leaving the 
enzyme permanently attached to the substrate, consequently, the synthesis of DNA is 
stopped.
Step 1
Step 2
O
II
O -P (O H )
F igure  20. M ec h a n ism  fo r  5 -fu  in h ibitin g  t h y m id y l a t e  sy n th a se
Even though 5-fluorouracil is well known to have strong anti-tumour activity its chief 
disadvantage, like most anticancer drugs, is its inability to discriminate between 
diseased and normal cells. As a result, it is toxic to both normal cells and diseased cells, 
resulting in a series of side effects which include: drying or darkening skin or nails, 
sensitivity of skin to sun light, thinned or brittle hair, headaches, loss of appetite, weight 
loss, tingling or numbness in hands, chills, fever, sore throat, cough, nausea and 
vomiting, mouth blisters, fatigue, diarrhoea, stomach pain, painful urination, red or 
coloured urination, unusual brushing or bleeding, yellowing of skin, rashes, black/tarry
24
stools and joint pain. Therefore, numerous attempts to prepare prodrugs of 5- 
fluorouracil have been attempted to diminish these unwanted side effects.84
1.4.2. 5-Fluorouracil prodrug derivatives
Over the years 5-fluorouracil prodrugs possessing a broader spectrum of anti-tumor 
activity and fewer toxic side effects have been sought diligently in a number of 
laboratories. For classification purposes we have decided to divide the various 5- 
fluorouracil prodrugs into nucleoside prodrug derivatives and base prodrug derivatives.
1.4.2.1. N u c le o s id e  ty p e  5 - f lu o r o u r a c i l  p r o d r u g  d e r iv a t iv e s  
As it was known that 5-fluoro-2-deoxyuridine (FUDR) 18 (F ig u re  21) is an active 
metabolite of 5-fluorouracil many groups used this knowledge to prepare prodrug 
derivatives possessing the same structural features. The 5-fluoro-2-deoxyuridine, 
although showing superior anticancer activity in some test systems, had no advantage 
over 5-fluorouracil when used clinically. This was attributed to its rapid metabolic 
break down to 5-fluorouracil in-vivo, and as the 5-fluoro-2-deoxyuridine 81 cytotoxicity 
is time dependent this allows for only moderate activity. Another of its metabolites, 5- 
fluoro-2-deoxyuridine-5-phosphate 11 (F ig u r e  17), was synthesised but this also 
proved not to be an effective chemotherapeutic agent, because it does not penetrate into 
the cells in sufficiently high concentration.
5-Deoxy-5-fluorouridine (DFUR) 19 (F ig u r e  21) 85,86 a structural analogue of the 
commercial available 5-fluorouridine (5-FURD) 20 (F ig u r e  21), exhibits anti-tumor 
activity with low host toxicity. Its favourable therapeutic index is considered to reflect 
preferential bioactivation in tumour cells as opposed to normal proliferative tissues. 
Activation results from cleavage of 5-deoxy-5-fluorouridine to 5-fluorouracil.
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Rosowsky et al. (1982) synthesised analogues of DFUR to examine the effect of 
structural modification of the 5’-region of the ribofuranose moiety on the activity of 
potential pro-drug derivatives of 5-fluorouracil. They showed that a number of the 5’- 
modified DFUR analogues that they prepared were active in-vivo with lower 
cytotoxicity 21 (Figure  21). Another derivative that has received attention over the 
years is l-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) 22 86 (Figure  21) and is used 
clinically as an effective anti-tumour agent.
F igure  21. S tr u c tu r es  fo r  FUDR, DFUR, 5-FURD, DFUR d er iv a tiv es  a n d  
fto r a fu r
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1.4.2.2. B a se  pr o d r u g  d e r iv a t iv e s  of 5-flu o r o u r a cil
Over the years a series of 5-FU derivatives have been reported. These have been 
prepared through N1, N3 or bis N1 and N3 modification 10 (Figure 22). However, 
because N1 is the synthetically more reactive amine the majority of 5-FU prodrugs 
generated have favoured substitution at this position.
F ig u r e  22. T h e  l o c a t i o n  o f  r e a c t i v e  n i t r o g e n 's  in  5 - f l u o r o u r a c il
It has been found that lipophilicity can increase the bioavailability of a drug. With this 
in mind a number of alkylated 5-fluorouracil derivatives 23 (F ig u r e  2 3 ) were prepared 
and tested for anti-tumour activity87. These substituted alkyl-5-fluorouracil derivatives 
were found to possess no anti-tumour activity, presumably because the bond between 
the 1-nitrogen of 5-fluorouracil and the a-carbon of the alkyl group in such compounds 
is too strong to break in in-vivo.
O
10
o
1R = H
R= alkyl
a ChL 
I 2
R
23
F ig u r e  23 . A l k y l a t e d  5 -flu o r o u r a c il  d er iv a tiv es
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This work led to the preparation of 5-fluorouracil derivatives where an ether oxygen 
was introduced at the a  position of the alkyl group 24 (Fig ure  24 ), this in turn allowed 
for the bond between nitrogen and carbon to become more labile to chemical or enzyme 
hydrolysis conditions, therefore generating 5-fluorouracil.
1R = H
R= alkyl
24
F igure  24. E ther  d e r iv a tiv es  of 5-flu o r o u r a cil
The 1-tetrahydrofuryl-, 1-ethoxymethyl- and acyloxyalkyl-5-fluorouracil derivatives 
belong to this class, and were found to possess moderate anti-tumour activity 88. 
Furthermore, it was found that compounds having a carbonyl group bound directly to 
the N1 of 5-fluorouracil show very strong anti-tumour activity. Examples of such 
compounds are l-acyl-5-fluorouracils (RX= alkyl or aryl) 25,86 l-alkoxy-carbonyl-5- 
fluorouracils (X=0, R= alkyl) 2689 and l-carbamoyl-5-fluorouracils (X=NH, R=alkyl) 
2790 (F ig u r e  25). But the l-acyl-5-fluorouracils and l-alkoxy-carbonyl-5-fluorouracils 
were unstable in water, and decompose readily91. Therefore, both of these prodrug 
designs are unsuitable for drug use.
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F igure  25. C a r b o n y l  d e r iv a tiv es  of 5-fluo ro uracil
However, moderate success was found with l-carbamoyl-5-fluorouracil 27 type 
prodrugs due to their stability in acidic media and moderate decomposition in neutral 
media, l-hexylcarbamoyl-5-fluorouracil (HCFU, Carmofur) has been used extensively 
on a number of cancers and ranks as one of the top anti-tumour agents used clinically.
Nevertheless, it is still accompanied by side effects.
Ozaki et al. (1986) synthesised a series of 5-fluorouracil derivatives possessing 
(alkylthio) carbonyl groups at the 1-, bis-1, 3 and, 3- position 28, 29 and 30, 
respectively (F ig u r e  2 6 )92
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F igure  26. A lk ylthio  c a r b o n y l  5 -flu o r o u r a cil  d er iv a tiv es
x=s
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Among them l-(octylthio) carbonyl-5-fluorouracil showed high activity and a greater 
in-vivo life span when compared to l-hexylcarbamoyl-5-fluorouracil (Carmofur) 31 and 
(tetrahydrofuryl)-5-fluorouracil (Tegafur) 32, which are both in clinical use (F ig u r e  
27).
C H 3
31 32
F igure  27. Str u c tu r es  fo r  C a r m o fu r  a n d  Teg a fu r
Other groups have found that the introduction of an alkoxybenzyl 33 and 
alkoxybenzesulfonyl 34 substituent into 5-fluorouracil at the N'position gave anti­
tumour activity equal to 5-fluorouracil and with lower toxicity93 (F ig u r e  28).
33 34
F igure  28. A l k o x y  5-flu o r o u r a c il  d er iv a tiv es
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1.5. 5-fluorouracil as a Tumour Activated Prodrug
While some of the 5-fluorouracil prodrugs discussed have had varying degrees of 
success, they are still accompanied by adverse side effects due to their poor selectivity 
for cancer cells. One approach designed to improve 5-fluorouracils selectivity, is to 
develop a tumour activated prodrug.
1.5.1. 5-Fluorouracil as a TAP activated by therapeutic radiation 
Although radiotherapy is one of the most common cancer treatments available, only two 
general types of radiation-activated prodrugs have been reported. These include 
prodrug derivatives of 5-fluorouracil and prodrugs that possess an aromatic quaternary 
salt.17 Nishimoto et al. (1992) reported the electrochemical synthesis of a novel N(l)- 
C(5 ’)-linked dimer 1 -(5 ’ -fluoro-6’ -hydroxy-5 ’ ,6 ’ -dihydrouracil-5 ’ -yl)-5 -fluorouracil 
(F ig u r e  29), by anodic oxidation of 5-fluorouracil in an argon purged aqueous solution 
containing NaCl as supporting electrolyte. They subsequently reported that the 5- 
fluorouracil dimer underwent a one-electron reduction by hydrated electrons on 
irradiation of the anoxic aqueous solution, thereby causing the N(l)-C(5’) bond to 
cleave releasing the 5-fluorouracil in high yield.94 Following on from this they 
synthesised a series of related 5-fluorouracil dimer derivatives i.e. 5-fluoro-l-(2’- 
oxocycloalkyl)uracil derivatives (F ig u r e  30 ), in the hope to find a new class of 
radiation activated prodrugs that release more efficient antitumour 5-fluorouracil under 
anoxia or hypoxia irradiation. Their study concluded that the 2'-oxo group present in 
the 5-fluoro-l-(2’-oxocycloalkyl)uracil derivative is a crucial feature in the prodrug 
design. Its presence allowed for efficient C (l’)-N(l) bond dissociation thereby 
releasing 5-fluorouracil in relatively high yields 47-96%. An open chain derivative 
(F ig u r e  3 0 ) 35 was also reported to have shown similar results for 5-fluorouracil
31
release under both hypoxia and aerobic conditions, but no significant therapeutic effects 
were observed.95,96
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Figure 29. N(l)-
C(5 ’ )-l inked-dimer, 1 -(5 ’ -fluoro-6 ’ -hydroxy-5 ’ ,6 ’ -dihydrouracil-5 ’ -yl)-5 -fluorouracil
F ig ure  30 . Series of 5-flu o r o -1 -(2 ’-o x o c y c lo a lk y l)u r ac il  d er iv a tiv es  a n d  a n
1.5.2. 5-Fluorouracil as a TAP activated bv tumour specific enzymes 
As mentioned earlier, this concept relies on the prodrug (active drug-peptide) being 
selectively activated to the drug by enzymes specific to the targeted area. The role of 
the conjugated peptide is not to physically locate the prodrug on to the tumour cells, but 
to serve as a substrate for (target) enzymes that are produced and secreted preferentially 
by the tumour cells.17 One example of this was reported by Khan et al. (2002) were
O O
R = Me 
R = t-Bu Me
35
OPEN c h a in  d e r iv a t iv e  35
they attempted to target deliver 5-fluorodeoxyuridine (FUDR) by taking advantage of 
the unique ability of prostate cancer cells to produce PSA.97,98,99. It has been reported 
that the peptide His-Ser-Ser-Lys-Leu-Gln-OH (HSSKLQ) (F igure 31) is a PSA specific 
peptide substrate and that it is efficiently and selectively cleaved by the cnzymatic 
activity of protease.100 On the basis of this they synthesised the prodrug by coupling the 
active drug 5-FUDR to the PSA-peptide via a self-cleaving diamino acid linker to 
produce the peptide-conjugate prodrug HSSKLQ-Leu-Aib-FudR (Fig u r e  32). They 
have shown that this approach permitted efficient conversion of the inactive 5- 
fluorouracil derivative back to the active 5-fluorouracil derivative by the enzymatic 
activity of PSA, which is highly expressed in prostate cells.101,97
o
F igure  31. PSA specific  peptide  H is -S e r -S er -L y s -L e u -G l u -OH
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F igure  32. Peptide  c o n ju g a ted  pr o d r u g  His -S er -S er-L y s -L e u -G l u -Le u -A ib - 
FUDR.
1.5.3. 5-Fluorouracil as a TAP activated by ADEPT
5-Fluorouracil has seen modest use in ADEPT. One group that initially investigated 5- 
FU use in ADEPT was Wallace et al. (1994)102. They took advantage of the microbial 
enzyme cytosine deaminase (CD) which converted the non-toxic anticancer prodrug 5- 
fluorocytosine (5-FC) (F ig u r e  33) 36 into the antitumour agent 5-fluorouracil.103 They 
chemically conjugated the CD enzyme to the L6 monoclonal antibody, forming a 
conjugate that bound to antigens on the H2981 lung adenocarcinoma. In doing this they 
generated a method where 5-FC 36 could be converted into 5-FU 10 at the tumour site.
F ig u r e  33. C o n v e r s io n  o f  5 - f lu o r o c y t o s i n e  36 t o  5-Fu 10 v ia  t h e  m ic r o b ia l
e n z y m e  c y to sin e  d e a m in a se  (CD).
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Another group that used 5-FU as an antigen directed prodrug was the group of Florent 
et al. (1998).104 They continued on from their initial work on doxorubicin prodrugs, 
which had seen them utilise one of the glycosidase enzymes, p-glucuronidase, the most 
widely used activating enzyme in ADEPT. They incorporated the 5-FU into three 
glucuronide-based prodrugs 37, 38 and 39 (F ig u r e  34). The three prodrugs were 
designed to be activated at the tumour site, through cleavage of the glucuronly moiety 
by E. coli glucuronidase to afford a rapid release of the corresponding 5-FU. The 
prodrug design was related to that of a peptide cleavage based mechanism with the 
liberation of 5-FU, initialised by a 1,6-elimination following enzymatic hydrolysis, to 
generate an unstable carbamic acid that decomposes to a free amino group (F ig u re
F igure  34 . Fl o r e n t ’s g l u c u r o n id e -b a s e d  p r o d r u g s .
ADEPT has also been used to reduce nitro benzyl carbamates to their corresponding 
amines or hydroxyamines using the bacterial nitroreductase from Escherichia coli B in
0
39
35
conjunction with cofactors NADH or NADPH i.e. 5’-[2-(2-nitrophenyl)-2- 
methylpropionyl]-2’-deoxy-5-fluorouridine (Fig u r e  35) 40.106’107
40
Figure  35. 5 ’-[2 -(2 -n itr o ph e n y l )-2 -m e th y l pr o pio n y l] -2 ’-d e o x y -5- 
flu o r o u r id in e  40
1.5.4. 5-Fluorouracil as a TAP activated by GDEPT
With the development of enzyme-prodrug gene therapy some success has been found 
with the cytotoxin 5-FU when used in GDEPT. This development utilised the non­
mammalian enzyme cytosine deaminase (CD) and the 5-FU prodrug 5-fluorocytosine. 
As in ADEPT the CD enzyme found in bacteria, fungi and yeast selectively converts the 
non-toxic 5-fluorocytosine to the thymidylate synthase inhibitor 5-FU through 
hydrolytic deamination. Therefore, when the gene that encodes the CD enzyme is 
introduced into the tumour cells it possesses the ability to convert the 5-FC prodrug into 
5-FU, thereby generating the anti-metabolites 5-FdUMP, 5-FdUTP and 5-FUTP while 
reducing the toxicity to normal tissue. GDEPT has also been used to reduce nitro 
benzyl carbamates to their corresponding amines or hydroxyamines using the bacterial 
nitroreductase from E. coli B in conjunction with cofactors NADH or NADPH i.e. 5’- 
[2-(2-nitrophenyl)-2-methylpropionyl]-2,-deoxy-5-fluorouridine40.107-110
OH
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1.5.5. 5-Fluorouracil and TAP activated by tumour hvpoxia
Lin et al. (1986) first introduced the cytotoxin 5-FU to the bioreductive alkylating agent 
concept.111 They synthesised a series of (o-and p-nitrobenzyloxycarbonyl) and (o- and 
p-nitrobenzyl)-5-fluorouracil derivatives (F ig u r e  36) with the potential to be activated 
preferentially by hypoxia cells using cellular nitroreductase to produce a highly reactive 
quinone methides and 5-iluorouracil.
R, = H, R2 =0C 0C H 2C5H4N 0 2-p 
R, =R2 = 0 C 0 C H 2C6H4N 02-p 
R1 = R2 CH2C6H4N 0 2-p 
R1 = CH2C6H4N 0 2-p, R2 = H 
R., = tetrahydrofuran-2-yl, R2 = CH2C6H4N 0 2-p
R1 = 2' deoxyribofuranosyl, R2 = CH2C6H4N 0 2-p
F ig u r e  36. S e r ie s  o f  5-FU n i t r o b e n z y l  a n d  n i t r o b e n z y l o x y c a r b o n y l  
d e r i v a t i v e s .
The group reported that one of the prodrugs that they synthesised, 3-(p- 
nitrobenzyloxycarbonyl)-5-fluourouracil (Figure  37), appeared to be superior to 5-FU 
in prolonging the survival time of mice bearing intraperitoneal implants of the P388 
leukaemia and Sarcoma 180. But, it was later reported that the 3-(p- 
nitrobenzyloxycarbonyl)-5-fluourouracil showed no hypoxic selectivity in cells, 
because the reduction potential of the benzene based compound was too low for 
efficient reduction by cellular NTRs (F igure  38).19 This problem has been some what 
eradicated since the discovery of the bacterial nitroreductase from E. coli B. This FM N  
containing flavoprotein is capable of reducing certain nitro-groups to the corresponding 
amines or hydroxylamines in the presence of a cofactor N A D H  or N A D P H . One 
prodrug of 5-FU which shows significant hypoxia selectivity is 5’-[2-(2-nitrophenyl)-2- 
methylpropionyl]-2’-deoxy-5-fluorouridine 40. It was found to release quickly the 
parent drug FUDR in quantitative yield when placed in reduction conditions so as to
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mimic the bioreduction in a hypoxia tumour cell. Numerous nitrobenzyl carbamate 
derivatives have been metabolised to their corresponding amines with E. coli B NTR. 
A variety of these have been proposed as GDEPT prodrugs in conjunction with NTR."17 
Therefore, 5-FU prodrugs possessing a nitrobenzyl or nitrobenzyl carbamate moiety 
could be reduced,60
Figure  37. Pr o d r ug  3 - ( p-n it r o b e n z y l o x y c a r b o n y l )-5 -fluourouracil
38
F
NH
N ^ O
H
F
N 0 2
j  NAD(P)H  
Nitroreductase (
NAD(P)
0
Y ^ N h
I.A C 0 2 +  - "NHN 0
H
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1.6. Photodynamic therapy (PDT)
Like many natural products, the use of light for its therapeutic properties has been well 
documented throughout history. The Egyptians used light to treat vitiligo and psoriasis 
by exposing the plaques to sunlight after topical application of bergamot oil. Despite 
this early awareness, advancement in phototherapeutic techniques had been 
considerably slow, and it was only in the second half of the last century that real 
progress was achieved. This development can be credited to advances in the 
understanding of the interactions between light and biological tissues, along with the 
arrival of sophisticated optical techniques that helped to illuminate the photophysical, 
photochemical and photobiological aspects of phototherapy. The two-phototherapeutic 
techniques available for the treatment of cancer at present are photochemotherapy and 
phototherapy. In phototherapy, endogenous molecules in the diseased tissue absorb the 
incident light; while with photochemotherapy the diseased tissue is irradiated at suitable 
intervals after the topical or systemic administration of a photosensitiser, which should 
preferentially accumulate in the diseased area.
An example of a relatively new photochemotherapy technique used for the treatment of 
cancers is photodynamic therapy (PDT). Over the past 25 years results from studies 
conducted worldwide have established photodynamic therapy as a useful treatment for 
certain cancer types. Since 1993, the use of Photofrin® (F i g u r e  39) a partially purified, 
commercially available hematoporphyrin derivative has been regulatory approved as a 
photodynamic therapy agent for cancers of the lung, digestive tract, and genitourinary 
tract in Canada, The Netherlands, France, Germany, Japan, and the United States.112’114 
This technique involves the administration of a tumour-localising photosensitising 
agent, followed by activation of the agent by light of a specific wavelength. This 
therapy results in a sequence of photochemical and photobiologic processes that cause 
irreversible damage to tumor tissues.115
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2(CH2)C02-Na+
R = CH3CHOH or CH2CH
F igure  39. Str u c tu r e  of  ph o to fr in®
1.6.1. Basic principles
It has been found that hydrophobic or amphiphilic dyes can readily cross cell 
membranes and partition in apolar compartments, such as mitochondrial, lysosomal or 
cytoplasmic membranes, from which they are cleared at a slow rate, owing to tumour 
tissue typically having poor lymphatic drainage.116'118 Reports have also shown that the 
hydrophobic photosensitisers are largely transported in the blood by serum lipoproteins. 
One component of the lipoprotein family, namely low-density lipoproteins (LDL), play 
a significant role in the accumulation of these photosensitisers in tumours. However, 
neoplastic cells express larger amounts of the LDL receptors than most normal cells.
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As a result more LDL’s containing photosensitisers are taken up by carrier cells via 
receptor-mediated endocytosis.119121
However, the actual amount of administered photosensitiser is limited since lipoproteins 
account for approximately 10% of the over all serum proteins, while at least 70% of the 
lipoproteins are represented by the high-density class. This limitation has been 
eradicated somewhat by the incorporation of the photosensitiser into a suitable 
liposomal vesicles, which selectively releases the drug to the serum lipoproteins.126'129 
Thus, the higher concentration of LDL’s and poor lymphatic drainage associated with 
tumour tissue when compared to normal tissue, could possibly explain why 
photosensitisers are more selective and retained longer in malignant tissue.
1.6.2 Mechanism of PDT
The photosensitizer (Ps) is illuminated with light of a suitable wavelength to excite it to 
its lowest excited singlet state S o—>S1 (Figure  40) The excited sensitizer (’Ps*) can 
then either decay back to ground state S I—»So (emitting fluorescence in the process) or 
undergo intersystem crossing (electron spin conversion) to the long lived reactive triplet 
state S 1 —>T I generating the triplet state photosensitiser (3Ps*). At this stage the 3Ps* 
can undergo two oxidative mechanisms. Type I or Type II mechanisms (S chem e
 ^  ^ 113,126
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F ig ure  40 . P o tential  PD T  m e c h a n ism .
Type II mechanism
Ps —» *Ps* —» 3Ps*
3Ps* + 30 2 —» Ps + ^ 2
'0 2  + substrate -> oxidized substrate
S chem e  1. Ty pe  I a n d  Ty p e  II m e c h a n ism s .
Type I mechanism
3Ps* + 0 2 -> Ps*+ + 0 2*
3Ps* + substrate -»  Ps* + substrate*+
Ps* + 0 2 -» Ps + O2"
0 2* -> H 0 2*
HO2* + substrate-H -> H20 2+ substrate*
In the Type I mechanism the 3Ps* interacts with biological substrates, by proton or
electron transfer, to form radicals and radical ions, which react with molecular oxygen
to form oxidized products by irreversible oxidation. In the Type II mechanism singlet
oxygen ( ^ 2  ) is generated as a result of electronic energy transfer from the triplet
excited state of the photosensitiser (3Ps*) to the triplet ground state of the oxygen
molecule(302) Ti-»So. Singlet oxygen then attacks electron rich sites in the
surrounding medium, thus giving rise to oxidised substrates. While it is believed that
43
both of the oxidative mechanisms are involved in the photodestruction of malignant 
tissue it is considered that the Type II mechanism to be the main process in
1 1 T 1 1  T7 _
photodynamic therapy. ’ ’ The oxidative products of both Type I and Type II 
reactions are highly reactive, with very short lifetimes in biological systems i.e. 40 
nanoseconds. Therefore, damage caused by these species occurs locally i.e. radius of 
action of 0.02^m, tissue damage will be limited to the illuminated areas containing both 
the photosensitizer and oxygen.128,129
1.6.3. Mechanisms of tumour destruction
It has been postulated that three mechanisms could be involved in the irreversible 
damage of tumour tissue when treated with PDT. These include the following:112
1) Direct killing of malignant cells, largely as a consequence of impairment of 
mitochondrial functions and the alteration of mitochondrial/cytoplasmic 
membranes.
2) Indirect cell killing due to photodynamic damage or shutdown of the (neo) 
vascular with loss of oxygen and nutrients to the tumour owing to disruption of 
the endothelium.
3) Additional anti-tumour contributions from the inflammatory and immune 
response of the host.
Although all three are thought necessary for the best long term response, their relative 
roles will vary considerably depending on the photosensitiser, its sub cellular and tissue 
distribution, the tumour type and its microvasculature, and the type and duration of the 
inflammatory and immune response elicited in the host.
Also, as a consequence of PDT the singlet oxygen generated by the photosensitiser will 
affect practically all of the cellular organelles due to the wide and varied sensitiser 
distribution within the cells. Subsequently, because there are multiple cellular targets
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for the singlet oxygen it has been proved difficult to distinguish between the events 
leading up to cell death. However, with the ongoing development in this area, more 
sensitive techniques are becoming available for the detection of photosensitiser in cells. 
With the use of innovative molecular and biochemical strategies the mapping of cellular 
events before and after photosensitisation, is bringing some clarity to the process of cell 
death via toxic oxygen treatment. Although there are multiple cellular targets available 
to the toxic oxygen one of the cellular components that has been studied and targeted by 
PDT in preference to others is the mitochondria.130
1.6.4. General properties of PDT sensitisers
In general, the majority of photosensitisers employed in cancer phototherapy have been 
based on porphyrins (Fig ure  41).
F igure 41 . P o r ph y r in  skeleto n
Hematoporphyrin and its chemical derivatives; hematoporphyrin derivative (HpD), and 
its purified forms Photofrin®, Photosan® and Photochem®, were the first 
photosensitisers employed in PDT and are referred to as first generation photosensitisers 
(Fig u r e . 42).113 However, although these photosensitisers are known to selectively 
accumulate in a variety of solid tumours for prolonged periods of time, they do suffer 
from three major drawbacks.129
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1) L ow  se lec tiv ity  betw een tumours and peritumoral tissue, consequently, skin  
photosensitiv ity  is a  major side effect.
2 ) A bsorption  in the red region is w eak  i.e. 630nm , and so deep tumours are 
difficu lt to treat.
3) The photosensitisers are a m ixture o f  at least 12 com ponents.
CH3C02H/H2S04 5%
co2r co2r
R = H, R\ R2 = CHOHMe
HpD Stage 1
Major component 
haematoporphyrin diacetate 
R1,R2 = CH(OAc)Me
1. Alkali
2. Neutralise
HpD Stage II
Mixture of oligomers, dimers, 
protoporphyrin (R1, R2=CH=CH2), 
haematoporphyrin, and 3(8)-hydroxyethyl 
-8(3)-vinyl-deuteroporphyrin(R1(R2)= 
CHOHMe, R2(R1)=CHCH2
Active oligomeric fraction Inactive monomeric
e.g. Photofrin, Photosan,Photochem porphyrins.
F ig ure  42 . Sy n t h e sis  o f  H pD
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As a result numerous new photosensitisers, referred to as second-generation 
photosensitisers, have been developed to try and overcome these limitations. This 
development has in turn led to the synthesis of a large number of novel photosensitisers 
with a variety of structures ranging from porphyrin-type compounds e.g. chlorins (41) 
and bacteriochlorins 42 to phthalocyanines 43, porphycenes 44 methylene blue 45 and 
texaphyrins 46 (F ig u r e  43). In designing an improved photosensitiser, a number of
131 133factors need to be considered and are outlined in Ta b l e  4:
Ta bl e  4. S om e  of the  properties a  sec o n d  g ener atio n  ph o to sen sitiser  sh o u ld  
p o s se ss .
Phvsico-chemical A photosensitiser should be easy to synthesise.
Have high chemical purity.
Possess a constant composition.
Large molar extinction coefficient in the red to absorb beyond 
the biological window of 650nm.
Low tendency to aggregation in an aqueous environment.
PhotoDhvsical Possess a high triplet quantum yield.
Long triplet lifetime.
Have a triplet energy >94kjmol'‘ with efficient transfer to 
produce singlet oxygen.
Pharmacological Efficient and high selective targeting for tumour tissue.
Fast clearance from the serum and healthy tissue 
i.e. easy elimination from the body.
Possess little or no dark toxicity.
Low systemic toxicity.
Photo-theraDeutic Efficient and preferential killing of malignant cells.
Lack of side effects.
Lack of mutagenic potential.
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Chlorine
41
C 02Me
Bacteriochlorine
42
Phtalocyanine
43
Porphycene Methylene blue
44 45
Texaphyrin
Figure 43 . 2 NIJ g en e r a t io n  photosensitisers
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Of the numerous photosensitisers available for PDT the phthalocyanines (Pc) 43 
(F igure  4 3 ) have received much attention.133'136 This has been partially due to their 
associated advantages when compared to Photofrin©. These include: purity, 
hydrophobicity (which has been reported to increase the affinity of photosensitiser for 
neoplastic tissue), higher extinction coefficients, excellent absorption range 650-800 nm 
(F igure  44), and no dark toxicity. However, even with these advantages they are 
associated with poor water solubility thus limiting their use for cancer therapy.
1.6.4.1. Im pr o v in g  the  w a t e r  so lu bil ity  of ph th a l o c y a n in es  
B ecause Pcs can chelate to both transition and non-transition m etals, nam ely  
alum inium , gallium , zinc and silicon , substitution o f  axial ligands can occur and be 
placed orthogonal to the m olecular plane. N o t on ly  does this prevent aggregation but, it 
also a llow s for ligand m odification , thus influencing the lipo/hyro-solubility  o f  the Pc so 
its partition am ong the various com partm ents o f  the tumour tissue can be som ew hat 
controlled. For exam ple in order to increase the hydrophilicity o f  the Pc so as to allow  
for direct injection polar substituents have been attached to the peripheral positions o f  
the m acrocycle e.g. su lphonic acid, carboxylic acid and hydroxy groups. A lso  the 
m acrocyclic photosensitiser silicon  (IY )-phthalocyanine 47 (F igure  45) bearing two  
axial ligands to the centrally coordinated m etal ion e.g. poly(ethylene g ly co l) chains, 
has been dem onstrated to have im proved the p hysicochem ical properties and 
pharm acokinetic behaviour o f  the PD T  photsensitiser. This is attributed to the low ering  
o f  aggregation betw een  Pc rings thus increasing the lifetim e o f  the sensitiser. 
A lternatively, hydrophobic photosensitisers can be adm inistered into different delivery  
system s such as liposom es or o il em u lsion s.137,138,134
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4Û0nm
Ultra violet
500nm 600nm ik 700nm
Visible Light Infrared
Ideal wavelength for photodynamic therapy ~650nm
F ig u r e  44: Id e a l  w a v e l e n g t h  fo r  ph o t o d y n a m ic  t h e r a py
R = peripheral substitutent R ^  / ^ R
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Fig u r e  45. Silico n (IY )-ph th a l o c y a n in e
1.7. Project Proposal
It is a common fact that when PDT is used on tumour tissue, the cells that localise the 
photosensitiser become terminal as a consequence of the toxic oxygen generated. As 
previously mentioned (section 1.6.3.) it had been thought that these cells die via one or 
as a result of all three of the aforementioned mechanisms. A shortcoming associated 
with the use of PDT treatment is its duration as once exposure to light is “ceased” the 
treatment stops. Therefore, it has been found that the entire tumour mass may not be 
destroyed during the light treatment, and as a result will only shrink in size, 
consequently redeveloping over time, which is obviously an undesirable outcome. 
Ideally, it would be desirable to have a normal “dark” cytotoxin present with the 
photosensitiser. Thus, when exposure to light has been “turned off’ the dark cytotoxin 
can be released and destroy any remaining living tumour tissue. Hence, it is the goal of 
this research to explore and develop ways in which to accomplish this. One possible 
way to achieve this is to develop a photosensitiser-prodrug that can be activated by the 
conditions generated during PDT treatment.
1.7.1 Cell response to oxidative stress
Cells constantly generate reactive oxygen species (ROS) during aerobic metabolism. 
To counter this effect, the cell possesses a number of antioxidant enzymes and repair 
activities that detoxify the ROS and repair damage caused by them. During normal cell 
growth most of these enzymes are expressed at low levels. However, bacterial, yeast 
and mammalian cells all have adaptive responses to deal with elevated levels of 
oxidative stress and the expression of many antioxidant enzymes are induced (Ta b l e  5). 
PDT causes oxidative stress within the environment where the photosensitisers are 
localised, thereby causing the cell to produce increased levels of reductase enzymes 139' 
148. We believe that we can manipulate this oxidative stress to our advantage. What we
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proposed to do is to link a “redox” activated prodrug into the photosensitiser. This 
prodrug will be activated by the reductase produced by the tumour to combat the 
oxidative stress of PDT, resulting in the release of a dark therapeutic. When the light 
therapy ceases the dark therapeutic will remain behind to destroy surviving tumour 
tissue. Outlined in F ig u r e s  46, 47 and 48 are the target compounds we are interested 
in. F ig u r e  46 shows the trigger-1 inker-effector design with 5 -F U , with the mechanism 
of reductase activation shown in F ig u r e  47. F ig u r e  48 shows the final target with the 
trigger-linker-effector conjugated into a phthalocynin photosensitiser.
T a b l e  5. L is t  o f  s o m e  o f  t h e  a n t i o x i d a n t  e n z y m e s  e x p r e s s e d  t o  p r o t e c t  t h e
C E L L  A G A I N S T  D A M A G E  C A U S E D  B Y  O X I D A T I V E  S T R E S S .
A n tio x id a n t  En zy m es  
Manganese superoxide dismutase 
Fumarase C 
Aconitase A 
Glucose-6-phosphate dehydrogenase 
Ferredoxin reductase 
Endonuclease IV 
Iron superoxide dismutase 
Copper-zinc super oxide dismutase 
Glutathione reductase 
Hydroperoxidase I and II 
Exonuclease III 
8-hydroxyguanine endonuclease 
Exonuclease III 
Methionine sulfoxide reductase
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Figure  46 . Or ig in a l  d r u g  d e sig n
1  N ^ O  
H
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F ig u r e  47. S ch em e f o r  r e d u c t a s e  o f  n i t r o  b e n z y l  5-FU .
Trigger— Linker— 5-FU Carrier 
N O 2— benzyl— 5-FU photosensitiser
y r - O NO.
N ^O
OH OH
(50)
F ig ure  48. M odified  d r u g  d e sig n  fo r  (50).
However, we envisaged a potential problem with the usage of a nitro-aromatic trigger; 
do human reductase enzymes (T a b l e  2.) possess the necessary redox potential to
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efficiently reduce nitro-aromatics? As a result we deemed it necessary to prepare a 
series of nitro-aromatics with varying redox potentials and conjugate them to the 
appropriate photosensitizer. However, if the human reductases are not able to reduce 
our trigger it will still be possible to activate our prodrug through the action of GDEPT 
and E. coli nitro reductase (F ig u r e  49).
N 02-benzy I—5-F U—Ps Thè conjugate prodruc
The cell
Cell death
Figure  49 . G eneral  schem e  for  5-FIJ pr o d ru g  a c t iv a t io n .
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2.0. Discussion -  Prodrug Photosensitisers
The strategy we propose for preparing the target compound 50A (Figure  50), involves 
the conjugation of a trigger-effector to a photosensitiser. Figure  50 outlines a general 
approach to the trigger-effector-linker and the final target.
Linker
O
F^ U ^ ^ b e n z y l - N 0 2
O
N O ,-benzy^
A.O '  N ' 
I
I
Linker/
N _ _ - s r  \
o
Linker,
50A
F igure  50. Pr o po sed  syn th etic  st r a t e g y  for  the n itr o b en zy l-5-F U  prodrug
2.0.1. Prodrugs of 5-fluorouracil containing the nitro-aromatic moiety 
We decided to start our study with the preparation of nitro-aromatic-5-FU-prodrugs that 
would best suit our prodrug design (Figure  50). After much review our attention was 
turned to Lin et al. (1986) and their work on nitro-aromatic-5-fluorouracil derivatives. 
The prodrugs that they designed seemed ideal for our study, as they were simple to 
prepare and provided a means to test our hypothesis. In order for our prodrug to be 
linked to a photosensistiser the N 1 of the 5-fluorouracil needed to be free for 
substitution. Lin et al. (1986) accomplished this by selectively synthesising a series of
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nitro-aromatic-5-fluorouracil-bioreductive agents. However, of the 5-FU derivatives 
reported we were only interested in two, namely, 3-(p-nitrobenzyloxycarbonyl)-5- 
fluorouracil 51 and 3-(p-nitrobenzyl)-5-fluorouracil 52 (Figure  51).
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F igure  51 S tr u c tu r e  of  3 -(n it r o b e n z y l o x y c a r b o n y l )-5-F U , 3 -(n itr o b en zy l)- 
5-FU  a n d  1,3-(n it r o b e n z y l )-5 -F U  pr o d ru g s
2.0.2. Preparation of 3-('p-nitrobenzvloxvcarbonyl)-5-fluorouracil 
The preparation of 3-(p-Nitrobenzyoxycarbonyl)-5-Fluorouracil 51 was attempted using 
the Lin et al. (1986) protocol for selective N3 substitution (Figure  52). An equimolar 
amount of 5-FU and triethylamine (TEA) were dissolved in dry DMSO and stirred at 
room temperature. To this reaction a solution of nitrobenzyl chloroformate in dry 
dioxane was added drop-wise over 10 minutes at room temperature. The reaction 
mixture was allowed to stir at room temperature for approximately 4 hours. TLC 
monitoring indicated that the reaction was completed within 3 hours. The Et3N HCl salt 
that was formed during this time was filtered and washed with a minimum amount of 
DMSO. The solution was then poured into a mixture of ice and water to precipitate the 
crude white product. TLC analysis indicated the presence of product plus some
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unreacted nitrobenzyl chloroformate. The latter was removed by washing the product 
mixture with dry chloroform, as the benzyl chloroformate is soluble in chloroform while 
the product is not. This method was repeated once more until TLC analysis showed 
only product, which was dried to yield the product 51 in 58% yield.
10 51
F ig u r e  52. P r e p a r a t io n  o f  51. Reagents i) DMSO, Et3N, NBC at RT.
2.0.3. Synthesis of 3-(p-nitrobenzvO-5-fluorouracil
We decided to use 1 mole equivalents of potassium carbonate, p-nitrobenzyl bromide 
and 5-FU, these were dissolved in DMSO. The reaction was heated to 100°C for one 
hour, TLC analysis showed the presence of two spots. To the hot reaction mixture was 
added a 10% potassium hydroxide solution, crystals formed and were collected, washed 
with FI2O and ethanol to yield 1,3-Bis- (p-nitrobenzyl)-5-fluorouracil 53 in 20% yield. 
The mother liquor was acidified to a pH of 2 with HC1 that resulted in the formation of 
white crystals that were collected and washed with H2O and ethanol to yield l-(p- 
nitrobenzyl)-5-fluorouracil 52 in 20% yield .
°  0,N— ^  ^  0
IT 1 2 ~ XO ^ N  O ^ N
H H
10 52
F ig u r e  53. P r e p a r a t io n  o f  52. Reagents i) DMSO, K2C 0 3, N B B  A T  100°C.
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2.0.4. Synthesis of N1 methoxv ether-5-fluorouracil
Both of these prodrugs were then examined for their suitability for linkage to a 
photosensitiser. Although a number of possible routes were available to achieve this we 
decided to use a methyl hydroxy linker (F ig u r e  54). Since 5-FlJ possesses two acidic 
NH moieties we can generate a bis hydroxymethyl 5-F U  prodrug derivative (F igure
55).
r-co n h 2 + ch 2o r-c o n h -c h 2o h
F i g u r e  54. G e n e r a l  s c h e m e  f o r  N - h y d r o x y m e t h y l a t i o n
O o
H
F i g u r e  5 5 .  R e a c t i o n  s c h e m e  f o r  N - h y d r o x y m e t h y l a t i o n  o f  5 - F U
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The hydroxy moieties can act as handles for the 5-FU prodrug to be attached to the 
photosensitiser, furthermore this methyl ester handle can be fragmented in vivo 
releasing the active 5-FU and the Pc (F ig u r e  56).
H
10
F ig u r e  56. In- vivo d e c o m p o s it io n  o f  a  t y p ic a lN - h y d r o x y m e t h y l  5-F U  p r o d r u g
The synthesis and suitability of such methyl hydroxy prodrug derivatives were 
investigated.
O n
O
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Trigger Linker Effector Carrier 
NO2 benzyl 5-FU CH20 carrier
0
N 0 2-benzyk
O
/ b e n z y l-N 0 2
O
F ig ure  5 7. Pr o d r u g  w it h  m eth y l  h y d r o x y l  link ers
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2.0.5. Preparation o fN 1 methoxv ether-5-fluorouracil
The synthesis o f  the N 1 m ethoxy ether-5-fluorouracil 54 (Figure  58) w as achieved  
using 30% form alin. The temperature w as not allow ed  to exceed  60°C as this led to 
decom position  o f  the product back to the starting material 5-F U  (polym erisation has 
also been reported).137
10 54
Figure  58. Rea c tio n  sch em e  fo r  the fo r m a tio n  of 5-FU. Reagents i) 30%
formalin at 60°C.
However, although the prodrug design is theoretically sound the synthesis of the target 
hydroxy methyl derivative-nitrobenzyl-5-FU prodrugs 55 and 56 (Fig ure  59) was 
unsuccessful. Instead of obtaining the desired products we obtained the fragmented 
prodrug starting materials for the reaction of 51, while 52 did not react at all.
To try and overcome this problem a temperature study was carried out. Ta b l e  6 
outlines the results of these studies. Unfortunately, changing temperature was deemed 
unsuccessful as neither 55 or 56 were generated.
Ta b l e  6. Ou t l y in g  r esu l ts  fr o m  tem per a tu r e  s t u d y
Reauired Prodrue Temperature^ Prodrue formation
55/56 Ambient No/No
55/56 30°C No/No
55/56 40°C No/No
55/56 70°C No/No
55/56 Reflux No/No
60
51 56
Figure  59. U n su c c e s sf u l  sy n th esis  u s in g N 3-a r o m a tic -5-FU.
Following on from this we decided to use an alternative pathway (F ig ure  60) by 
starting with the hydroxy methyl-5-FU prodrug 54. Following a modified procedure to 
the one Lin et al. (1986)37 used for the synthesis of 51 we set up two reactions, one 
containing a solution of nitrobenzyl chloroformate in dry dioxane while the other 
contained the nitrobenzyl bromide. Both were added dropwise to a solution of hydroxy 
methyl-5-FU 54 in dry DMSO containing the base triethylamine. The reactions were 
allowed stir at room temperature while monitored by TLC. After 5-6 hours only the 
nitrobenzyl chloroformate reaction showed evidence of product formation. At this stage 
we quenched the reactions by pouring onto ice-cold water. The precipitate that formed 
was isolated and collected. On analysis it was observed that the reaction had in fact not 
worked and that the new spots were that of the starting materials. The reaction was 
repeated using the same reagents in different stiochiometries (Ta b l e  7). However, none 
of these changes were successful.
°  °  ' F \  o W  '
HO
10 54
I T  J J  '  •
0
i t  - v  \  ' w  »x "J jHO 
55
F
2'
10 54 56
F igure  60. U n su c c e s sf u l  sy n th esis  u s in g N 1 m e th o x y  eth er -5-F U
Ta b l e  7. R e su l t s  fo r  stiochm etric  a d d it io n  of n itr o  be n z y l  d er iv a tiv es  .
Nitrobenzyl chloroformate 
Equiv. Amt.
Nitrobenzyl bromide 
Eauiv. Amt.
Prodrue formation
1 1 No
2 2 No
3 3 No
4 4 No
5 5 No
Ta b l e  8. R e su l t s  fro m  d ilu tio n  s t u d y .
Nitrobenzyl chloroformate 
DMSO vol
Nitrobenzyl bromide 
DMSO vol.
Prodrue formation
2.5 2.5 No
5 5 No
10 10 No
15 15 No
30 30 No
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T a ble  9. R esu lts  fo r  b a se  st u d y .
Base tvDe Nitrobenzyl chloroformate 
Prodrug formation
Nitrobenzyl bromide 
Prodrug formation
K2C 0 3 No No
KOH No No
Pyridine No No
DBU No No
NaOH No No
TEA No No
Thus, both pathways to prepare the target N 1 methoxy 5-FU prodrugs 55 and 56 failed. 
The failure to generate prodrug 56 was attributed to the heat that is required to induce 
the formation of the N-hydroxy methyl group, as this consequently cleaves the 
nitrobenzyl group from 56. This then led us to believe that by forming the N-hydroxy 
methyl prodrug 54 first, we could then avoid using heat. However, the methoxy seemed 
to be sensitive to the conditions used as only the products 51 and 52 were obtained. 
Therefore, we abandoned this approach and decided to look at more stable linkers.
W e turned our attention to the possib ility  o f  introducing a linker that possesses a labile 
term inal functional group, w h ich  m ay allow  for the attachment o f  a photosensitiser with  
out the u se o f  heat. W e decided  to incorporate an ester derivative that w ould  allow  for 
linkage through a reactive terminal functional group. To test this w e decided to prepare 
three types o f  5-F U  esters, l-benzyloxycarbonylm ethyl-5-fluorouracil 57, 1-
alloxycarbonyloxym ethyl-5-fluorouracil 59 and 1-hexanedioic acid benzylester- (5- 
fluorouracil) m ethyl ester 60 (Fig ure  61).
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2.0.6. Synthesis of *N ester derivatives of 5-fluorouracil
H N ^ y F i V o ^
O
'-A,
F
57 58
0
x Y
59 60
F ig u r e ; 6 1 .  E s t e r  d e r i v a t i v e s  o f  5 - F U .
Il was thought that the l-alloxycarbonyloxymethyl-5-fluorouracil 59 ( F i g u r e  61) could 
possibly be linked to the photosensitiser 59A through a metathesis reaction ( F i g u r e  62). 
While the esters l-benzyloxycarbonylmethyl-5-fluorouracil 57 and 1-hexanedioic acid 
benzylester-(5-fluorouracil) methyl ester 60 ( F i g u r e  61), can be linked through the 
transesterfication reaction ( F i g u r e  63)or an esterfication reaction ( F i g u r e  64) once the 
benzyl group is deprotected.
64
F ig ure  62 . R ea c tio n  S c hem e  fo r  the sy n t h e sis  of 59 u sin g  
r e a c t io n . Reagents i) Grubbs Catalyst.
m e t a t h e s i s
F i g u r e  63. R e a c t i o n  s c h e m e  f o r  t h e  s y n t h e s i s  o f  57A o r  60A
TRANSESTERFICATION REACTION CONDITIONS.
USING
F i g u r e  64. R e a c t i o n  s c h e m e  f o r  t h e  s y n t h e s i s  o f  57A  o r  60A u s i n g
E S T E R F I C A T I O N  R E A C T I O N  C O N D IT IO N S .
Both l-alloxycarbonyloxymethyl-5-fluorouracil and l-benzyloxycarbonylmethyl-5- 
fluorouracil were prepared in the following manner.149 The 5-FU was allowed to react 
with 37% formalin at 60°C for 45 minutes. All traces of water were removed and the 
residue was dissolved in dry acetonitrile. An equimolar amount of triethylamine and 
the corresponding chloroformate were added to the solution, to afford both 1- 
alloxycarbonyloxymethyl-5-fluorouracil 59 and l-benzyloxycarbonylmethyl-5- 
fluorouracil 57 in yields of 74% and 69% respectively. The disubstituted by-product 
l,3-benzyloxycarbonylmethyl-5-fluorouracil 58 was also generated in a yield of 18%.
o n O
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F i g u r e  65. G e n e r a l  s c h e m e  f o r  t h e  s y n t h e s i s  o f  57 a n d  59. Reagents i) 37% 
formalin at 60°C, ii) acetonitrile, Et3N allylchloroformate , iii) acetonitrile, 
Et3N and benzylchloroformate.
Not only would the synthesis of 1-hexanedioic acid benzylester- (5-fluorouracil) methyl 
ester 60 allow for a non-thermal mild linkage reaction, but it would also enable us to 
examine the effect linker length has on the cleavage of the drug from the 
photosensitiser. The synthesis of 60 was similar to that reported by Menger et al. 
(1997).151 Initial preparation required the synthesis of a hexanedioic acid benzyl ester 
methyl ester. This was carried out by refluxing (using a dean stark apparatus) a mixture 
of adipic acid 61 ( F i g u r e  66), benzyl alcohol in toluene with acid catalyst, to give the 
hexanedioic acid benzyl 62 ( F i g u r e  66) in 69% yield after work-up.150 This monoester 
was then dissolved in dry DMF containing cesium carbonate in order to abstract the 
acidic hydrogen prior to the addition of chloromethyl phenyl sulfide. This afforded the 
product hexanedioic acid benzyl ester(phenylsulfanyl)methyl ester 63 ( F i g u r e  66) in a 
yield of 71%. Following on from this the hexanedioic acid 
benzylester(phenylsulfanyl)methyl ester was dissolved up in dichloromethane. To this a
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solution of sulfuryl chloride made up in dichloromethane was added slowly. The colour 
changed from clear to orange indicating the generation of the desired chloromethyl ester 
plus the very reactive benzenesulfenyl chloride side product. In order to trap this 
reactive side product we used cis-4-cyclohexene-l,2-dicarboxylic acid.151 This trapping 
reaction was signified by the orange colour been converted back to its original clear 
colour. After work-up the product hexanedioic acid benzyl ester chlormethyl ester 64 
(F ig u r e  66) was obtained in a yield of 92%. To a stirred solution of 5-FU in dry DMF, 
a 3-fold excess of triethylamine was added. To this reaction mixture a solution of 
hexanedioic acid benzyl ester chlormethyl ester in DMF was slowly added and allowed 
to stir over-night. The triethylamine hydrochloride formed was filtered and the DMF 
was removed using a high vacuum pump. The product hexanedioic acid benzyl ester -  
5-fluorouridine-methylester 60 (F ig u r e  66) was obtained in 47% yield prior to SGC 
purification.
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64 60
F i g u r e  6 6 .  S y n t h e s i s  o f  h e x a n e d i o i c  a c i d  b e n z y l  e s t e r - 5 - f l u o r o u r i d i n e -
METHYLESTER. Reagents: (i) benzyl alcohol, p-toluenesulfonic acid, toluene; (ii) 
CsaCOj, PhSCH2Cl2, DMF; (iii) SO2CI2, cis-4-cyclohexen-l, 2-dicarboxylic acid, 
CH2CI2; (iv) 5-FU, EtNj, DMF.
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F ig u r e  67. D e b e n z y l a t i o n  o f  57 a n d  60. Reagents i) acetic acid, 10% Pd/C and 1,4- 
cyclohexadiene.
We attempted to then generate the acid derivative of the 5-FU prodrugs 57 and 60 by 
selectively cleaving the benzyl moiety. Using both Felix et al. (1978) and Menger et al. 
(1997) procedures we dissolved the esters in acetic acid and stirred until completely 
dissolved (F ig u r e  67).158,151 To this we added 10% Pd/C and 1,4-cyclohexadiene 
(hydrogen source) and allowed the reaction to stir. After approximately 2 hours TLC 
monitoring showed the formation of a new base line spot. The reaction was filtered 
through celite and washed with acetic acid and evaporated till dry. However, on 
analysis of the white solid we discovered that the entire benzyl ester was cleaved 
leaving only the 5-FU (F ig u r e  68).
F ig u r e  68. U n s u c c e s s f u l  d e b e n z y l a t i o n  r e a c t io n  o f  57  a n d  60.
This led us to try the Tsuji procedure (1 9 7 9 ), 159 which uses anisole and aluminium 
trichloride as reagent (Fig u r e  69). Mechanistically, the aluminium trichloride has a 
high affinity for oxygen hence coordinating itself to the carbonyl oxygen, which in turn 
assists in the generation of the benzyl cation that is then trapped by anisole.
CI-AICI2 R-C=0
I r +0  +  CH,Ph +  Cl
1 2
a ic i2 l
o n
c h 3o c 6h5
57 and 60
CH3OC6H5.CH2Ph +  HCI
F ig u r e  69. T s u ji d e b e n z y l a t i o n  r e a c t i o n  m e c h a n i s m .
However, as with the Felix et al. (1978) and Menger’s et al. (1997) methods a base line 
spot formed after approximately 10 minutes. The reaction was diluted with ethyl 
acetate and treated with dilute HC1. The organic layer was separated and concentrated 
to give a white residue. On analysis it was discovered that the reaction was again 
yielding only 5-FU.
2.0.7. Substitution of nitroaromatic moiety
Due to the unforeseen problems associated with the synthesis of a suitable nitrobenzyl 
5-FU  prodrug with an appropriate linker we decided to abandon this approach. An 
alternative approach to link our prodrug into PcSi was to use the nucleoside 5- 
fluorouridine 20 (Figure  70). Since not only is 5-fluorouridine a metabolite of 5-FU , it 
also possesses a sugar attachment with a primary hydroxy group that could act as a 
possible linker to the photosensitiser.
F igure  70. 5-Fu r d  20 a n d  P s c o n ju g a ted  5-FU  p r o d r u g  50.
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Given that the prodrug 3-(p-Nitrobenzyoxycarbonyl)-5-fluorouracil is too labile for 
further modifications to its structure, we decided to concentrate on the more stable 3-(p- 
nitrobenzyl)-5-fluorouracil prodrug. Therefore, with the p-nitrobenzyl moiety acting as 
the trigger for the prodrug we set about synthesising a series of 3-(p-nitrobenzyl)-5- 
fluorouridine prodrug derivatives that would eventually be linked to a photosensitiser 50 
(F igure 70).
2.1. 5-Fluorouridine protection
Due to the expense of 5-fluorouridine 20 (Figure  70) it was decided to initially work on 
the inexpensive parent nucleoside uridine 67 (Fig ure  71). This provided us with a 
cheap starting material to use in our protocol design.
We attempted to eliminate any possibility of unwanted side reactions by selectively 
protecting the two secondary hydroxyl groups C-2 and C-3, while leaving the primary 
hydroxyl at C-5 free to react with the photosensitiser. Of the numerous protection 
groups available for this selective protection [i.e. cyclic acetals and ketals, chiral 
ketones, cyclic ortho esters, silyl derivatives, cyclic carbonates and cyclic boronates]160 
it was decided to use the isopropylidene group 68 (Fig ure  71), because it has been 
proven to be a cheap and reliable method of simultaneously masking the C- 2 and C-3 
hydroxyls of the nucleoside.
0 0 o
20 67 68
F ig ure  71. Str u c tu r es  of 5 -FU R D , u r id in e  a n d  a c e t o n id e .
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2.1.1. Nucleoside protection using tosic acid
We decided to apply a method developed by Reese et al. (1975)161,134 to protect the 2’,
3’ hydroxy groups of both uridine and 5-fluorouridine. This method involved the 
stirring of the nucleoside overnight with p-toluenesulfonic acid in the presence of 2,2- 
dimethoxypropane in dry acetone. The nucleosides were successfully converted to the 
protected nucleosides 68 and 69 (F ig u r e  72). After recrystallisation the protected 
nucleosides 68 and 69 were obtained in 83% and 70.1% yields, respectively.
F ig u r e  72. P r e p a r a t i o n  o f  a c e t o n id e s  68 a n d  69. Reagents: i) TsOH, 2,2- 
dimethoxypropane, acetone, 25°C, 16 hours.
2.2. Nitro-aromatic nucleoside synthesis
The conjugation of the nitrobenzyl moiety to 20, 68 and 69 was attempted using a 
similar procedure to that of Lin et al. (1 9 8 6 ) were he reported the synthesis of the 
prodrug 3-(p-nitrobenzyl)-deoxy-5-fluorouridine.
0 0
0
F ig u r e  73. R e a c t io n  s e q u e n c e  f o r  t h e  s y n t h e s is  o f  2 ’3 - is o p r o p y lid e n e -N 3-(p- 
n it r o b e n z y l) -u r id in e .
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The procedure we followed involved treating the protected nucleoside with nitrobenzyl 
bromide and potassium carbonate in DMF. The reaction was allowed to stir at room 
temperature until all starting materials were consumed (monitored by TLC). The 
reaction mixture was filtered and concentrated; further washes with ethyl acetate were 
required to remove the remaining potassium bromide. The crude product was further 
purified by silica gel chromatography to generate 2’3-isopropylidene-N3-(p- 
nitrobenzyl)-uridine 70 (Fig ure  73) and 2’3-isopropylidene-N3-(p-nitrobenzyl)-5- 
fluorouridine 71 (Fig ure  73), in 66%  and 78% yields, respectively.
Using a similar procedure as above we generated the N3-(p-nitrobenzyl)-5-fluorouridine 
prodrug 72 (Fig u r e  74 in 78% yield from the unprotected 5-fluorouridine.
F igure  74. Str u c tu r e  o f N 3- (p -n it r o b e n z y l)-5 -flu o r o u r id in e  72.
2.2 .1 . Enhancing the reduction potential of nitro-benzvl-5-FURD prodrugs
With the successful development of a synthetic protocol to 72 we now turned our
attention to the introduction of other fiintionalized nitro aromatics.
It has been reported that the reduction potential of nitro aromatic compounds can be 
increased by the presence of electron withdrawing substituents (Fig u r e  75). So 
substitutents like acetyls, nitro, halogens and to some extent methyl groups should 
enhance the reduction potential of the nitro group.
OH OH
72
76
Electrons been pulled from the ring 
Favouring N 0 2 reduction
F igure  75. E ffect  of elec tr o n  w it h d r a w in g  su b st it u e n t  on  n itr o -arom atic
R IN G .
The position of the electron-withdrawing group (ewg) in relation to the nitro moiety has 
also a major influence over the ease of reduction. It has been reported that ewg 
positioned at the 4 position of the benzene ring allows for the highest reduction 
potential, while the ewg postioned at the 2  positions generates the lowest (F ig ure  76).
The further the EWG is from N 0 2 
the higher its reduction potential
F igure  7 6. T he effect  of e w g  po sitio nin g  o n  the  n it r o -ar o m a tic  r in g .
This phenomenon can be partially explained by way of resonance, where the 4-postion 
substituent allows for extended resonance of the reduction intermediate followed by the 
3 and 2 postion. It should be noted that substituents at the 3 and 2 position can interfere 
with reduction via steric hindrance.
F igure  77. N itro ar o m a tic  r in g  r e s o n a n c e .
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With this in mind we attempted to synthesise a series of nitro-aromatic prodrug 
derivatives that should possess more desirable reduction potentials. Since, we have 
already synthesised a 4-nitrobenzyl-5-fluorouridine derivative, we believed it possible 
to prepare the new derivatives using these similar reaction conditions (F ig u r e  78). The 
only problem that could arise is that the substitutents could sterically hinder the benzyl 
halide therefore inhibiting the reaction from occurring.
F ig u r e  78. S e r ie s  o f  p o t e n t i a l  n i t r o -a r o m a t ic  -5  -F U  p r o d r u g s  .
Using the same procedure for the synthesis of 72, we generated N -(4- 
nitrobenzylfuran)-5-fluorouridine 73 in 48% yield, N3-(4-chloro-2-nitrobenzyl)-5- 
fluorouridine 74 in 54% yield and N3-(3-nitrobenzyl)-5-fluorouridine(75) in 70% yield 
(F ig u r e  79). Thus, steric hinderence was not a problem.
78
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F ig u r e  79. R e a c t i o n  s c h e m e  f o r  t h e  g e n e r a t io n  o f  p r o d r u g s  73,74 a n d  75. 
Reagents i) appropriate benzyl halide, DMF, K2CO3 .
73 R =
74 R =
75 R =
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2.3. Choice of Photosensitiser
Although we could have picked a number of photosensitisers suitable for PDT we 
decided to limit our search to one that was commercially available and would allow for 
the direct substitution of our prodrug in a single step. In doing so we found that the 
photosensitiser dihydroxysilicon phthalocyanine 76 (Fig ure  80) offers each of the afore 
mentioned criteria.
76 77
F igure  80. D ih y d r o x y sil ic o n  p h th a l o c y a n in e  a n d  its pr o d r u g  d e r iv a tiv e .
Not only is this phthalocyanine commercially available but it also offers two free 
hydroxyl groups for prodrug linkage 77 (Figure  80). Thus, the decisive advantage of 
using this class of photosensitiser is that it allows for double substitution of the prodrug, 
thereby delivering two parts prodrug to one part photosensitiser to the cell.
To test if this compound could be synthesised we decided to use the cheaper compound 
2’3-isopropylidene-N3-(p-nitrobenzyl)-uridine 70 (Fig u r e  73) and attempt to couple it 
to the phthalocyanine carrier 76 using a typical condensation reaction and sodium 
hydride reaction. 134, 137, 162 To test that our prodrug-photosensitiser could be 
synthesised we examined both procedures.
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2.3.1. Condensation reaction
A condensation reaction was reported for the conjugation of PEG groups to 
dihydroxysilicon phthalocyanine 7 6 .162 Therefore, we initially attempted to synthesise 
the target compound using these conditions. This involved refluxing the 2’3- 
isopropylidene-N3-(p-nitrobenzyl)-uridine 70 with dihydroxysilicon phthalocyanine 76 
(F igure  81) in dry D M F while monitoring by TLC. After approximately 1 hour a fast 
eluting spot formed that became more intense as the reaction proceeded. However, this 
spot appeared to be a co-elution of two fractions. This was clarified when the mobile 
phase was adjusted. The reaction was stopped after 3 hours. An identical reaction was 
allowed to run over-night but the resulting TLC profile was indistinguishable to that of 
the 3-hour reaction. The reaction was cooled to room temperature, filtered,
concentrated to give a blue residue that was re-dissolved in dry THF. The fractions 
were separated and collected by flash chromatography, to give the product 78 in 26% 
yield.
76 70
78 R =
O O
X
F ig u r e  81. The pr epa r a t io n  of 78 u sin g  bo th  c o n d e n sa t io n  a n d  h y d r ide  
pr o c e d u r e s .
O-R
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2.3.2. Sodium hydride reaction
This reaction type was reported for the conjugation of large dendritic substitutents to the 
phthalocyanine.134 The compounds 70, 76 and sodium hydride were dissolved in 
toluene and heated to 80°C for 4 days and monitored by TLC. Multiple spots were 
formed after a couple of hours and no change was observed after 4 days. To ensure that 
the reaction had gone to completion an identical reaction was allowed run for 7 days but 
no difference was observed in the TLC profile of the 4 day and 7 day reactions. The 
purification of the crude product involved initially removing the unreacted Pc by 
flushing through a silica gel (DCM: MeOH v/v 10:0.5) column prior to dissolving the 
crude material in THF and passing it through a size exclusion column (SX-3 
polystyrene) to isolate the product. Since our product is the largest entity in the mixture 
we concluded that it should be the first to elute. However, on TLC analysis of the 
eluted product more than one spot was observed. Therefore, the eluted crude mixture 
was dissolved in dry THF and gravity filtered to remove any insoluble starting material. 
The crude product was filtered twice more and concentrated down to a minimum to 
allow for it to be applied to the silica-gel column (SGC). The first fraction to elute off 
the column was collected along with the other fractions. The first fraction was analysed 
by MS and UV-Vis and it was determined to be the prodrug derivative dioxysilicon-2’3- 
isopropylidene-N3-(p-nitrobenzyl)-uridine-phthalocyanine 73 in 32% yield. The UV- 
Vis spectrum (Figure  83) showed a distinctive red shift of lOnm, which is highly 
characteristic for axially alkoxy substituted PcSi (Ta b l e  10). Electrospray ionization 
(ESI) for Pc’s is rare but compound 78 did ionize by ESI with a molecular parent ion 
peak at 1399, which takes into account the ionized product and Na+(F igure 82).
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F i g u r e  82. M a s s  s p e c t r a  o f  c o m p o u n d  78 
T a b l e  10. U V-Vis d a t a  f o r  t h e  p r o d r u g  78.
ComDOund fin DMSO) Wavelength fnm)
76 672
78 682
83
W avelength (mu)
F igure  83 UV-Yis of 76 a n d  78
Although both methods, condensation and hydride, gave the targeted conjugated Pc-5- 
FU prodrug 78 obvious advantages were noted for the condensation method over the 
hydride method. As can be seen from Ta b l e  11 the condensation method has the added 
advantage of not only generating the Pc-5-FU prodrug in 26% yield but the reaction 
time is short, 3 hours with purification only taking a single silica-gel column (SGC). In 
comparison apart from the slightly superior yield of 32% the hydride reaction procedure 
requires longer reaction times and is more tedious to purify.
Ta b l e  11. C o m par iso n  of the c o n d e n sa t io n  a n d  h y d r id e  pr o c ed u res  to
G E N E R A T E  PC-5-FU C O N J U G A T E  P R O D R U G .
Data Condensation Hvdride
Yield 26% 32%
Time 3 hours 4-7 days
Purification SGC SGC, gel permeation, SGC
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2.3.3. Synthesis of the 5-FU prodrug pthalocvanine conjugate 
Now that we have developed a robust method to prepare our Pc-conjugates we set about 
generating a series of 5-FU-prodrug conjugates, using the condensation reaction 
protocol. We therefore, refluxed N3-(p-nitrobenzyl)-5-fluorouridine 72 (Figure 74) 
with the dihydroxysilicon phthalocyanine 76 in dry DMF while monitoring by TLC, the 
molecular model of which is shown in F igure  85. The reaction was stopped after 3 
hours had elapsed as no other spots were formed; we again noted two co-eluting spots. 
The reaction was cooled to room temperature, filtered and concentrated down to a 
minimal volume were it was purified by column chromatography. Separation of the 
fractions proved cumbersome with only one fraction being isolated. The UV-Vis 
spectrum (F igure  86) for this sample gave an absorption at 678nm, which showed a 
red-shift of 8 nm when compared to the absorbance of the phthalocyanine starting 
material (Ta b l e  12). However, on analysis of this fraction via mass spectrometry we 
obtained a cluster with a molecular mass of 1347 (Figure  87), this value takes into 
account the molecular mass of 1332 for the compound bis(3-(p-nitrobenzyl)-5- 
fluorouridine)phthalocyaninosilicon (79) (Figure  84), which still leaves a mass 
difference of 15. This difference could be attributed to the addition of a methyl group to 
one of the hydroxyl groups in the nucleoside. Thus, 1347 would be an M+1 peak for 
such a compound. An alternative explanation for the mass difference of 15 would be 
the possiblity of two Li+ being present. We believe this to be very unlikely since this 
would lead to an M+2 ionisation that would give an M/2 cluster. This same peak was 
observed a second time from a second reaction, thus it is indeed a real peak, but a 
reliable assignment can’t be made.
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F ig ure  84.
F igure  85.
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Sy n th e sis  of 79. Reagents for reaction: i) DMF and reflux 3hours,
M o lec u la r  m o d e l  of 79  (H y per c h em  M M +)
86
W avelength (lun)
F ig u r e  86. UV-Vis spe c tr a  o f  76 a n d  79
Ta b l e  12. UV-Vis d a t a  fo r  th e  p r o d r u g  79
Compound (in DMSO) Wavelength (nmi
76 670
79 678
87
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F i g u r e  87. M a s s  S p e c t r u m  o f  79
We also used the same procedure to prepare the 5-FURD prodrug bis-(5-fluorouridine) 
phthalocyaninosilicon 80 from 5-flurouridine 20 and dihydroxyoxysilicon 
phthalocyanine 76 (F ig ure  88), to generate the product 80 in a 10% yield, the molecular 
model of which is shown in Figure  89. This product was confirmed again via mass 
spectrometry and UV-Vis analysis. The UV-Vis spectrum (F igure  90) gave a peak red 
shifted by lOnm in the red (Ta b l e  13). Mass spectral analysis (Figure  91) showed a 
molecular ion peak of 1089, which takes into account the molecular mass of 1066 for 
the product bis-5-fluorouridine-phthalocyaninosilicon 80 plus a sodium ion (M+Na).
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F ig u r e  8 8 . S y n t h e s is  o f  80. R eagents for reaction: i) D M F and reflux 3 hours.
F ig u r e  89. M o l ec u la r  m o d e l  of 80  (H y per c h em  M M +)
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F ig u r e  90. UY-Vis spe c tr a  fo r  c o m po u n d  80
Ta b l e  13. UV d a t a  f o r  the p r o d r u g  80
Compound (in DMSO) Wavelength (nm)
80 680
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F ig u r e  92. S y n th e s is  o f  80A, 80B a n d  80C. Reagents for reaction: i) DMF and 
reflux 3 hours.
A similar procedure was used to prepare prodrugs 80A, 80B and 80C from N -(4- 
nitrobenzylfuran)-5-fluorouridine 73, N3-(4-chloro-2-nitrobenzyl)-5-fluorouridine 74 
and N3-(3-nitrobenzyl)-5-fluorouridine75 respectively (F ig ure  92). The appropriate 5- 
FU  prodrug was refluxed with dihydroxyoxysilicon phthalocyanine 76 (Figure  92). To 
generate the respective products 80A, 80B and 80C in a 41%, 28% and 30% yield. 
These products were confirmed by UV-Vis analysis (Ta b l e  14.). Like prodrugs 80, 79 
and 78 a lOnm red shift peak was observed for each prodrug. However, when mass 
spectral analysis was attempted using electrospray ionisation no molecular ion peaks 
were found.
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T a b le  14. UV d a t a  f o r  t h e  p r o d r u g s  80 A, 80B a n d  80C
Compound fin DMSO) Waveleneth fnm)
80A 682
80B 682
80C 682
2.4. Conclusion.
The ultimate aim o f  this project was the preparation o f  a trigger-effector - 
photosensitiser, which was achieved through the synthesis o f  the five 5-FU- 
photosensitisers prodrugs 79, 80, 80A, 80B and 80C. This was achived with ease when 
the condensation procedure was used resulting in yields ranging from 10% to 41%.
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3.0. More Selective 5-FU Prodrugs: The Synthesis of a Novel 5-FU Prodrug 
To improve 5-FU anticancer selectivity we attempted to prepare a 5-FU prodrug that 
incorporates both a nitro benzyl trigger and a lipophilic handle. We believed that this 
type of 5-FU prodrug may possess enhanced cellular uptake through the action of the 
lipophillic handle, while the nitro moiety would be activated by cancerous tissue. 
Although various 5-FU lipophillic prodrugs have been prepared in the past ( s e c t io n  
1.4.2.2) we believed that a lipophilic carrier ester linked to 5-FU would have enhanced 
lipophilicity and good in-vivo cleavage lability. Our choice of carrier is the isopropyl- 
(2R, 3S)-3-(N-acetyl) amino-2-hydroxy-3-phenylpropionate 83 (F ig u r e  93),165 a 
derivative of the Taxol 85 side chain (2R, 3 S)-N-benzoyl-3 -phenylisoserine 84 (F ig u re  
93).1
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83 84
 ^ H
O H
P h
85
F ig ure  93. Po ssib le  lipophilic  h a n d l e s  a n d  Ta x o l  m o lecule
93
The proposed 5-FU  prodrug that incorporates the taxol side-chain ester 76 is outlined in 
F igure  94 , and its preparation is outlined in Fig ure  95.
86
F ig u r e  94. 5 -F U  p r o d r u g s  8 6 .
72
Fig u r e  95. 5-FU p r o d r u g  72.
We believe that 86 (F ig u r e  95) is an interesting prodrug candidate since, the nitro 
benzyl group will deactivate the 5-FU until it reaches the target area where it can be 
activated either by the reduction environment of the hypoxic cancerous tissue or through 
the administration of nitroreductase. Furthermore, the synthetic strategy we are 
employing requires the 3N-amine to be protected to prevent unwanted side reactions and 
the nitro benzyl group will act as the protection group.
To prepare 86, we needed to conjugate ester 83 to the nitrobenzyl-5-FU prodrug 72. A 
retrosynthetic analysis of our target 86 is outlined in Fig u r e  96.
94
Fig u r e  96.
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Prior to the synthesis of 86 we needed to prepare ester 83, once prepared we believed 
that it can be readily conjugated to 72. Outlined in F ig u r e  9 7  is a proposed synthetic 
route to 83 involving an asymmetric Sharpless aminohydroxylation.
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F ig u r e  9 7 .  P r o p o s e d  s y n t h e t i c  s c h e m e  f o r  83. Reagents i) IP A, trimethylsilyl 
chloride, reflux 4hr, ii) K20 s 0 4, (DHQ)2PHAL, Li0H.H20 , NBA, 
tBu0H/H20,4°C, iii) Li0H.H20 , IPA/H20 , HC1, 0°C.
3.1. Preparation of Ester 83
Using the Sharpless asymmetric aminohydroxylation reaction166,167 we set about 
synthesising 83. Using cinnamic acid 87 as starting material we carried out an 
esterification reaction through the use of trimethylsilyl chloride mediated acidic 
dehydrating conditions to obtain the isopropyl cinnamate 88 in 7 1 %  yield (F ig u re  9 8 ) .
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F igure  98. R e a c tio n  sch em e  for  the  sy n th esis  of iso pr o pyl  c in n a m a t e  88. 
Reagents: i) propan-2-ol, trimethylsilyl chloride, reflux 4hr.
The Nitrogen source in an asymmetric aminohydroxylation reaction has two 
fundamental roles:166
(1) To act as a co-oxidant thereby aiding the aminohydroxylation reaction.
(2) To incorporate a primary amide moiety into the structure of the ester.
We attempted to synthesise primary bromo-amides from di-bromoisocyanuric acid 
90,168 which was prepared from cyanuric acid 91, LiOH and bromine (F igure 99), this 
reagent can then be used in the aminohydroxylation reaction to generate ester 83.
Figure  99.Pr epa r a t io n  of d i-b r o m o iso c y a n u r ic  a c id  90. Reagents i) Li0H,H20  
and Br2.
When the di-bromoisocyanuric acid was refluxed with the appropriate primary amide in 
the dark for 5-6 hours a N-bromo primary amide resulted in moderate to high yield. 
The two primary amides we prepared by this method were N-bromoactamide (NBA) 92 
and N-bromobenzamide (NBB) 93 which were prepared in yields of 85% and 91%, 
respectively.
O H O H
91 90
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N-bromoactamide 92 ( F i g u r e  100) could also be prepared by dissolving the acetamide 
in bromine and subsequently treating it with potassium hydroxide until the solution 
turned yellow, an excess of calcium hydroxide was then added to the mixture.169 Hot 
dichlormethane was then used to extract the NBA from a brine solution, which 
precipitated upon treatment of hexane to give NBA in 37% yield. Both bromoamides 
proved to be quite stable to storage below 0°C over several weeks.
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F i g u r e  100. S y n t h e s i s  o f N B A a n d N B B .  Reagents : i) di-bromoisocyanuric acid 90 
in DCM.
3.1.1. Asymmetric aminohvdroxylation
The synthesis of the isopropyl 83 methyl 95 and t-butyl 96 esters was achieved by using 
standard aminohydroxylation conditions ( F i g u r e  101).167 An alkaline solution of 
potassium osmate was treated with tert-butyl alcohol and chiral ligand (DHQ)2PHAL at 
room temperature followed by dilution, which resulted in a homogenous solution. This 
solution was cooled with rapid stirring to 4°C. Subsequently, N-bromoacetamide was 
added in one portion, followed by either one of the esters. Overnight stirring resulted in 
the formation of 83, 95 and 96, respectively. Isolation was adapted from the Sharpless 
procedure. Addition of sodium sulphite was essential to allow for the effective ethyl 
acetate extraction of organics. Silica chromatography (1:1 ethyl acetate:hexane)
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followed by ethyl acetate/hexane crystallisation provided each of the aforementioned 
esters in respective yields of 75% 83, 58% 95 and 88% 96.
OMe
94a
Ot-butyl
94b
F i g u r e  101. R e a c t i o n  s c h e m e  f o r  s y n t h e s i s  o f  s i d e  c h a i n  d e r i v a t i v e s . Reagents: 
i) K20 s 0 4> (DHQ)2PHAL, Li0H.H20 , NBA, tBu0H/H20,4°C.
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3.1.2. P-Benzamido side chain formation
We also decided to prepare the benzamido derivative 97 ( F i g u r e  102) with the 
intention to couple it to 72. This was achieved using two different procedures outlined 
in F i g u r e s  103 and 104.
The first procedure involved using Sharpless asymmetric aminohydroxylation with 
NBB 93 instead of NBA 92 to generate 84 in 30% yield. Followed by hydrolysis to its 
respective acid via sapanofication yielding 97 in 10% yield. ( F i g u r e  102).170,176 
In the second procedure, compound 83 was prepared via asymmetric 
aminohydroxylation and was then hydrolysed in boiling 10% HC1 over 3 to 4 hours. 
The organic impurities were isolated through an isopropyl ether/hexane wash, to yield 
the acid 98. Conversion of acid 98 to the hydrolysed benzamido product 97 ( F i g u r e  
103) proceeded efficiently via direct benzoylation, although the formation of sodium 
benzoate gum did hamper the isolation leading to a yield of 72% .165’170’176
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F ig u r e  102. R e a c t io n  sc h e m e  f o r  t h e  p r e p a r a t io n  o f  97. R eagents i) IP A , 
trim ethylsilyl chloride, reflux 4hr, ii) K 2OSO4, (D H Q )2PFIAL, L i0 H .H 20 ,  N B B , t- 
B u 0 H /H 20 ,4 ° C , iii) L i0 H .H 20 ,  IPA /H 20 ,  HC1, 0°C.
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F i g u r e  103. R e a c t i o n  s c h e m e  f o r  t h e  p r e p a r a t i o n  o f  97. Reagents i) HC1, refux, 4 
hrs, ii) BzCl, NaOH, H2O.
3.1.3. Protection of 83 prior to coupling
The next step toward the preparation of 83 involved a DCC coupling. Since 
epimerisation is known to occur under DCC conditions we envisaged a need to protect 
83 prior to its use.172 Therefore, a decision had to be made whether to start the 
laborious task of selectively protecting the C’-2 hydroxy group ( F i g u r e  104) of the side 
chain with various protecting groups prior to coupling, or to try to find an easier quicker 
alternative.
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F i g u r e  104. H y d r o x y l  g r o u p  o f  83 t h a t  n e e d s  t o  b e  p r o t e c t e d  p r i o r  t o  c o u p l i n g
We decided to convert the isoserine side chain to an oxazolidine 99 ( F i g u r e  105), as 
this structure holds the configuration during the esterification reaction and protects the 
C’-2 hydroxy group from unnecessary side reactions.166
101
Ph C 02R R = CH(CH3)2
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Figure  105. Ox a z o l id in e 99.
3.1.4. Oxazolidine formation
Following a modified Commercon procedure173 for the synthesis of oxazolidines we 
successfully generated our lipophilic oxazolidine 99. This was achieved by preparing a 
toluene solution of 83 ( F i g u r e  106) and treating it with PPTS and 2-methoxypropene. 
Another quantity of PPTS was added and the reaction mixture was heated to 80°C while 
collecting the distillate in a dean stark flask to help drive the reaction to completion. A 
constant reaction volume was maintained with the addition of a toluene/2- 
methoxypropene solution. Upon completion of the 2-methoxypropene additions, a 
small quantity of PPTS was added to ensure product formation and the mixture 
concentrated. Isolation of the product was achieved by silica gel chromatography to 
give 100 in a 10-15% yield ( F i g u r e  106).
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F i g u r e  106. R e a c t i o n  s c h e m e  f o r  t h e  s y n t h e s i s  o f  o x a z o l i d i n e  100 a n d  101.
Reagents: i) 2-methoxypropene, PPTS, toluene, 80°C; ii) UOH.H2O, 
IPA/H2O, HC1, 0°C
Hydrolysis of the ester was achieved by saponification, with lithium hydroxide. Careful 
work up of the resulting salt was achieved through low temperature protonation with 
hydrochloric acid, and then extraction with ethyl acetate gave the desired acid. The 
resultant product 101 was stored below 0°C until required for esterification.
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3.2. Synthesising the Lipophilic-5FU Prodrug
We attempted the synthesis of 86 using DCC coupling conditions. However, prior to 
this it was decided to first test the reaction conditions using the uridine and 5-FURD 
derivatives 68 and 69, respectively (Fig u r e  107).
68 69
F ig ure  107. U ridine  68 a n d  5-F U R D  69 d e r iv a t iv e s .
By using a modified esterfication procedure174 we attempted to generate the desired 
prodrugs (F ig u r e  108). The oxazolidine acid 101 was activated with DCC in toluene at 
room temperature. The reaction was brought to 80°C followed by the addition of 
DMAP and nucleosides 68 and 69 (F ig u r e  108). The mixture was stirred for 
approximately 2 hours until the reaction was complete (reaction monitored by TLC). 
However, the isolation/purification of the product proved tedious because there was an 
appreciably amount of urea contamination, as a result of the urea being partially soluble 
in both the aqueous and organic layers. Therefore, yields ranged from 25% for (102) 
and 45% for 103. The molecular model of 102 is shown in F ig u r e  109.
104
R ea c tio n  sch em e  fo r  sy n th esis  of 5 -F U  pr o d r u g  
Reagents: i) DCC, DMAP, toluene, 80°C, 2hr.
103 R = H 
102 R = F
68 R = H
69 R = F
i
F ig u r e  108. c t r 102 a n d  103.
F ig u r e  109 M o l e c u l a r  m o d e l  o f  102.
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3.3. Deprotection of the Nucleoside Esters
At this point we decided to try to deprotect the hydroxyls in a one step reaction thus 
generating the coupled prodrug (Fig ure  110). If this could be achieved we would then 
turn our attention to the synthesis of prodrug 86.
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F igure  110. On e  po t  d epr o tec tio n  of a c e t o n id e s .
It has been found that several Bronsted acid reagents such as acetic acid, HBr(aq), 
HCl(aq) and F^SO^aq) can be used to selectively cleave terminal isopropylidene 
groups.175 However, although these acidic conditions resulted in cleavage of the 
isopropyl groups the unfavourable a-hydroxyl activated ester hydrolysis was found to 
be unavoidable. (Fig u r e  111).
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Fig ure  111. U n a v o id a b l e  h y d r o x y l  a c t iv a t e d  ester  h y d r o l y sis .
Therefore, these reagents could not be used for the deprotection of our target prodrugs. 
Milder reaction conditions would be needed for its deprotection. Compared to protic 
conditions, Lewis acid based reagents are scarce. A number of Lewis acids have been 
reported for the cleavage of the terminal isopropylidenes in the presence of an internal 
one. Some of these Lewis acids include FeC^ 6H2 0 /Si0 2 , CuCL FbO in ethanol and 
Zn(N0 )3  6H20  in acetonitrile (F ig ure  112). It would seem that in-situ hydrolysis of 
these salts provide the necessary protic medium for hydrolysis. We attempted to take 
advantage of a gentler Lewis acid Zn(NO)3 6H2O in acetonitrile175 which has been used 
previously for the selective cleavage of terminal isopropylidenes.
Zn+ + 6H20  ’ [Zn(H20)6]2++ H20
-  H30 + + [ Zn(H20)50H]+
F ig ure  112. Fo r m a tio n  of a c idic  c o n d itio n s  u s in g  Zn(N0)3 6H20.
However, before we attempted to selectively deprotect our prodrugs we decided to first
test the conditions on the oxazo lid in e 101 and 2 ’,3 ’-isopropylideneuridine 6 8  (F ig u r e
107
113). We dissolved 68 in acetonitrile upon which the Zn(N0 )3  6H20  was added and 
stirred at 27°C. The reaction was monitored by TLC until only a single baseline spot 
remained, after 50 hours a spot that was consistent with uridine remained and was 
confirmed by *HNMR. This reaction was repeated at 50°C with uridine formation after 
8 hours (Ta ble  15.).
F ig u r e  113. Gen e r a tio n  of u r id in e .
Reagents i) acetonitrile, Zn(NO)3 6H20  heated to 50°C.
Like-wise, oxazolidine 101 was dissolved in acetonitrile with Zn(NO)3 6H2O and stirred 
at 27°C (Figure  114). The reaction was monitored over approximately 20 hours until 
only the unprotected side chain spot remained by TLC. Again this reaction was 
repeated at 50°C to yield the acid in 10 hours (Ta b l e  15.).
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F ig u r e  114. D e p r o t e c t io n  o f  o x a z o l id in e  8 8 .
Reagents i) acetonitrile, Zn(NO)3 6H20  heated to 50°C.
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T a b le  15. R e s u l t s  f o r  d e p r o t e c t io n  o f  68 a n d  101 u s in g  Zn(NO)3 6H20  a t  27°C 
a n d  50°C.
Compound number 27°C. 50°C.
10 1 2 0  hours 10  hours
68 50 hours 8 hours
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F igure  115. Re a c tio n  sch em e  for  d epr o tec tio n  of 5-FU  p r o d r u g .
Reagents i) acetonitrile, Zn(NO)3 6H20  heated to 50°C.
Following this, the prodrug derivatives 102 and 103 (F ig u r e  115) were treated as above 
and monitored by TLC. However, after approximately 30 hours at 27°C and 16 hours at 
50°C two TLC spots indicative of the products of ester hydrolysis. Confirming not only 
the isopropylidene protections have been eliminated, but that the unfavourable ester 
hydrolysis reaction had occurred (T a b le  16.). Therefore, the one-pot deprotection 
reaction was unsuccessful, since ester hydrolysis occurred simultaneously to 
isopropylidene cleavage.
T a b le  16. R e s u l t s  f o r  d e p r o t e c t io n  o f  102 a n d  103 u s in g  Z n(N O ) 3 6H20  a t  27°C 
a n d  50°C.
Compound number 27°C. 50°C.
10 2 30 hours 16 hours
103 30 hours 16 hours
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As a result of this we decided to abandon the synthesis of 86, and instead use prodrug 
102 to examine the effect of the ester side chain 83 had on 5-FURD activity. When 
prodrug 102 was tested against SW480 and 4T1 cell lines over a 3 and 5 day period at a 
concentration between 0.1 -0.7|ig/ml we obtained an IC50 value of >7(ig/ml. Instead of 
killing the cells the prodrug has in fact promoted their growth. When this value is 
compared to the 5-FURD 20 and the acetonide derivative of 5-FURD 69 we see that a 
similar value to 69 is obtained. It would seem that the cytoxicity is inhibited through 
the protection of the nucleoside diols, therefore, deactivating the drug. This can be 
explained by the fact that the nucleosides 68 and 69 cannot be converted directly to the 
phosphate metabolites, i.e. pathway is blocked by the acetonide protecting group, unlike 
nucleoside 20. It also appears that the cytotoxicty is further decreased by substitution of 
the oxazolidine moiety. Again this is probably due to the fact that the primary alcohol 
of the prodrug is protected, therefore, prohibiting the direct generation of the phosphate 
metabolites.
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F i g u r e  116. P o s s i b l e  r e a c t i o n  p a t h w a y  f o r  t h e  5 -F U  p r o d r u g  102.
I l l
3.4. Conclusion
Using prodrug 102 as our initial isopropyl deprotection model we found that the ester 
linkage of 102 was too labile to the Lewis acid conditions used, resulting in ester 
hydrolysis simultaneous to isopropyl deprotection. Because of this we abandoned the 
preparation of prodrug 86 until a more subtle deprotection condition could be found. 
However, because the prodrug possesses some lipophilic character through its 
oxazolidine attachment its cellular uptake should be somewhat enhanced when 
compared to 5-FU. This was tested by examing the cytotoxicity of 102 on SW480 and 
4T1 cell lines. The 3 and 5-day cytotoxicity study resulted in IC50 values of >7|ag/ml 
for both studies. However, because the highest concentration tested was 7p,g/ml further 
test would need to be carried to determine the cytotoxic dose of the prodrug. Also the 
synthesis of prodrug 86 in its protected form could also be carried out and tested under 
hypoxia conditions to examine its activation and activity.
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4.0 Novel Deprotection of Acetonides.
As discussed in section 2 the initial design of our nitrobenzyl prodrug 50 incorporated a 
photosensistiser linked via the N 1 of the 5-fluorouracil. In order to prepare this we 
needed to selectively substitute a nitrobenzyl moiety at the N3 of 5-FU hence leaving a 
single hydroxy free for substitution into the photosensitiser. To achieve this we used 
the procedure developed by Lin et al. (1986), which utilises the following conditions, 
1,4-dioxane, benzyl chloroformate, triethylamine dissolved in DMSO at RT (F igure 
117).
However, it was discovered that the conditions used by Lin et al. (1986) did not work 
for 2,3-isopropylidene-5-fluorouridine 69. On investigation it was discovered that when 
the reaction was heated above 50°C an unexpected transformation took place that 
yielded the removal of the isopropylidine protection group to give the parent nucleoside, 
5-fluorouridine 2 0 .
It was therefore initially thought that this new cleavage condition could be used to 
selectively cleave our prodrug 10 2  thereby overcoming the problem of ester hydrolysis 
(F igure  118).
With this in mind it was decided to carry out a study to determine the optimum cleavage 
reaction conditions; by examining the effect of base, temperature, solvent and reagents, 
and secondly to use these results to obtain an understanding of the reaction mechanism. 
Due to the expense of 5-FU we decided to use the less expensive 2,3- 
isopropylideneuridine 68 in these studies.
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F ig u r e  117 . G e n e r a l  d e p r o t e c t i o n  s c h e m e .
Reagents i) 1,4-dioxane, benzyl chloroformate,triethylamine and DMSO at 
>50°C
F ig u r e  118. G e n e r a l  d e p r o t e c t i o n  s c h e m e  f o r  p r o d r u g  102.
Reagents i) 1,4-dioxane, benzyl chloroformate.triethylamine and DMSO at >50°C
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4.1. Base and Temperature Study
Since the organic base triethylamine (TEA) was used in the initial reaction we decided 
to investigate the effect of various bases on the reaction. We first attempted the same 
reaction except at room temperature with the following bases 1 ,8- 
diazabicyclo[5.4.0]undecene (DBU), K2CO3 , pyridine and 4-dimethylaminopyridine 
(DMAP). However, as can be seen from the results in T able 17 no reaction occurred 
after 24 hours at room temperature (RT).
Ta b l e  17. Re su l t s  fro m  B a se  s t u d y  a t  ro o m  tem per a tu r e
Base stoichiometry mMole Temp °C Time hrs Reaction Completion
TEA 1 RT 24 No
DMAP 1 RT 24 No
DBU 1 RT 24 No
K2CO3 1 RT 24 No
Pyridine 1 RT 24 No
Consequently, we decided to repeat these reaction conditions at higher temperatures 
with TEA. We initially increased the temperature to 30°C and the reaction was 
monitored over a two-hour period, with no observable change. The temperature was 
then increased to 50°C and then gradually to 85°C. It was at this temperature that a 
base line spot was observed by TLC while the spot indicative of 2,3-isopropylidene- 
uridine started to disappear. After approximately 12 hours only two spots were 
observed by TLC. At which point the solution was filtered, concentrated and the 
fractions were isolated by flash chromatography (2:3 chloroform:ethyl acetate). 
Analysis of the two spots by NMR showed that the faster eluting spot was the benzyl 
carboxylic acid and the base line spot was in fact uridine.
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We then investigated the other bases (DMAP, DBU, K2CO3 and pyridine) at 85°C. A 
solution of 2,3-isopropylideneuridine in dry DMSO with 1 equivalent of base was 
prepared and allowed to dissolve. To this a 1 equivalent benzyl chloroformate-dioxane 
solution was added drop-wise, and allowed to stir at room temperature for 12 hours. All 
reactions were monitored by TLC. The results of these reactions are shown in Table 18.
T a b l e  18. R e s u l t s  f r o m  B a s e  s t u d y  a t  85°C.
Base Stoichiometry 
in Mole
TemD°C Time hrs Reaction Completion
Triethy lamine 1 RT-85 36 Yes
DMAP 1 RT-85 36 Partial
DBU 1 RT-85 36 Trace
K2CO3 1 RT-85 36 No
Pyridine 1 RT-85 36 Partial
However, while monitoring the reaction by TLC we noticed the formation of a new spot 
for both the DMAP and pyridine reactions. Also, on addition of the DMAP a base line 
spot formed and therefore masked the formation of the product. Even though each of 
the reactions were allowed to run for a total of 36 hours, only the TEA reaction went to 
completion, while both the DMAP and pyridine reactions went to partial completion 
[i.e. 2,3-isopropylideneuridene spot still evident on TLC], The reactions with DBU and 
K2CO3 gave no product. Using the same conditions we then examined the effect of 
base stoichiometry on the reaction. We used the two bases TEA and DMAP since these 
bases gave the best results ( T a b l e  18.). A series of reactions were set up using different 
equivalents of base (0.5-6.0 equivalents) ( T a b l e  19.). Again only the TEA gave 
complete reaction while the DMAP showed partial reaction. Therefore, not only did 
this demonstrate that TEA is the best base for this cleavage reaction but also that its
stoichiometry has no effect on the reaction.
116
Ta ble  19. Re su l t s  fr o m  Tea  a nd  d m a p  base  st u d y .
Base TvDe Stoichiometry mMole Time hrs Result RT Result 85°C
TEA 0.5 36 N Yes
TEA 1.0 36 N Yes
TEA 2.0 36 N Yes
TEA 3.0 36 N Yes
TEA 6.0 36 N Yes
DMAP 0.5 36 N Partial
DMAP 1.0 36 N Partial
DMAP 2.0 36 N Partial
DMAP 3.0 36 N Partial
DMAP 6.0 36 N Partial
We now decided to eliminate specific reagents so as to determine the effect of the 
reagents on the reaction. As a result we decided to first assess the combined role of 
benzyl chloroformate and dioxane. To do this we needed to set up both a “control 
reaction” and a “test reaction”. The control reaction had all the reagents present while 
the test reaction had dioxane removed. As T a b l e  20. below shows the control reaction 
went to completion while the test reaction did not react at all. This led us to believe that 
the presence of dioxane is crucial for reaction success.
Ta b l e  20. Re a c t io n  d e p e n d e n c e  o n  d io x a n e
Reaction tvDe TemD°C Time hrs Reaction ComDletion
Control RT-85 36 Yes
Test RT-85 36 No
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A second reaction was set up to examine the effect of benzyl chloroformate, the control 
had all reagents present, while the test reaction had benzyl chloroformate removed. As 
Ta b l e  21 . shows the control reaction gave product formation while the test reaction did 
not, even after 36 hours had elapsed. It would appear that the presence of both dioxane 
and benzyl chloroformate is imperative for selective acetonide cleavage.
Ta b l e  21 . Re a c t io n  d epe n d e n c e  o n  b e n zy lc h lo r o fo r m a te .
Reaction tvoe TemD°C Time hrs Result
Control RT-85 36 Completion
Test RT-85 36 None
This subsequently led us to assess the role of dioxane and benzyl chloroformte in this 
reaction.
4.2. Dioxane study
While studying the role of 1.4-dioxane on the reaction we discovered that when a 
freshly purchased bottle of 1,4-dioxane was used no reaction occurred. However, when 
we reverted back to the aged 1,4-dioxane a complete conversion to the parent 
nucleoside resulted. From this we concluded that the 1,4-dioxane must generate a 
species when left over time that is essential for reaction success. However, as it is 
known that 1,4-dioxane generates peroxides over time we needed to examine if the 
cleavage reaction was in fact due to the peroxides formed in the 1,4-dioxane. We 
therefore decided to set-up a series of reactions using different grades of 1,4-dioxane 
(i.e. shelf live), and also a single reaction containing 30% solution of hydrogen 
peroxide. The results for which are shown in Ta b l e  22.
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Ta b l e  22. D io x a n e /pero x id e  stud y
Reaction Time (hour) Reaction Completion
Fresh batch of dioxane 48 No
Anhydrous batch of dioxane 48 No
Original dioxane batch 1 2 Yes
30% Hydrogen peroxide 0.5ml 2 Yes
As Ta b l e  22 . shows when the anhydrous and fresh 1,4-dioxane was used no reaction 
occurred, as opposed to the original 1,4-dioxane batch, which resulted in deprotection. 
Furthermore, the reaction containing peroxides also gave cleavage. This would indicate 
that the peroxides formed in the old batch were indeed driving the reaction. Therefore, 
supporting our hypotheses that the peroxides formed over time in the 1,4-dioxane were 
influencing the original reaction. However, it was also observed that when the benzyl 
chloroformate was omitted from the reaction containing peroxide no reaction occured. 
From these studies it would appear that the required reagents for this cleavage reaction 
are peroxide, tertiary amine and acid chloride. This hypothesis was further tested and 
confirmed by a series of experiments outlined in Ta b l e  23
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Ta ble  23. B en zy l  c h lo ro fo r m a te  a nd  pero x id e  a d d itio n  st u d y .
Benzvl derivative Peroxide Solvent TEA Reaction Completion
Yes Yes DMSO Yes Yes
Yes Yes DMSO No Yes
No Yes DMSO Yes No
No Yes DMSO No No
Yes No DMSO Yes No
Yes No DMSO No No
An investigation into the effect of peroxide stoichiometry was carried out and results are 
outlined in T a b l e  24. We discovered that 100^1 of 30% peroxide was required to 
deprotect the acetonide (0.33mmol). It was also discovered that when the peroxide 
quantity was increased to 2ml that the reaction still went to completion ( T a b l e  24.). 
However, as demonstrated previously when the peroxide was removed no reaction took 
place. This study demonstrates that the cleavage reaction is independent of peroxide 
stoichiometry.
Ta b l e  24. R esu lts  from  per o x id e  s t u d y  o n  0 .3 3 m m o l  ac eto n id e
Peroxide amt Benzvl amt mMole DMSO ml Reaction Completion
lOOul 0.33 3 Yes
2 0 0 jj.1 0.33 3 Yes
0.5ml 0.33 3 Yes
1 .0ml 0.33 3 Yes
2 .0ml 0.33 3 Yes
0ml 0.33 3 No
lOOyl 0 3 No
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4.3. Benzyl Chloroformate Study
Following on from the previous study we decided to investigate the effect of the 
stoichiometry of benzyl chloroformate on the reaction. Reactions with 0.5, 1.0, 1.5, 2.0 
and 5 equivalents of benzyl chloroformate were examined and the results are outlined in 
T a b l e  25. No obvious difference was observed when the reactions were compared by 
TLC. This study indicates that the benzyl chloroformate may be acting as a catalyst 
since the reaction is independent of benzyl chloroformate stoichiometry, and all of the 
benzyl chloroformate is isolated from the reaction mixture as the acid.
T a b l e  25. R e s u l t s  f r o m  b e n z y l  s t u d y  ( i n  H20 2, TEA, 85°C a n d  d m s o ).
Acid chloride (eauiv) Time/temDerature Reaction completion
0.5 2 hr/85°C Yes
1.0 2 hr/85°C Yes
1.5 2 hr /85°C Yes
2.0 2 hr /85°C Yes
5.0 2 hr/85°C Yes
We also examined the order of addition of reagents, (i.e. peroxide first followed by 
benzyl chloroformate and also the reverse order). It was noticed that a specific order 
needed to be followed; benzyl chloroformate first followed by peroxide and heat. When 
we added the peroxide before the benzyl chloroformate and heated to 80°C the reaction 
did not go to completion and did not change much after 3 hours. We also tried to add 
the peroxide to the benzyl chloroformate direct but it would not mix so it had to be 
diluted with DMSO and left to react. But again no reaction was observed after 12 
hours.
121
4.4. Solvent Study
We set up a solvent study to determine the effect of solvent on both reaction rate and 
yield. It was also found that when we changed the solvent from DMSO to DMF no 
reaction occured (Table 26.). It would appear from these results that DMSO is the 
solvent of preference for this cleavage reaction. This fact was further verified when we 
used methanol, acetonitrile and toluene, no reaction took place. We subsequently 
decided to study the effect of dilution on the reaction. A minimum amount of DMSO 
was added just to keep the solutes in solution and followed the reaction protocol, again 
no reaction was observed.
T a b l e  26. R e s u l t s  o f  s o l v e n t  s t u d y .
Solvent Time / temperature Reaction Completion
DMSO 1 hr /85 °C Yes
DMF 1 hr /85 °C No
Methanol 12 h/ 85°C No
acetonitrile 12 h/85°C No
toluene 12 h/ 85°C No
4.5. pH Effects
We suspected that the reaction medium turns from neutral to acidic over the course of 
the reaction, we decided to test this by monitoring the pH of the reaction by taking 
aliquots at different stages. The initial pH was 6-7 when the reaction was initially 
heated to 85°C. As the reaction started, an exotherm occurred and the temperature 
increased to 110° C, and the pH was 5. When the reaction temperature settled down to 
85°C the pH was found to have dropped to a value of 3. This result demonstrates that as 
the reaction progresses acid is being generated, thus the deprotection reaction is aided
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by acidic conditions. This result may also explain why the addition of base lowers the 
rate of reaction (Ta b l e  27.).
Ta b l e  27. pH St u d y  (in  per o x id e , 85°C a n d  DMSO).
Stase Tem perature °C n il
1 85 6-7
2 1 1 0 5
3 85 3
Therefore, because an acid species is being generated during the course of the reaction it 
would seem logical to assume that the acid chloride could supply the required acid 
moiety, via hydrolysis (Figure  119). This assumption was supported by the 
confirmation of the presence of the carboxylic acid viaNMR analysis.
O
U
+  H C I
However, because the reaction uses peroxides for its progress we cannot rule out a 
radical reaction. We decided to test this theory. If the reaction is indeed a radical 
reaction then it should be inhibited by the presence of a radical scavenger. We decided 
to test this hypothesis by setting up 5 reactions using four different scavengers. As can 
be seen (T a b l e  28.) all reactions were inhibited by the scavengers. These results 
further support that the reaction may indeed be a radical reaction.
F igure  119. H y d r o l y sis  of a c id  c h lo r id e .
Reagents i) H2O.
123
T able  28. E ffect  of a d d itio n  of sc a v e n g er .
Scavenaer Time/temperature Reaction Completion
Methanol 2 hr/85°C No
Pyrogallol 2 hr/85°C No
1,4-cyclohexadiene 2 hr/85°C No
T ritylmethy lchloride 2 hr/85°C No
Blank 2 hr/85°C Yes
*Each reaction was allowec to run for 36 hours
But the question remains as to the role of benzyl chloroformate in the radical reaction. 
We believed that it had to be playing a vital part in the reaction because without it the 
reaction would not proceed. Given that benzyl groups can form stable radicals we 
decided to test if other benzyl derivatives could work in this reaction, this will aid us in 
determining if benzyl chloroformate is behaving as a radical. Results of these studies 
are outlined in Ta b l e  29 . When phenyl chloroformate was used no reaction occurred, 
this reagent possesses an acid chloride but is lacking a benzyl carbon. These results 
indicate that a radical intermediate may indeed be involved in this reaction.
T a ble  29 . E ffect of d iffer en t  b e n z y l  r e a g e n t s .
Radical Base Time Reaction Completion
p-nitrobenzyl- chloroformate Yes < lhr Yes
p-nitrobenzyl-chloroformate No < 2 0  min Yes
Benzyl- chloroformate Yes < lhr Yes
Benzyl-chloroformate No < 2 0  min Yes
p-nitrophenyl-chloroformate Yes 36 hr No
p-nitrophenyl-chloroformate No 36 hr No
124
4.6 Reaction Mechanism
Prior to the study our initial understanding of the reaction mechanism was inconclusive. 
However, after post-test analysis we believe that the reaction may be occurring through 
two possible mechanisms, 1) a hydrolysis reaction or 2) a free radical reaction. This 
was founded on the following observations:
4.6.1. Hydrolysis reaction mechanism
(1) An acid chloride is necessary for reaction success. (Section 4.3.)
(2) The acid chloride is hydrolysed generating an acid. (Section 4.5.). Acidic medium 
is generated as the reaction progresses. (Section 4.5.)
(3) The reaction rate is slower when TEA is present.
(4) The possible formation of a peroxyacetic acid 81 ( F i g u r e  120).
It has been reported that a peroxyacetic acid can be prepared from acetic acid and 
hydrogen peroxide in the presence of an acid catalyst.163’ 164
F i g u r e  120. F o r m a t i o n  o f  p e r o x y a c e t i c  a c i d .
Therefore, it is plausible to assume the acidic conditions necessary for deprotection is 
provided through the formation of a peroxy acetic acid and subsequent HC1 by­
products. This would explain points 1-4 above. Thus, there are possibly three acid 
sources present 1) hydrolysised acid, 2) HC1 and 3) peroxyacid. ( F i g u r e  121)
O O
(81)
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F igure  121. Ge n e r a t io n  of a n  ac idic  e n v ir o n m e n t  th ro ug h  h y d r o ly sis  a n d
P E R O X Y A C I D  F O R M A T I O N .
4.6.2. Possible free radical role?
(1) Hydrogen peroxide was necessary for reaction success. (Section 4.2.)
(2) Heat was required to initiate the reaction (Section 4.1.)
(3) The addition of radical scavengers inhibited the reaction. (Section 4.5.)
(4) Reaction was dependent on the formation of stable radical intermediates. 
(Section 4.5.)
It is possible that radicals are formed during the reaction and may ultimately lead to 
acetonide deprotection. The fact that radical scavengers inhibit the reaction (T a b l e  28.) 
and that the presence of a benzyl carbon is required (Ta b l e  29.) indicates that a radical 
species maybe formed. Outlined in F ig ure  122 is a proposed mechanism as to the 
possible role of a radical species in this reaction. This mechanism does explain the 
formation of acidic species as the reaction progresses.
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F i g u r e  122 .  P o s s i b l e  r a d i c a l / h y d r o l y s i s  r e a c t i o n  m e c h a n i s m .
The key to the su ccess o f  this reaction depends on the generation o f  acid, whether it 
occurs by hydrolysis or radical or both (F igure 123).
« A  hn
H 0 ____ 0  o  V  0 < n N  0 <?^ NH 0 ^  H O ----- ________________-  HO---- .. .O  ■
O O -H
H ,0 /  \
F ig u r e  123. S chem e  f o r  th e  d epr o te c tio n  of  2 ,3 -iso pr o py l id en eu r id in e .
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A final study was carried out to determine the selectivity of the acetonide group over 
other labile protecting groups using our reaction conditions. We decided to use 5-trityl- 
2, 3-isopropylideneuridine 82 ( F i g u r e  124) which is labile to both acidic and basic 
conditions. Following the aforementioned deprotection reaction conditions (with and 
without the presence of base) we discovered that the trityl group was selectively cleaved 
while the acetonide remained unaffected (48% and 34% yield, respectively).
O
82
HNA
68
F ig u r e  124. R e a c t io n  sc h e m e  f o r  s e l e c t i v e  d e p r o t e c t io n  o f  5 - t r i t y l - 2 ,  3- 
i s o p r o p y lid e n e u r id in e  82.
4.7. Conclusion
In conclusion, while preparing prodrug 50 we discovered a new deprotection procedure 
to deprotect the nucleosides 2,3-isopropylidene-5-fluorouridine and 2,3- 
isopropylideneuridine to their parent nucleosides. This was achieved by developing and 
optimising the reaction conditions; 30% hydrogen peroxide 200^1, a 1:1:1 stoichometry 
of acetonide, benzyl chloroformate in the presence or absence of base, dissolved in 
DMSO at 85°C. Yields ranged between 42-58% ( T a b l e  30. & 31.) after 20 minutes 
when no base was present, while similar yields were obtained with base after 1 hour.
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However, although we initially thought that this procedure could selectively remove the 
isopropyl moiety of prodrug 102, thus generating prodrug 105. We deemed that the 
reaction conditions would be too harsh, thereby cleaving the more labile ester.
We also found that by using our reaction conditions we could selectively remove the 
trityl group of 5-trityl-2,3-isopropylideneuridine thus generating 2,3- 
isopropylideneuridine, in a 48% yield, leaving the isopropylidene intact.
The reaction scheme is believed to follow that of a free radical/acid hydrolysis 
mechanism, since both reactions produce the acidic environment necessary for 
acetonide cleavage. However, further test would be needed for a definitive answer.
T a b l e  30. Yields for reaction with in the absence of base.
Protected Nucleoside P r o d u c t Y i e l d
2,3 -isopropylidene-5-fluorouridine 5-fluorouridine 45%
2,3-isopropylideneuridine Uridine 58%
5-trityl-2,3-isopropylideneuridine 2,3 -isopropylideneuridine 48%
T a b l e  31. Yields for reaction in the presence of TEA
Protected Nucleoside P r o d u c t Y i e l d
2,3 -isopropylidene-5 -fluorouridine 5-fluorouridine 42%
2,3-isopropylideneuridine Uridine 50%
5-trityl-2,3-isopropylideneuridine 2,3 -isopropylideneuridine 34%
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5.0. B io lo g ic a l  D a ta
The biological data reported within this thesis was carried out by Aisling Redmond of 
Dr. Susan Me Donald’s cellular biology research group at DCU.
It was decided to test the 5-FURD and 5-FU prodrugs for cytotoxicity using normal 
oxygenated conditions prior to their hypoxic cytotoxicity evaluation using human colon 
cancer cell line and 4T1, a murine mammary cancer cell line. The cell lines were 
cultured under standard conditions, allowed to attach overnight in 96-well plates and 
then treated for three and five days to determine the IC50 values (inhibitory 
concentration that killed 50% of the cells). From T a b l e  34 it can be seen that most 
toxic compounds were the derivatives of 5-FU, specifically the ester derivatives, with 
IC50 values ranging from 1.53|_iM to >250|aM for three day treatment in the SW480 cell 
line and 0.25(iM to >302)aM for five day treatment. The IC50 values were lower for the 
4T1 cell line, ranging from 0.035p.M to >250(iM for three day treatment and 0.013jjM 
to 150p.M for five day treatment.
T a b le  34. S h o w in g  i c 50 v a l u e s  f o r  4 t1  a n d  sw 4 8 0  c e l l  l in e s
Compd. IC50 Values 4T1 cell Line IC50 Values SW480 Cell Line
3 Days 5 Da\/s 3 Days 5 Days
ufl/ml mM ug/ml mM ufl/ml mM ug/ml mM
5-FU 10 0.05 0.38 0.02 0.15 0.80 6.15 0.40 3.08
FU 51 0.25 0.81 0.01 0.03 3.50 11.33 1.00 3.24
FU 52 60 226 5 19 40 151 80 302
FU 53 ND >100 >250 60 150 ND >100 >250 ND >100 >250
FU 57 0.10 0.45 0.01 0.04 2.50 11.26 0.70 3.15
FU 58 0.09 0.20 0.06 0.13 0.70 1.53 0.60 1.31
FU 59 0.009 0.035 0.005 0.018 0.40 1.64 0.06 0.25
FU 60 0.3 0.79 0.005 0.013 4.50 11.90 2.00 5.29
FURD 20 0.005 0.02 ND <0.001 <0.004 0.10 0.38 0.06 0.23
FURD 69 ND >100 >332 70 233 ND >100 >332 ND >100 >332
FURD 71 ND >7 >16 ND >7 >16 ND >7 >16 ND >7 >16
FURD 72 ND >3 >8 ND >3 >8 ND >3 >8 ND >3 >8
FURD 102 ND >7 >13 3.5 6.40 ND >7 >13 ND >7 >13
*ND = Not Determined
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F ig u r e  125. Str u c tu r es  for  the  bio lo g ic a lly  tested  p r o d r u g s .
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The metabolites of 5-FU 10 are 5-fluorouridine-tri-phosphate, 2'-deoxy-5'-fluororidine 
mono-phosphate, and 2-deoxy-5-fluorouridine-triphosphate ( s e e  s e c t i o n  1.4). These 
are intracellular toxic forms of 5-FU and result in both DNA and RNA directed damage. 
The 5-FURD derivative 20 shows higher toxicity at lower concentrations than 5-FU 10 
this can be ascribed to 20  being in its nucleotide form, and therefore “skipping” a 
mctabolic step. The 5-FU ester derivatives 60 and 57 show increased activity at 
increased concentrations. Demonstrating that the protection groups have lowered the 
activity of 5-FU. The 5-FURD prodrug 72 does not have as good activity as 20 and this 
is presumably due to the presence of the nitro-aromatic group, which would appear to 
be deactivating the 5-FU. No activity is observed for prodrugs 69 and 71 at the 
concentrations used due to the hydroxyls being protected therefore preventing the 
formation of the tri-phosphate metabolite. We also believe that prodrug 71 is further 
inhibited due to the presence of nitro-aromatic groups as was the case with 72.
Prodrug 59 has comparable activity to 20, we believe that the carbonate ester linkage is 
very labile and releases 5-FU rapidly. The prodrug derivative 58 containing two 
carbonate esters shows good cytotoxicity but with one order of magnitude less than 59. 
We believe that 5-FU is being released more slowly in 58 than in 59 since two groups 
must be hydrolysed instead of one (Figure 126).
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Both the nitrobenzyl prodrugs 52 and 53 show similar cytotoxicity within the studied 
concentrations. They both have similar cytotoxicity profiles to 72. Thus, when 
compared to the standard 5-FU 10 it can be seen that the aromatic nitro group is 
inhibiting the cytotoxicity of 5-FU perhaps by slowing down its reaction with 
thymidylate synthase. Flowever, because our interest remains with the generation of 
hypoxic sensitive nitrobenzyl 5-FU prodrugs that can be linked into our Pc, it was 
decided to next evaluate the nitrobenzyl prodrugs cytotoxicity under hypoxic 
conditions. As mentioned in the introduction, hypoxia results in elevated levels of 
reductase, we believe that such conditions could be used to determine if mammalian 
reductase can reduce the nitro benzyl protection group. Thus, cells were cultured under 
hypoxic conditions (2% 0 2) for 24, 48 and 72hrs to determine their sensitivity to 
hypoxia treatment. Derivatives 52 and 53 were tested under hypoxia. Both prodrugs 
were incubated with the 4T1 cells for 72hr and showed a significant increase in 
cytotoxicity under hypoxic conditions, indicating that activation by endogenous one- 
electron reductases may be occurring (Figure 127).
F ig u r e  127. G ra p h ic  p l o t  s h o w in g  p r o d r u g s  52 a n d  53 c y t o t o x i c i t i e s  u n d e r  
HYPOXIC CONDITIONS OVER 3 DAYS.
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Perhaps the greatest killer of most cancer patients results from cancer metastasis, this is 
where cancer cells from the original tumour invade other areas of the body. Normally 
metastasised cells are immune to chemotherapy, in some cases the chemotherapy may 
actually enhance invasion.
5.1. Metastasis Results
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Fig u r e  128 .M et a sta sis  R e su l t s  fo r  pr o d r u g s  10,69,59 a n d  53
Research into metastasis inhibition, that is the prevention of invasion by metastasised 
cells, is becoming a very hot topic. An unexpected result involving metastasis 
inhibition was discovered for prodrugs 53, 59 and 69. The cellular assays used in these 
studies involve using BD Biocoat matrigel invasion chambers. Cells which, migrate 
through the chambers, are stained with crystal violet and detected by UV-visible 
spectroscopy. It was discovered that wells containing 53, 59 and 69 showed lower 
invasion than the 5-FU 10 ( F i g u r e  128). From these results it would appear that 
prodrugs 53, 59 and 69 are potential invasion inhibitors for metastasis. This result is 
also of interest since these compounds could aid in developing models to explain why 
cancer cells are activated to metastasis.
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5.2. F u t u r e  w o r k
We are currently awaiting (a new high sensitivity MALDI system will be installed here 
at DCU in early 2005) to analyse the metabolites from the above cellular cultures by 
mass spectrometry to determine/prove that the nitrobenzyl groups are indeed being 
converted to the respective quinmethides/fluorouracil via reduction. Parallel to this 
evaluation of the potential activation of these compounds in-vitro using a bacterial 
nitroreductase will be assesed in the next six months. If these experiments demonstrate 
that nitroreductase can indeed convert our prodrugs to the active form then we have also 
opened up the door for the potential use of Gene-Directed Enzyme Prodrug Therapy 
(GDEPT) with our compounds.
A SAR study will also be initiated on prodrugs 59 and 58 to try and determine why they 
exhibit such excellent activity. These same compounds are to be tested against 5-FU 
resistant cancer cell lines, and their cytotoxicity against normal mammalian cell lines 
will also be evaluated. If activity is observed against 5-FU resistant cell lines then 59 
and/or 58 have excellent potential as new therapeutics! Furthermore, if the cytotoxicity 
of 59 and 58 is the same or lower than 5-FU then both of these compounds have 
excellent potential as cancer treatment candidates!
Thus, our initial idea of linking a deactivated nitrobenzyl 5-FU prodrug to a Pc, were it 
could be activated by reductases under oxidative stress (or hypoxic conditions) appears 
to be promising based on the results obtained to date. The Pc-nitrobenzyl 5-FU 
prodrugs are to be tested soon under light irradiance conditions.
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General Methodology
lH NMR spectra were measured at 400 MHz, using a Brucker AM 400 spectrometer. 
13C NMR spectra were measured on the same instrument at 100 MHz. IR spectra were 
recorded using a Perkin Elmer 2000 FT-IR spectrometer. Mass spectra were analysed 
on an Esquire-Bruker/Hewlett Packard LC-MS 1100 series, equipped with an electro­
spray ion source. Optical rotations were measured on a Perkin Elmer 343 Polarimeter. 
Thin layer chromatography was conducted using Riedel de Haen silica 60F254 plates in 
the solvent systems specified in the text. TLC detection was achieved through UY 
absorbency. Flash chromatography was carried out using Riedel de Haen silica gel 60. 
Butanols and lower molecular weight alcohols were dried over magnesium, followed by 
distillation onto activated molecular sieves. Ethers were dried by sodium/benzophenone 
reflux, followed by distillation: diethyl ether was pre-columned through alumina. 
Chlorinated solvents, aliphatic hydrocarbons and benzene were dried over calcium 
hydride, followed by distillation. Toluene was purified by treatment with ice cold­
concentrated sulfuric acid, 30% caustic soda solution, brine followed by pre-drying over 
MgS0 4 , before fractional distillation over P2O5. Triethylamine and pyridine were 
stored over KOH, before decanting and distilling from calcium hydride and lithium 
aluminum hydride respectively. Acetone was stored over CaS04, prior to distillation. 
Acetonitrile was dried over P2O5, before fractional distillation from calcium hydride. 
DMF and DMSO were dried over calcium hydride before distillation on to activated 
molecular sieves. Ethyl acetate was purified by distillation. Distilled solvents were 
stored under nitrogen gas.
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6.0. Potential 5-Fluorouracil Prodrug
6.0.1. Preparation of l-alloxvcarbonyloxvmethvl-5-fluorouracil 59149
0  iv 
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5-FU (1.3g, lOmmol) and 37w% formaldehyde in aqueous solution (2.0g, 25mmol) 
were added to water. The reaction was heated to 60°C under agitation for 30 minutes. 
The resultant solution was concentrated and dried in a vacuum oven at 60°C for 48 
hours. The oily product was then dissolved in dry acetonitrile (30ml) preceeded by the 
addition of triethylamine (1.37g 13.5mmol). The solution was then agitated under 
nitrogen at room temperature, followed by the dropwise addition of allyl chloroformate 
(1.54g, 12.4mmol). After stirring at room temperature for 3 hours the mixture was 
filtered and acetonitrile removed under reduced pressure. The crude product was then 
dissolved in dichloromethane (30ml) and washed three times with HC1 (IN), saturated 
NaHC03 aq (30ml x 2) and water (30ml x 2). The organic layer was dried over sodium 
sulfate overnight, suction filtered and concentrated by rotary evaporation. The product 
was isolated using silica gel chromatography (methanol-dichloromethane, 1 :10 , v/v) to 
yield (1,8g, 74%) of 59 as a white solid.
TLC, Rf = 0.71 (methanol-dichloromethane, 1:10, v/v).
5JH (400MHz, DMSO-de) 8 (ppm) 4.60-4.63 (m, 2H, 0-CH2-CH=), 5.25-5.37(m, 2H,
CH=CH2), 5 .6 0 (s, 2H, N-CH2-0), 5.89-5.98(m, 1H, CH=CH2), 8.14(d, 1H, J= 8.0Hz,
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CH-CF), 12.03 (bs, 1H, NH). S13C (100MHz, DMSO-d6) 5 (ppm) 68.71, 73.68, 119.15, 
129.74 (d, J= 34 Hz) 132.06, 140.94, 149.59, 153.71, 157.85, (d, J= 26 Hz), S19F 
(DMSO-d6) -  169.03(d, IF, J= -6.3Hz).
6.0.2. Preparation of l-benzvloxvcarbonvloxvmethvl-5-nuorouracil 57 and 1.3- 
benzYloxvcarbonyloxvmethvl-5-fluorouracil 58
10 58 57
5-FU (1.3g, lOmmol) and formalin (1.78g, 22mmol) were stirred at approximately 60°C 
for 45mins. The oily product was dried under vacuum and was then dissolved in dry 
acetonitrile (30ml) followed by the addition of triethylamine (1.37g 13.5mmol). The 
solution was then agitated under nitrogen at room temperature, followed by the 
dropwise addition of benzylchloroformate (2.12g, 12.4mmol). After stirring at room 
temperature for 3 hours the mixture was filtered and acetonitrile removed under reduced 
pressure. The crude product was then dissolved in dichloromethane (30ml) and washed 
three times with HC1 (IN), saturated NaHC0 3  aq (30ml x 2) and water (30ml x 2). The 
organic layer was dried over sodium sulfate overnight, suction filtered and concentrated 
under vaccum. The product was further purified using silica gel chromatography (5:2 
chloroform:ethyl acetate) to yield 57 (2.03g in 69%) as a white solid and 58 in 18%.
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1 -Benzyloxycarbonyloxymethyl-5-fluorouracil 57 
TLC, Rf 0.39 (ethyl acetate-hexane, l:lv/v).
SXH (400MHz, DMSO-d6) 5 (ppm) 5.18(s, 2H, -CH2-Ph), 5.61 (s, 2H, N-CH2-0), 7.38- 
7.42-7.46(m, 5H, aromatic), 8.14(d, 1H, JF = 6.55, CH-CF), 12.03 (bs, 1H, NH). 813C 
(100MHz, DMSO-ds) 5 (ppm) 69.92, 73.74, 128.78, (d, J= 34 Hz) 129.56, 129.91, 
135.22, 138.62, 140.92, 149.63, 153.86, 157.98 (d, J= 26 Hz).S19F (DMSO-d6) - 
169.02(s, IF).
l,3-Benzyloxycarbonyloxymethyl-5-fluorouracil 58 
TLC, Rf 0.32 (ethyl acetate-hexane, l:lv/v).
8lU (400MHz, DMSO-d6) 5 (ppm) 5.19(d, 4H, J =2.0Hz, -CH2-Ph + -CH2-Ph), 5.70 (s, 
2H, *N-CH2-0), 5.85 (s, 2H, 3N-CH2-0), 7.37-7.40(m, 10H, aromatic), 8.32(d, 1H, JF =
6.4, CH-CF). 8 13C (100MHz, DMSO-d6) 5 (ppm) 68.70, 123.95, (d, J= 7.9 Hz), 124.67 
(d, J= 38H z), 129.02, 139.42, 141.76, 142.80, 146.33, 147.60, 149.83, 157.35 (d, J= 
27H z). 519F (DMSO-d6) -  167.50(d, IF, J= -6.2 Hz).
6.0.3. Preparation of aliphatic diacid monoester 62 lj0
O 0
61 62
Adipic acid 61 (7.3g, 0.05mole), benzyl alcohol (8.1g, 0.075mole), p-toluenesulfonic 
acid (0.095g, ,05mmole) and toluene (40ml) were combined in a flask equipped with a 
dean-stark trap and heated to reflux until 1.35ml of water was collected. The reaction 
was then cooled to room temperature, diluted with water (30ml) and the pH adjusted to 
8 with 6N NaOH (10ml). The aqueous layer was separated and washed with diethyl
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ether (2 x 25ml). Fresh ether (20ml) was added to the aqueous phase and the pH was 
adjusted to 2 by acidifying with 6N HC1 (6ml). The organic portion was then separated, 
dried over NaSOa and concentrated under vaccum to give 8.2g in 69.5% of 62 as a clear
TLC, Rf = 0.70 (ethyl acetate-hexane, 1:1, v/v)
8!H (400MHz, CDCls -d6) 8 (ppm) 1.64 (m, 4H, CH2-CH2), 2.39 (m, 4H O O C H 2 + 
C=OCH2), 5.14 (s, 2H, CH2-Ph), 7.28-7.41 (m, 5H, aromatic), 8.84(bs, 1H, OH). 813C 
(100MHz, CDC13 -d6) 8 (ppm) 24.47, 34.26, 66..72, 127.46, 127.93, 128.32, 128.69, 
129.42, 136.35, 173.78, 179.47.
6.0.4. Preparation of hexanedioc acid benzyl ester (nhcnvisuHanvT) methyl ester 63
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(62) 63
Aliphatic diacid monoester 62 (3.9g, 16.5mmol) and cesium carbonate (5.37g, 
16.5mmol) were combined in DMF (50ml). The reaction was stirred for 30 minutes at 
room temperature and then at 70°C for 15 minutes. Following this the reaction was 
cooled to room temperature and stirred for 30 minutes, and chloromethyl phenyl sulfide 
(2.37g, 15mmol) was added via a syringe. The mixture was stirred for 3 hours at room 
temperature and then at 70°C for 15 minutes. The reaction mixture was then cooled to 
room temperature and diluted with water (100ml). The reaction was allowed to stir 
until the cesium carbonate went into solution (lOmin). The DMF/H20 mixture was 
extracted by washing the solution with diethyl ether (4 x 50ml). The ether extracts were
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then washed with IN NaOH (50ml), brine (4 x 50ml) and dried over MgS0 4 . The 
product was concentrated on the rotary evaporator to yield 4.2g in 71% of 63 as a clear
51H (400MHz, CDC13 -d6) 8 (ppm) 1.67-1.76 (m, 4H, CH2-CH2), 2.35-2.44 (m, 4H 
C=OCH2 + O O C H 2), 5.14 (s, 2H, CH2-Ph), 5.45 (s, 2H, 0-CH 2-S), 7.28-7.51 (m, 10H, 
aromatic). 8 13C (100MHz, CDC13 -d6) 8 (ppm) 24.62, 24.66, 34.23, 34.31, 66.60, 
68.30,127.78, 128.67, 129.02, 129.60, 130.72, 135.20,136.48, 172.92, 173.40.
6.0.5. Preparation oriicxanedioic acid benzyl ester chloromethvl ester 64
O ~cr ^  y 0sA = /  c i^ 0
63 64
0 o
The diester 63 (2.83g, lOmmol) was dissolved in CH2C12 (40ml) and was purged with 
argon for 5 minutes. Sulfuryl chloride (1.63g, 12mmol) in IN CH2Cl2(24ml) was added 
slowly to the reaction mixture. A colour change was observed from clear to dark orange 
after 1 hour of stirring at room temperature. Cis-4-cyclohexen-l, 2-dicarboxylic acid 
(1.7g, lOmmol) was added to the reaction mixture. The colour reverted back to its 
original clear colour after 30 minutes of stirring. The white precipitate that formed was 
filtered and the solution was concentrated in vacuo to an oily residue. The residue was 
dissolved in diethyl ether (25ml) washed with 10% NaHCCb (1 x 25ml), H20  (2 
x25ml), dried over MgSC>4 and filtered to yield 2.6g (92%) of 64 as a white solid.
S*H (400MHz, CDCI3 -d6) 8 (ppm) 1.59-1.6 l(m, 4H, CH2-CH2), 2.29-2.31 (m, 4H 
C=OCH2 + C=OCH2), 5.13 (s, 2H, CH2-Ph), 5.70 (s, 2H, 0-CH2-Cl), 7.33 (s, 5H,
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aromatic). 513C (100MHz, CDC13 -d6) 5 (ppm) 24.30, 24.52, 33.93, 34.18, 66 .66, 69.04, 
128.627, 128.652, 128.980, 136.36, 171.68, 173.45.
6.0.6. Preparation of hexandioic acid ben/vl ester (5-fluoro-2,4-dioxo-3,4-dihvdro-2l I- 
pyrimidin-l-lvVmethvl ester 60151
To DMF (5ml) 5-FU (0.50g, 4.05mmol) was added and stirred for 10 minutes. To this 
solution a 3-fold excess of triethylamine ( 1 .2 g, 12.15mmol) was added via a syringe and 
stirred at room temperature for 30 minutes. Hexanedioic acid benzyl ester chloromethyl 
ester (1.14g, 4.05mmol) was then dissolved 64 in DMF (5ml) this solution was then 
added dropwise to the reaction mixture and allowed to stir overnight. The precipitate 
that formed was gravity filtered and the DMF was removed via high vacuum pump 
assisted rotary evaporator to yield a yellow residue gum. The product was isolated 
using silica gel chromatography (40% ethyl acetate/ dichloromethane) to yield 0.7g 
(45%) of 60 as a white solid.
TLC, Rr 0.70 (ethyl acetate-dichloromethane, 40%,).
6lH (400MHz, CDCI3 -d6) 5 (ppm) 1.66-1.70(m, 4H, CH2-CH2), 2.37-2.42 (m, 4H 
C=OCH2 + C=OCH2), 5.12 (s, 2H, CH2-Ph), 5.64 (s, 2H, 0-CH 2-N), 7.36(s, 5H, 
aromatic), 7.64 (d, 1H, JF= 5.4 Hz, CH-CF), 10.11 (sb, 1H, NH). 513C (100MHz,
CDCI3 -d6) 5 (ppm) 24.28, 24.46, 33.76, 34.09, 66.71, 70.16, 128.63, 128.66, 128.98(d,
J = 5.4 Hz), 136.29, 140.58(d, J = 239Hz), 150.00, 157.74(d, J = 27 Hz), 173.52,
173.84. 8 19F (CDCI3 -d6) -  164.93.( d, J= 5 Hz)
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6.1. Synthesis of Nitro-Aromatic Precursors of 5-FU
6.1.1. Preparation of 3-(p-nitrobenzyloxvcarbonvl)-5-fluorouracil SI37
Nitrobenzyl chloroformate (1.42g, 6 .66mmol) in dioxane (6ml) was added dropwise to 
a solution of 5-FU (0.84g, 6 .66mmol) and triethylamine (0.66g, 6 .66mmol) in DMSO 
(5ml). The reaction was stirred for 5 hours, filtered and poured into a solution of ice 
water (100ml). The white solid precipitate that formed was collected and washed with 
ice water. The solid was allowed to dry over night and was suspended in CH Ch (25ml) 
with stirring for 1 hour. The residue was suction filtered and washed twice more with 
CHCI3. The product was allowed to dry overnight under vacuum to yield 0.98g (48%) 
of 51 as a white solid.
TLC, Rf 0.41 (chloroform-ethyl acetate, 2:1.5, v/v).
81H (400MHz, DMSO-de) 5 (ppm) 5.50(s, 2H, 0-CH2), 7.74 (d, 2H, Jab = 8 .6 , AH's on 
aromatic ring,) 8.22 (d, 2H, JF = 7.2 Hz, CH-CF), 8.25 (d, 2H, JAB = 8 .6 , BH's on 
aromatic ring), 12.05 (s, 1H, NH). 6 13C (100MHz, CDC13 -d6) 5 (ppm) 68.70, 123.90, 
128.82 (d, J = 21 Hz), 139.42, 142.80, 146.33, 147.60, 149.83, 157.44 (d, J = 27 Hz). 
819F (CDCI3 -d6) 8 (ppm) -  165.24 (d, IF, J = 7.4Hz).
6.1.2. Preparation o f 3-('p-nitrobenzYl)-5-fluorouiaci](52) and l.3-Bis-(p-nitrobenzvl)-
5-fluorouracil 53152
0
F
o
52
NO.
53
Potassium carbonate (1.38g, O.Olmole), p-nitrobenzyl bromide (2.16g, O.Olmole) and 5- 
FU (1.3g, O.Olmole) were dissolved in DMSO (15ml). The reaction mixture was heated 
to 80°C for 1 hour under agitation. A 10% potassium hydroxide solution (50ml) was 
then added to the hot solution. The warm solution was suction filtered, the crystals that 
remained on the filter paper were collected and washed with H2O (2 x 25ml) and 
ethanol (2 x 10ml), to yield (0.8g, 20%) of 1,3-Bis- (p-nitrobenzyl)-5-fluorouracil 53 as 
an orange/red powder. The orange/red mother liquor was acidified to a pH of 2 with 
HCl(conc), white crystals formed that were suction filtered and washed with H2O (2 x 
10ml) and ethanol (2 x 15ml). To yield 0.4g (20%) of l-(p-nitrobenzyl)-5-fluorouracil 
51 as a white/orange solid.
3 -(p-nitrobenzyl)-5 -fluorouracil 52.
TLC, Rf 41 (chloroform-ethyl acetate, 2:3,v/v).
8 ’H (400MHz, DMSO-d6) 8 (ppm) 4.96 (s, 2H, 0-CH 2-lN), 7.57 (d, 2HA, Jha= 8.7 Hz 
aromatic ring), 8.19-8.28 (m, 3H, 2Hb in aromatic ring and CH-CF), 11.92 (bs, 1H, 
3NH). 8 13C (IOOMHz, DMSO-de) 8 (ppm) 50.70, 124.04, 128.77,130.38 (d, J = 21 Hz),.
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144.52, 147.27, 150.0.3, 157.78 (d, J = 27 Hz). 819F (DMSO-d6) 5 (ppm) -  169.06(d, 
IF, J= -6 .6Hz).
1,3-Bis- (p-nitrobenzyl)-5-fluorouracil 53.
TLC, Rf 0.62 (chloroform-ethyl acetate, 2:3,v/v).
8JH (400MHz, DMSO-d6) 8 (ppm) 5.08 (d, 4H, O - O ^ N  and 0-CH2-3N), 7.53(d, 2H, 
Ha aromatic), 7.60 (d, 2H, Hb aromatic), 8.14(d, 2H, Ha aromatic), 8.18 (d, 2H, HB 
aromatic), 8.41 (d. 1H, CH-CF). (100MHz, DMSO-d6) 8 (ppm) 44.38, 51.95,123.95(d, J 
= 18 Hz). 128.79, 129.87(d, J = 27 Hz), 144.17, 144.46, 150.13, 157.16(d, J = 27 Hz). . 
S19F (DMSO-d6) 8 (ppm) -  167.12 (d, IF, J= -6.4Hz).
6.2. Protected Nucleosides
6.2.1. Preparation o i'2 '.3?-isopropylidcneuricline 68154,161
O
OH OH
67 68
To a solution of uridine 67 (10.4g, 42.5mmol) and 4-toluenesulfonic acid monohydrate 
(1.2g, 6.3mmol) in dry acetone (200ml) one portion of 2,2-Dimethoxypropane (27.5g, 
264.0mmol) was added. The reaction mixture was allowed to stir for 12 hours at room 
temperature. Afterwhich time it was neturalised with 2.5M sodium methoxide in
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methanol and filtrered through Celite. The solvent was removed via rotary evaporation 
and recrystallised from water to yield 11.19g (83%) of 68 .
TLC, Rf 0.25 (ethyl acetate-chloroform, 1:1, v/v)
Vmax (KBr) 3244, 1704, 1675 cm'1.
8XH (400MHz, DMSO-de) 5 (ppm) 1.28 (s, 3H, (CH3)2C), 1.48 (s, 3H, (CH3)2C), 3.57 
(m, 2H, H-5’), 4.06-4.08 (m, 1H, H-4’), 4.74 (dd, 1H, Jr .r  =6.4 Hz, J3M- = 3.8 Hz, H- 
3’), 4.88 (dd, 1H, J2V}-=6.4 Hz, J2M- = 2.6 Hz, H-2’), 5.16 (bs, 1H, OH), 5.62 (d, 1H, J=
7.9 Hz, NCH=CHCO) 5.82 (d, 1H, J r .2. =2.4 Hz, H -l’), 7.78 (d, 1H, J= 7.9 Hz, 
NCH=CHCO), 11.38 (bs, 1H,NH).
8 13C (100MHz, DMSO-ds) 8 (ppm) 25.46, 27.34, 61.58 (C-5’), 80.79 (C-2’), 84.00 (C- 
3’), 86.82 (C-4’), 91.46 (C -l’), 102.06 (C-5), 113.34(C-Me2), 142.29(C-6), 150.68(C- 
2), 163.63(C-4).
6.2.2. Preparation of 5-fluoro-2’.3’-isopropylideneuridine 69
20 69
Compound 20 (1.10g, 4.2mmol) and 4-toluenesulfonic acid monohydrate (0.12g, 
0.63mmol) were dissolved in dry acetone (20ml). One portion of 2,2- 
Dimethoxypropane (2.75g, 26.40mmol) was added to the reaction mixture and stirred 
for 12 hours at room temperature. The reaction was neturalised with 2.5M sodium
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methoxide in methanol. The reaction mixture was filtered through Celite, and solvent 
removed under vacuum to yield (69) (0.89g, 70.1%) as a white solid.
51H (400MHz, DMSO-d6) 8 (ppm) 1.27 (s, 3H, (CH3)2C), 1.48 (s, 3H, (CH3)2C), 3.62 
(m, 2H, H-5’), 4.10 (m, 1H, H-4’), 4.74 (dd, 1H, Jy-v =9.6 Hz, J3M> = 3.3 Hz, H-3’), 
4..87 (dd, 1H, J2’.3’=8.9 Hz, J2M. = 2.6 Hz, H-2’), 5.29(bs, 1H, OH), 8.18 (d, 1H, J= 7.1 
Hz, NCH=CFCO), 11.92 (bs, 1H, NH).
513C (100MHz, DMSO-d6) 8 (ppm) 25.47, 27.33, 61.45 (C-5’), 80.54(C-2’), 84.09(C- 
3’), 86.83(C-3’), 91.30(C-1’), 113.29(C-Me2), 126.16(d, J= 27 Hz, C-6), 141.40(C-2), 
149.36(C-5), 157.5l(d, J = 21 Hz, C-4)
819F(DMSO-d6) 8 (ppm) -167.99 (d, J= -6.7Hz)
6.3. Synthesis of Nitro-Aromatic Precursors of 5-FURD Prodrugs
6.3.1. Preparation of N'-(4-nitrobenzvD-2\ 3'-isopropvlidene-5-fluorouridine 71
HO
Br -N O ,
HO
N O ,
69 71
G e n e r a l  p r o c e d u r e
A mixture of 2,3-isopropylidene-5-fluorouridine 69 (302.2mg, lmmol), 4-nitrobenzyl
bromide (248.44mg, 1.15mmol) and K2C 0 3 (250mg, 1.18mmol) were stirred in dry
DMF (12.5ml) at room temperature for 3 hours. The solution was gravity filtered and
concentrated in-vacuo and allowed to cool. To the residue a minimum amount of ethyl
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acetate was added to precipitate any remaining salt. The solution was suction filtered 
and the collected precipitate was washed with ethyl acetate. The collected precipitate 
was purified by silica gel chromatography (ethyl acetate-hexane, 1 :1 , v/v) to yield 310 
mg (78%) of 71 as a clear syrup that was solidified to a white powder by the addition 
ethyl acetate
Yield 195.6 mg (84%) as a clear syrup;
TLC, Rf 0.41 (ethyl acetate-hexane, 1:1, v/v); H 'nM R (400MHz, DMSO-d6) 5 (ppm) 
1.04(s, 3H, CCH3), 1.23(s, 3H, CCH3), 3.41 (m, 2H, H-5’), 3.94(m, 1H, H-4’), 4.52(d,
1H, H-3’), 4.65(dd, 1H, H-2’), 4.86(s, 2H,benzyl CH2), 5.08(d, 1H, 5’-OH), 5.64(s, 1H, 
H’-l), 7.32(d, 2H, HA-aromatic ring), 7.94(d, 2H, HB-aromatic ring), 8.11 (d, 1H, H-6). 
C13NMR (100MHz, DMSO-ds) 5 (ppm) 25.48(CCH3), 27.31 (CCH3), 44.25(benzyl), 
61.39(C-5’), 80.59(C-3’), 84.38(C-2’), 87.20(C-4’), 92.52(C-1’), 113.18(C(CH3)2), 
123.90(2C, Cc-aromatic ring), 125.60(C-6), 128.99(2C, Ce-aromatic ring), 140.91(C-2), 
144.43(1C, CD-aromatic ring), 147.11(1C, CA-aromatic ring), 158.50(C-3). F19NMR 
(DMSO-d6) 8 (ppm) -166.42 (d, J= -6.7Hz) m/z (El) 460.3 (M++Na CigHioOsNsF! 
requires 437.3)
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6.3.2. Preparation of NJ-(4-nitrobenzvlV2\ 3'-isopropylidene-uridine 70
Br X  v— NO.
NO,
The general procedure was employed to prepare 70 using 2,3-isopropylidenc-uridine 68 
(283.2mg, lmmol), 4-nitrobenzyl bromide (248.44mg, 1.15mmol). The collected 
product was purified by silica gel chromatography solvent system.
Yield 70 280mg (64%) as a clear syrup; TLC, Rf 0.26 (ethyl acetate-hexane, 2:1, v/v); 
H1NMR (400MHz, DMSO-d6) 5 (ppm) 1.28(s, 3H, CCH3), 1.47(s, 3H, CCH3), 3.56(m, 
2H, H-5’), 4.13(d, 1H, H-4’), 4.75-4.76(m, 1H, H-3’), 4.91-4.92(m, 1H, H-2’), 
5.08(benzyl CH2), 5.18(d, 1H, 5’-OH), 5.85-5.87(m, 2H, H -l’ and H-6), 7.52(d, 2H, 
HA-aromatic ring), 7.93(d, 1H, H-6), 8.18(d, 2H, HB-aromatic ring). C13NMR (100MHz, 
DMSO-df,) 5 (ppm) 25.50(CCH3), 27.34(CCH3), 43.47(benzyl, CH2), 61.52(C-5’), 
80.82(C-3’), 84 .30(02’), 87.20(04’), 91 .72(01’), 101.10(05), 113.21(C(CH3)2), 
123.92(2C, Cc-aromatic ring), 128.86(2C, CB-aromatic ring), 141.16(C-6), 145.06(1C, 
Co-aromatic ring), 147.08(1C, CA-aromatic ring), 150. m/z (El) 442.2 (M++Na 
Ci9H20O8N3Fi requires 419.2)
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6.3.3. Preparation of N3-(4-nitrobenzvl>5-fluorouridine 72
o o
HO
OH OH
o
+ Br
OH OH
7220
The general procedure was employed to prepare 72 using 5-fluorouridine 20 (262.2mg, 
lmmol), 4-nitrobcnzyl bromide (248.44mg, 1.15mmol) and K2CO3 (250mg, 1.18mmol). 
The collected residue was purified by silica gel chromatography (4:1 ethyl acetate- 
hexane v/v) to yield 72, 310 mg (78%) of a clear syrup that was solidified to a white 
powder from ethyl acetate: mp 156-158 °C; TLC, Rf 0.42 (ethyl acetate-hexane, 4:1, 
v/v) H lNMR (400MHz, DMSO-d6) 5 (ppm) 3.59-3.64(m, 1H, H-4’), 3.72-3.76(m, 1H, 
H-3’), 3.88-3.89(m, 1H, H-2’), 4.00-4.07(m, 2H, H-5’), 5.11-5.20(m, 3H, 5’-OH and 
benzyl CH2), 5.36(t, 1H, 3’-OH), 5.50(d, 1H, 2’-OH), 5.77-5.78(m, 1H, H -l’), 7.58(d, 
2H, HA-aromatic ring), 8.18(d, 2H, He-aromatic ring), 8.53( d, 1H, H-6). C13NMR 
(100MHz, DMSO-ds) 5 (ppm) 44.22 (benzyl), 60.21 (C-5’), 69.17(C-3’), 74.34(C-2’), 
84.85(C-4’), 89.95(C-1’), 123.89(2C, CB-aromatic ring), 124.48(d, J= 27Hz, C-6), 
128.97(2C, Cc-aromatic ring), 140.92(C-2), 144.54(1C, Co-aromatic ring), 147.09(1C, 
CA-aromatic ring), 149.52(C-5), 156.88(d, J= 21 Hz,C-l). Fl9NMR (DMSO-d6) 5 (ppm) 
-166.38. m/z (El) 437.3 (M++K C^HieOsNsFj requires 398.3)
6.3.4. Preparation of N'1-(4-nilroben/vlfLiran)-5-nuorouridine 73
o o
HO
OH OH o h  o h
73
The general procedure was employed to prepare 73 using 5-fluorouridine (262.2mg, 
lmmol), 2-bromomethyl-5-nitrofiiran (248.44mg, 1.15mmol) and K2CO3 (250mg, 
1.18mmol). The collected residue was purified by silica gel chromatography (4:1 ethyl 
acetate-hexane v/v) to yield 73, 310 mg (78%) of a clear syrup that was solidified to a 
white powder from ethyl acetate; TLC, Rf 0.42 (ethyl acetate-hexane, 4:1, v/v) HXNMR 
(400MHz, DMSO-d6) 5 (ppm) 3.59-3.61(m, 1H, H-4’), 3.70-3.75(m, 1H, H-3’), 3.86- 
3.90(m, 1H, H-2’), 4.01-4.04(m, 2H, H-5’), 5.01-5-09(m, 3H, 5’-OH and benzyl CH2), 
5.55(bs, 1H, 3’-OH), 5.75(d, 1H, 2’-OH), 7.0-7.66(m, IH, H -l’), 7.72(d, 1H), 8.12(d, 
2H,), 8.40(d, 1H, H-6). C13NMR (100MHz, DMSO-d6) 5 (ppm) 44.01 (benzyl), 60.29 
(C-5’), 69.31(C-3’), 74.22(C-2’), 84.85(C-4’), 89.69(0-1’), 122.84, 130.37, 134.86,
138.73,148.04, 149.59, 156.93(d, J=21Hz)
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6.3.5. Preparation o f NJ-f4-chloro-2-nitrobenzvl)-5-fluorouridine 74
ci -ci
o 2n
74
The general procedure was employed to prepare 74 using 5-fluorouridine (262.2mg, 
lmmol 4-chloro-2-nitrobenzyl bromide (248.44mg, 1.15mmol) and K2CO3 (250mg,
1.18mmol). The collected residue was purified by silica gel chromatography (4:1 ethyl 
acetate-hexane v/v) to yield 74, 310 mg (78%) of a clear syrup that was solidified to a 
white powder from ethyl acetate: TLC, Rf 0.62 (ethyl acetate-hexane, 4:1, v/v) H*NMR 
(400MHz, DMSO-de) 5 (ppm) 3.58-3.60(m, IH, H-4’), 3.72-3.77 (m, IH, H-3’), 3.88- 
4.01(m, IH, H-2’), 4.16-4.19(m, 3H, H-5’), 5.40-5.42(m, 3H, 5’-OH and benzyl CH2), 
5.55(t, 1H, 3’-OH), 5.72(d. IH, 2’-OH), 7.43(d, IH, H -l’), 7.77(dd, 2H,aromatic), 
8.16(d, 1H, aromatic), 8.55(d, 1H, aromatic). C13NMR (100MHz, DMSO-de) 6 (ppm) 
41.22 (benzyl), 60.08 (C-5’), 69.01(C-3’), 74.37(C-2’), 84.75(C-4’), 90.00(C-1’), 
124.45, 124.84(d, J=27 Hz), 130.39, 132.95, 134.06, 149.14, 149.46, 156.90 (d, J= 
21 Hz), 170.75.
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6.3.6. Preparation o f N3-(3-nitrobcnzyl)-5-lliioro»ritline 75
o
NOj
HO
OH OH
O
+ Br
OH OH
75
The general procedure was employed to prepare 75 using 5-fluorouridine (262.2mg, 
Immol), 3-nitrobenzyl bromide (248.44mg, 1.15mmol) and K2CO3 (250mg, 1.18mmol). 
The collected residue was purified by silica gel chromatography (4:1 ethyl acetate- 
hexane v/v) to yield 75, 310 mg (78%) of a clear syrup that was solidified to a white 
powder from ethyl acetate: TLC, Rf 0.68 (ethyl acetate-hexane, 4:1, v/v) H'NMR 
(400MHz, DMSO-de) 5 (ppm) 3.60-3.61(m, 1H, H-4’), 3.69-3.70(m, 1H, H-3’), 3.72- 
3.75(m, 1H, H-2’), 4.00-4.15(m, 2H, H-5’), 5.09-5.2l(m, 2H, 5’-OH and benzyl CH2), 
5.76(d, 1H, 2’-OH), 6.74(m, 1H, H -l’), 7.55(d, 2H, aromatic), 7.89(d, 2H, aromatic), 
8.43(d, 1H, aromatic). C13NMR (100MHz, DMSO-d6) 8 (ppm) 37.95 (benzyl), 60.26 
(C-5’), 69.28(C-3’), 74 .23(02’), 84.86(C-4’), 89.74(C-1’), 113.03,114.64,124.41 (d, J=
21 Hz), 138.51, 140.79(C-2), 153.92,156.59(d, J=21Hz), 163.15.
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6.4. Preparation of 5-FURD-Photosensitiser Conjugates
6.4.1. Preparation of Bis(3-(p-nitrobenzvl)-2\3- isopropylideneuridine) 
phthalocvaninosilieon 78 [method 1-condensation]
HO
si_ ;X < i,oh i  a
~0 ,a ;  >  +  _  o  N O
F=N N— if HO ;
W
V
76 70
78
Dihydroxysilicon phthalocyanine 76 (16.1mg, 0.028mmol) and 4-nitrobenzyl-uridine 70 
(92.44mg, 0.28mmol) were dissolved in dry DMF (10ml). The solution was refluxed 
for 3 hours, cooled and gravity filtered. The filtrate was concentrated by rotary 
evaporation and purified by silica gel chromatography, (CHC13-MeOH, 10:0.5, v/v). 
Three fractions were collected. Fraction 1 yielded product Bis(3-(p-nitrobenzyl)- 
uridine)phthalocyaninosilicon 78 in lOmg (26%). Fraction 2 was un-reacted (70) while 
the final fraction was unreacted dihydroxysilicon phthalocyanine 76.
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6.4.2. Preparation of Bis(3-(p-nitrobenzvl)-2’.3- isopropylideneuridinc)
phthalocvaninosilieon 78 [Method 2-Sodium Hydride]
Sodium hydride (12.0mg, 0.28mmol) was added to a mixture of dihydroxysilicon 
phthalocyanine 76 (16.1mg, 0.028mmol) and 3-(p-nitrobenzyl)-uridine 70 (92.44mg, 
0.28mmol) dissolved in dry Toluene (10ml). This solution was heated to 80°C for 96 
hours. The reaction mixture was poured into water (10ml), extracted with toluene and 
the toluene fraction was concentrated under vacuum. The crude product was purified by 
a silica gel column (DCM: MeOH v/v 10:0.5). The collected Pc was then purified by 
size exclusion column chromatography (SX-3 polystyrene) to give 12mg (32%) of 78. 
UV/Vis (DMSO): A,max =682nm 
m/z (El) 1399 (M++N a,requires 1376)
6.4.3. Preparation of Bisi5-fluorouridine)phthalocvaninosilicon 80
Method I was employed using 76 (12.66mg, 0.022mmol) and 5-fluorouridine 20 
(250mg, 0.95mmol). The crude product was purified by silica gel chromatography 
(CHCh-MeOH, 10:1.0, v/v). Three fractions were collected. Fraction 1 yielded 
14.3mg (61%) of 80. Fraction 2 yielded 5-fluorouridine and fraction 3 was un-reacted 
dihydroxysilicon phthalocyanine.
OH OH
80
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UY/Vis (DMSO): A,max =680nm 
m/z (El) 1089 (M++Na requires 1066)
6.4.4. Preparation of Bis(3-(p-nilrobcnzvD-5-fliiorouridine)phthalocvaninosilicon 79
Method I was employed using 76 (16.1mg, 0.028mmol) and 3-(p-nitrobenzyl)-5- 
fluorouridine 72 (111.44mg, 0.28mmol) were dissolved in dry DMF (10ml). The crude 
product was purified by silica gel chromatography, (CHCl3-MeOH, 10:0.5, v/v). Three 
fractions were collected. Fraction 1 yielded 15.8mg (42.3%) of 79. Fraction 2 was un­
reacted p-nitrobenzyl-5-fluorouridine while the final fraction was unreacted 
dihydroxys ilicon phthalocyanine.
UV/Vis (DMSO): Xmax =678nm 
m/z (El) 1347 (M+ requires 1319)
HO
OH OH
79
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6.4.5. Preparation o f :
Bis(N3- (4-nitrobenzvlfuran)-5-Huorouridine) nhthalocvaninosilicon 80A
Bis(N3- (4-chloro-2-nitrobenzv0-5-fluorouridine) phthalocvaninosilicon 80B 
Bis(N3-(3-nitrobenzvl)-5-fluorouridine) phthalocvaninosilicon 80C
80A R1 = 0 2N—1 ^ 1 — ^
80B R1 
80C R1
Method I was employed using 76 (16.1mg, 0.028mmol) and appropiate 5-fluorouridine 
derivative 73 (112mg, 0.28mmol), 74 (120mg, 0.28mmol) and 75 (111.44mg, 
0.28mmol) were dissolved in dry DMF (10ml). The crude product was purified by 
silica gel chromatography, (CHCl3-MeOH, 10:0.5, v/v). Three fractions were collected. 
Fraction 1 for each yielded 80A in 15.4mg (41%) 80B in ll.Omg (28%) and 80C in
11.4mg(30%). Fraction 2 was un-reacted 5-fluorouridine derivatives 73, 74 and 75 
while the final fraction was unreacted dihydroxys il icon phthalocyanine 76.
6.5. Novel Deprotection of Acetonide Derivative
G e n e r a l  p r o c e d u r e
The appropriate acetonide (0.33mmol) and benzyl derivative (0.33mmol) were 
dissolved in DMSO (4.0ml) in the presence of *triethyamine (0.33mmol). To this 30% 
hydrogen peroxide was added (200ul). The reaction was allowed to stir at 85°C.
The benzyl derivative was removed by chloroform extraction (5x7ml). The peroxide 
was removed by stirring the reaction in activated alumina for 2 hours. The reaction 
mixture was filtered and concentrated to give an oily residue. The residue was titurated 
with dry acetonitrile, to yield the parent nucleoside in moderate yield.
*triethyamine can be either present or not present during reaction.
T a b l e  3 2 . S h o w in g  y i e l d s  f o r  r e a c t i o n  w it h  in  t h e  a b s e n c e  o f  b a s e .
Protected Nucleoside P r o d u c t Y i e l d
2,3 -isopropylidene-5 -fluoro uridine 5-fluorouridine 45%
2,3-isopropylideneuridine Uridine 58%
5 -trityl-2,3 -isopropylideneuridine 2,3-isopropylideneuridine 48%
T a b l e  33. S h o w in g  y i e l d s  f o r  r e a c t i o n  in  t h e  p r e s e n c e  o f  TEA
Protected Nucleoside P r o d u c t Y i e l d
2,3-isopropylidene-5-fluorouridine 5-fluorouridine 42%
2,3-isopropylideneuridine Uridine 50%
5-trityl-2,3-isopropylideneuridine 2,3 -isopropylideneuridine 34%
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6.5.1 Preparation of 5 '-0-tritvl-2\3’-isopropvlidcnciiridine 94155
O
(68) 82
Acetonide 68 (1.8796g, 6.0mmol), trityl chloride (1.84g, 6 .6mmol), triethylamine 
(1.5ml) and DMAP (58.2mg, 0.3mmol) were dissolved in dichloromethane (15ml). The 
reaction mixture was stirred overnight at room temperature under nitrogen. After which 
time ice cold water (2 0 ml) was added to the reaction mixture and the product was 
extracted with dichloromethane (20ml). The aqueous phase was washed twice with 
dichloromethane ( 10 ml), and the organic layers were combined and washed with 
saturated ammonium chloride (20ml), water (20ml), then dried over NaS04. The 
solvent was removed by evaporation and the resulting residue was recrystallised from 
water to yield 82 (2.25g, 71%)
8lH (400MHz, DMSO-de) 5 (ppm)1.26 (1H, s, (CifcfcC), 1.47 (3H, s, (ClfcfcC), 3.33 
(2H, m, H-5’), 4.14-4.15 (1H, m, H-4’), 4.70 (1H, dd, J3-.2- =6.2 Hz, J3 .4’ = 3.4 Hz, H- 
3’), 4.98 (1H, dd, J2’-3’ =6.2 Hz, JT-v = 2.6 H z ,), 5.51(1H, d, J= 7.9 Hz, NCH=CHCO, 
H-5), 5.85 (1H, d, JV-r =2.4 Hz, H -l’), 7.21-7.38 (15H, m, aromatic), 7.73 (1H, d, J=
7.9 Hz, NCH=CHCO, H-6), 11.42 (1H, bs, NH).
513C (100MHz, DMSO-ds) 5 (ppm) 18.89, 25.56, 27.36, 56.39, 64.42, 80.8, 84.01, 
86.35, 92.22, 102.01, 113.58, 126.98, 127.26, 127.48, 127.87, 128.12, 128.21, 128.28, 
128.47,128.58, 128.98, 143.79, 148.11, 150.56, 163.58.
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6.6. Preparation of a More Lipophillic 5-FU Prodrug
6.6.1 Initial preparation
6 .6 .1.1. P r e p a r a t i o n  o f  d i b r o m o i s o c y a n u r i c  a c i d  82168
Cyanuric acid 91 (I2.9g, lOOmmol) and LiOH (8.4g, 200ml) were added lo water 
(1000ml). The solution was stirred until all reagents fully dissolved. At this time 
bromine (63.9g, 400 mmol) was slowly added. After the bromine was dissolved, the 
solution was placed in the refrigerator overnight. The solution was then suction filtered, 
and the filtrate was dried in vacuo to yield 91) as a white powder (22.02g, 86.4%).
8 'H (400MHz, DMSO-df,)8 (ppm) 11.25 (bs, 1H, OH)
8 13C (100MHz, DMSO-do) 8 (ppm) 61.82, 150.26.
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6.6.1.2. P r epa r a tio n  of  N -b r o m o a c eta m id e  92
O O
ANHBr
92
To a solution of acetamide (4.48g 92.8mmol) in dichloromethane (500ml) was added 
dibromoisoeyanurie acid 90 (16.00g, 111.4 mmol) and the suspension was refluxed in 
the dark for 6 hours. The reaction mixture was extracted with dichloromethane (2 x 
150ml) and the solvent removed under reduced pressure to afford the crude product as 
an orange precipitate. The crude product 92 was purified by recrystallisation with ethyl 
acetate to yield (10.8g, 85%)
6.6.1.3. A l t e r n a t i v e  p r e p a r a t i o n  o f  N - b r o m o a c e t a m i d e  92169 
Acetamide (20.00g, 338.58mmol) was dissolved in bromine (54.0g, 337.90mmol). The 
solution was cooled to 0°C. An ice cold aqueous 50% potassium hydroxide solution 
was then added in portions with swirling and cooling until the mixture became light 
yellow in appearance. The near solid reaction mixture was allowed to stand at 0°C for 3 
hours. The mixture was then treated with sodium chloride (40g) and dichloromethane 
(200ml). The top layer of the biphasic layer that formed was decanted while boiling. 
The extraction was repeated twice more with 200ml and 100ml portions of 
dihloromethane. The combined extracts were dried over Na2S0 4  gravity filtered and the 
filtrate was diluted with hexane (500ml) (gentle stirring was required). The white 
needles of 92 were collected by suction filtration, washed with hexane and air dried to 
give a yield of 17.14g (37%) (lit. m.p. 102-105). M.p (lit. m.p. 102-105°C) 103-105°C
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6.6.1.4. P r epa r a tio n  o f N -b ro m o b en za m id e  93
o O
n h2 NHBr
93
To a solution of benzamidc (5.62g 46.4mmol) in dichloromethane (300ml) was added 
dibromoisocyanuric acid (90) (8.00g, 92.8 mmol). The suspension was refluxed in the 
dark for 5 hours. The reaction mixture was suction filtered and the collected precipitate 
was washed with dichloromethane (2 x 150ml). The filtrate was collected and the 
solvent was removed under reduced pressure to yield 93 as a white powder. (8.9g, 
96%). M.pt. (lit. m.pt. 129-131°C) 129-131°C
6.6.2. Amino hydroxvlation derivatives
6.6.2.1 P r e p a r a t i o n  o f  i s o p r o p y l  c i n n a m a t e  88
Cinnamic acid 87 (14.80g, 99.89mmol) was dissolved in dry propan-2-ol (500ml). To 
this solution was added trimethylsilyl chloride (24.00g 220.91mmol). The mixture was 
refluxed for 4 hours and the solvent was removed under reduced pressure. The residue 
was dissolved in ether (150ml), washed with 10% aqueous sodium carbonate (2 x
87 88
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50ml), and once with brine (50ml). The organic layer was dried over MgS04, gravity 
filtered and concentrated under vacumm to yield 13.3g, (71%) of 8 8 .
5'H  (400MHz, CDCl3-d6) 5 (ppm) 1.27 (d, 6H, J = 6.3 Hz, (CH3)2CH), 5.14 (sept, 1H, J 
=6.3 Hz (CH3)2CH), 6.38 (d, 1H, CH=CHCO, Jfrans = 16Hz), 7.29-7.46 (m, 5H, 
aromatic), 7.63 (d, 1H, CH=CHCO, Jtrans  ^ 16Hz)
513C (100MHz, CDCl3-d6) 5 (ppm) 22.28, 68.01, 119.11, 128.36, 129.20, 130.50, 
134.834, 144.61, 166.68.
6 .6 .2 .2 . P r e p a r a t io n  of is o p r o p y l- (2 R ,3 S ) -3 - (N -a c e ty l)a m in o -2 -h y d r o x y -3 -  
p h e n y lp r o p in o a te  83170
o
Lithium hydroxide monohydrate (2.83g, 67.49mmol) was dissolved in water (190ml). 
To this solution was added potassium osmate dihydrate (0.35g, 0.95mmol) and the 
solution was then further diluted with tert-butanol (380ml). (DHQ)2PHAL (0,49g, 
0.63mmol) was then added and the reaction mixture stirred for 10 minutes at 20°C. The 
reaction mixture was diluted with water (379ml) and cooled to below 4°C. Isopropyl 
cinnamate 88 (12.00g 63.08mmol) was poured into the reaction mixture, followed by N- 
bromoactamide (92) (ll.OOg, 79.73mmol). The reaction mixute was then stirred for 20 
hours at 4°C. After this time sodium sulfite (lOg) was added and the reaction mixture 
was allowed stir for an additional 30 minutes. The reaction mixture was then extracted 
with ethyl acetate (3x150ml). The organic extracts were combined, washed with brine
and dried over MgSC>4. The solvent was removed in vacuo to yield a brown gum, 
which was purified by flash chromatography ( 1 : 1  ethyl acetate in hexane) and 
recrystallised from ethyl acetate to yield 83 (11.95g, 75%).
Rf 0.27 (ethyl acetate-hexan, 1:1, v/v)
[a]D20-25.1 (0.61, CHC13)
Vmax (KBr) 3302, 3067, 2988, 2923, 2890, 2716, 1742, 1655,15001 cm' 1 
8 ^  (400MHz CDCl3-d6) 8 (ppm) 1.30 (dq, 6H, J2’.2”= 8.4 Hz, J2M'= 6.3 Hz, H-2’, H- 
2” ), 1.99 (s, 3H, CH3CONH), 3.46 (d, 1H, J0H-i = 4.0 Hz, OH), 4.49 (dd, 1H, Ji.0H= 4.0 
Hz, Ji_2 = 2.2 Hz, H-l), 5.12, (qq, 1H, Jr .2>= 6.3 Hz, H -l’), 5.56 (dd, 1H, J2.NH= 9.3Hz, 
J2.i= 2.3 Hz, H-2),6.45, (d, 1H, JNh-2= 9.3 Hz, NH), 7.28-7.38 (m, 5H, aromatic)
8 13C (100MHz, CDCI3 -d6) 8 (ppm) 21.88, 22.7, 23.37, 54.94, 70.94, 73.83, 127.31, 
128.08, 128.94, 139.28, 170.14,172.76.
6 .6 .2 .3 . Pr epa r a t io n  of m eth y l- (2 R ,3 S )-3 -(N -a c ety l) a m in o -2 -h y d r o x y -3- 
ph en y lpr o pin o a te  95
The same procedure used to prepare 83 was used to prepare 95 using lithium hydroxide 
monohydrate (482mg, 11.50mmol), water (30ml), potassium osmate dihydrate (147mg,
0.399mmol),DHQ)2PHAL (390mg, 0.50mmol) and methy cinnamate 94a (1.75g, 
10.80mmol).
Yield 1.5g (58%)
TLC, Rf 0.25 (ethyl acetate-hexane, 2:1, v/v)
O
A
94a 95
[a]D20 +8.2 (0.4, EtOH)
5JH (400MHz DMSO-de) 5 (ppm) 1.76 (s, 3H, CH3CONH), 3.59 (s, 3H, CH3C=OCH), 
4.54 (dd, 1H, Ji-oh = 8.8 Hz, Ji_2 =3.6 Hz, H-2), 5.08 (d, 1H, J0H-i = 3.6 Hz, H-l), 5.88 
(br, 1H, OH), 7.23-7.38 (m, 5H, aromatic), 8.20 (d, IH, J = 8.8 Hz NH)
813C (100MHz, DMSO-de) 5 (ppm) 22.48, 52.21, 58.79, 72.60, 126.58, 127.56, 128.12, 
142.12, 170.04, 171.26.
ES-MS m/z 260.2 (M + Na), C12H15N 1O4 requires M = 237
6 .6 .2 .4 . P r e p a r a t io n  o f  t - b u t y l -  (2 R ,3 S )-3 - (N -a c e ty l)a m in o -2 -h y d r o x y -3 -  
p h e n y lp r o p in o a te  96
^ C Q ;t-Butyl
Ph"
94b
O
X
H3C NH 
Ph"^ 
96
^CO,t-Butyl
OH
The same procedure used to prepare 95 was used to prepare 96 using lithium hydroxide 
monohydrate (42.8mg, 10.2mmol), water (3ml), potassium osmate dihydrate (147mg,
0.399mmol), (DHQ)2PHAL (39mg, 0.5mmol) and t-butyl cinnamate 94b (204mg,
0 .68mmol).
Yield 180mg (88%)
TLC, Rf 0.27 (ethyl acetate-hexane, 1:1, v/v)
[a]d20-21.9 (0.32, CHC13)
6lH (400MHz, CDCI3 -d6) 5 (ppm) 1.43 (s, 9H, C(CH3)3), 1.93 (s, 3H, CH3CO), 3.22 
(br, 1H, OH), 4.35 (dd, 1H, Ji.0H= 3.0 Hz, J,.2 =2.3 Hz, H-l), 5.49 (dd, 1H, J2.Nh = 7.4 
Hz, H-2), 6.27 (d, 1H, J= 9.3 Hz NH), 7.21-7.32 (m, 5H, aromatic)
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S13C (100MHz, CDCI3 -d6) 5 (ppm) 23.62, 28.19, 54.57, 73.72, 84.43, 127.24, 128.06, 
128.99, 139.47, 169.54, 172.44.
ES-MS m/z 302.4 (M + Na), C 15H21N 1O4 requires M = 279
6.6 .2 .5 . P r e p a r a t io n  o f  i s o p r o p y l-  (2 R ,3 S )-3 -b e n z a m id o -2 -h y d r o x y -3 -  
p h e n y lp r o p in o a te  84171
In 30ml of an aqueous solution of Li0H/H20 (806mg, 10.2mmol), K20 s0 2(0H)4 
(147mg,0.4mmol) was dissolved by stirring. After the addition of acetonitrile (120ml), 
(DHQ)2PHAL (1.558g,2.mmol) was added, and the mixture stirred for 10 minutes to 
give a clear solution. Water (30ml) was subsequently added, and the mixture cooled to 
0°C. After addition of isopropyl cinnamate 88 (1.902g, lOmmol), N-bromobenzamide 
(4.0g, 20mmol) was added in one portion, and the mixture was stirred at 0°C for 10 
hours. Over the course of the reaction, the colour changed from a deep green to yellow 
colour. The reaction was worked-up by the addition of saturated aqueous sodium 
sulphite (30ml) (5%w/v) and the reaction mixture was let stir for an additional hour. 
The two phases were separated, and the aqueous phase was extracted with ethyl acetate. 
Both the acetonitrile and ethyl acetate phases were combined and washed with 3N HC1, 
water, brine and the organic layer was then dried over anhydrous MgS04. The solvent 
was removed by rotary evapotartion to afford a crude product that was purified by silica 
gel chromatography (ethyl acetate: hexane 1:1) and recrystallised from ethyl acetate to 
yield (84) (1.34g, 40%).
O
A
88 84
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TLC, Rf 0.68 (ethyl acetate-hexane 1:1, v/v)
[a]D20 -20 .6  (0.6, CHC13)
5JH (400MHz, CDCI3 -d6) 8 (ppm) 1.28 (q, 3H, J=  6.2 Hz H-2’), 1.32 (q, 3H, J=  6.2 Hz 
H-2” ), 3.38 (d, 1H, J= 3.6 Hz, OH), 4.61 (dd, 1H, J i _o h =  2.2 Hz, Ji_2 = 5.8 Hz, H-l), 
5.12-5.20 (m, 1H, H -l’), 5.78 (dd, 1H, J2-nh=  11.0 Hz, J2_i= 1.8 Hz, H-2), 7.1 (d, 1H, J=
8.9 Hz, NH), 7.3-7.5 (m, 8H, aromatic), 7.83 (d, 2H, J=7.7 Hz, aromatic)
513C (IOOMHz, CDCb -d6) 6 (ppm) 21.99, 22.09, 54.98, 71.49, 73.75, 127.27, 127.41, 
128.26, 129.08, 132.14, 134.62, 139.13, 167.14, 172.87.
6 .6 .2 .6 . P r e p a r a t io n  o f  i s o p r o p y l- (4 S ,5 R )-N -a c e ty l-2 ,2 -d im e th y l-4 p h e n y l-1 ,3 -  
o x a z o l id in - 5 - y l  c a r b o x y l a t e  1 0 0 153
X I  IL 'sCaiprH3C NH r n iDr A  /  \
3 '•___/C O  Pr____  H,C N ^ /O
PT OH X
97 100
Compound 97 (1.89g, 6.83mmol) was dissolved in toluene (20ml). 2-Methoxypropene 
(0.6ml) and 4-toluenesulfonic acid monohydrate (0.06g, 0.32mmol) were then added 
and the reaction mixture was let stir at room temperature. After one hour more 4- 
toluenesulfonic acid monohydrate (0.06g) was added and the reaction was then heated 
to 80°C. The distillate was collected in a scale-receiving flask. A solution of 2- 
methoxypropene (3.1ml) in toluene (14ml) was added dropwise to the reaction mixture 
to maintain constant reaction volume. Subsequently, more 4-toluenesulfonic acid 
monohydrate (0.06g) was added to the reaction mixture and the mixture stirred for 10 
minutes at 80°C. The reaction was cooled to room temperature whereupon saturated 
sodium bicarbonate (10ml) was added to the reaction mixture. The aqueous layer was
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separated and extracted with dichloromethane (2 x 10ml). The combined organics were 
dried over MgSCU, gravity filtered and evaporated under vacuum (<40°C). Flash 
chromatography (1:2 ethyl acetate: hexane) yielded (100) as a white wax (0.56g, 26%) 
TLC, Rf 0.35 (ethyl acetate-hexane, 1:1, v/v)
S‘H (400MHz, CDC13 -d6) 5 (ppm) 1.31 (dq, 6H, Jr .2-= 2.0 Hz, J2m = 6.2 Hz, H -2\ H- 
2” ), 1.72 (s, 3H, CH3), 1.80 (s, 1H, CH3), 1.85 (s, 1H, CH3) 4.46 (d, 1H, J= 3.9 Hz, H- 
1), 5.12-5.19(m, 1H, H -l’), 5.31 (d, 1H, J= 3.9Hz, H-2), 7.28-7.42 (m, 5H, aromatic) 
813C (IOOMHz, CDC13 -d6) 5 (ppm) 21.97, 22.14, 25.17, 26.26, 26.30, 64.61, 70.30,
82.52, 98.68, 126.51, 128.61, 129.53, 140.58, 168.88, 170.35.
6 .6 .2 .7 . P r e p a r a t io n  o f  is o p r o p y l- (4 S ,5 R )-N -a c e ty l-2 ,2 -d im e th y l-4 p h e n y l-1 ,3 -  
o x a z o l id in - 5 - y l  c a r b o x y l i c  a c id  101
Oxazolidine 100 (0.4g, 1.31mmol) was dissolved in proan-2-ol (0.6ml). Lithium 
hydroxide monohydrate (0.12g in 0.2ml water, 2.86mmol) was added dropwise over 10 
minutes at 0°C. The reaction mixture was stirred for a further 10 minutes. The reaction 
mixture was then concentrated by rotary evaporation and then diluted with water (2ml) 
and washed with isopropyl ether (2ml). The aqueous layer was acidified to pH 3 with 
HC1 (IN) and extracted with dichloromethane (3x3ml). The organic extracts were 
washed with brine (2ml), and dried over MgS04 and evaporated to yield 101 (250mg, 
52%) as a white solid.
100 101
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8*H (400MHz, CDCI3 -d6) 8 (ppm) 1.70 (s, 3H, CH3), 1.76(s, 3H, CH3), 1.78(s, 3H, 
CH3), 4.49 (d, 1H, J2.i= 4.0 Hz, H-2), 5.26 (d, 1H, Ji.2= 4.1Hz, H-l), 6.20 (bs, 1H, 
C 0 20H) 7.28-7.36 (m, 5H, aromatic).
8 13C (100MHz, CDC13 -d6) 8 (ppm) 24.93, 26.26, 26.33, 64.62, 81.97, 99.19, 126.44,
128.83 , 129.71, 140.12, 169 .59 , 173.00
ES-MS m/z 286.3 (M + Na), C 14H 17N 1O4 requires M = 263
6.6 .2 .8 . P r e p a r a t io n  o f  (2 R ,3 S )-3 -a m in o -2 -h y d r o x y -3 -p h e n y lp r o p a n o ic  a c id  
H Y D R O C H L O R I D E  98165
O
The isopropylidene ester 83 (1.195g, 4.50mmol) was added to 1:2 hydrochloric acid: 
watermixture (100ml) and the mixture was heated to reflux for 2 hours. The reaction 
mixture was then concentrated by rotary evaporation and washed with isopropyl ether: 
hexane (1:1, 3x5ml). The aqueous layer was collected and evaporated to dryness via a 
vacuum oven to yield 98 (0.94g, 95%) as a white solid.
M.p(lit. m.p. 224-226°C ) 223-225°C 
[a]D20 = -14.1° (c 0.32 MeOH)
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6.6.2.9. P r e p a r a t i o n  o f  (2 R ,3 S )-N -b e n z y l-3 p h e n y lis o s e r in e  97176
0
hci.nh2 0
P h
A
N H  O
O H
O H
98 97
To a solution of 98 (219mg, 1.00ml) in water (10ml) containing sodium bicarbonate 
(500mg) was added a solution of benzoyl chloride (0.14ml, 1.2mmol) in 
dichloromethane (5.0ml). The mixture was stirred for 16 hours at room temperature. 
The reaction mixture was acidified with 0. IN HC1 and the crude product was extracted 
with ethyl acetate (3x40ml). The combined organic extracts were dried over anhydrous 
MgSCU gravity filtered and concentrated by rotary evaporation to yield a crude residue. 
The residue was purified by silica gel chromatography (ethyl acetate in hexane, 2:1) to 
give 97 (205mg, 72%) as a white solid.
TLC, Rf 0.30 (ethyl acetate-hexane, 2:1, v/v)
m.p. 166-168°C
[a] D20-35.5° (0.50, EtOH)
SHl (400MHz DMSO-de) 8 (ppm) 4.38 (d, 1H, J= 4.3Hz, H-l), 5.46(dd, 1H, J= 8.8 Hz, 
J= 4.2 Hz, H-2), 5.65 (bs, 1H, OH), 7.22-7.57 (m, 8H, aromatic), 7.83 (d, 2H, aromatic, 
3=7.2 Hz), 8.61 (d, 1H, J= 8.9 Hz, NH), 12.73 (br, 1H, C 02H).
813C (lOOMHz, DMSO-ds) 8 (ppm) 56.16, 73.92, 127.38, 127.48, 127.66, 128.44,
128.76, 131.88, 134.52, 140.49, 166.54, 173.82.
ES-MS m/z 308.5 (M + Na), C i5H2iN i0 4 requires M = 285
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6 .6 .2 .10 . P r e p a r a t io n  o f  2 ’,3 ’- i s o p r o p y lid e n e -5 ’-0 - ( ( - 4 ” S ,5 ” R ) - N - a c e t y l - 2 ”  ,2 ”  - 
d im e th y l-4 ”  -p h e n y l-  1 ”  ,3 ”  - o x a z o lid in e -5  ’ ’ - c a r b o x y la t e ) - u r id in e  
103174
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Oxazolidine 101 (0.298g, 1.13mmol) and dicyclohexylcarboiimide (0.259g, 1.26mmol) 
were stirred in toluene (1ml) for 5mins. Uridine isopropylidene 68 (0.30g, 1.06mmol) 
and 4-dimethylaminopyridine (0.069g, 0.056mmol) were added as a slurry in toluene 
(15ml), the mixture was heated at 80°C for 20 minutes. The reaction was cooled to 
20°C and saturated sodium bicarbonate (12ml) was added. The aqueous layer was 
extracted with dichloromethane (3x5ml) and the combined organics were dried 
(MgS04), gravity filtered and concentrated under vacuum. 103 was isolated by silica 
gel chromatography (5:1 ethyl acetate) as a white powder (0.245g, 45%).
TLC, Rf 0.42 (ethyl acetate-hexane, 5:l,v/v)
[aj d20 = -40.5° (0.06, chloroform)
S'H (400MHz, C D C I3  -d6) 5 (ppm) 1.18 (s, 3H, acetonide), 1.29 (s, 3H, acetonide), 1.50 
(s, 3H, C H 3 C O N ), 1.73 (s, 3H, oxazolidine) 1.76 (s, 3H, oxazolidine) 4.29-4.31 (m, 1H, 
H-5’), 4.33-4.38 (m, 2H, H -4\ H-5’) 4.47 (d, 1H, J= 4.0Hz, H-2” ), 4.80 (dd, 1H, dJ3-.2- 
=6.4 Hz, J3’-4’ =4.4Hz, H-3’), 4.97 (dd, 1H, Jr .y =6.4 Hz, J2M- =4.4Hz, H-2’), 5.25 (d,
1H, J 1 ”_2” =4.0Hz, H -l” ), 5.55 (d, 1H, Jr .2- = 2.0Hz, H -l’), 5.62 (dd, 1H, J5-1 =2.0Hz, 
N C H = C H C O ,) ,  7.21-7.28 (m, 5H, aromatic), 7.32(d, 1H, J= 7.5 Hz, N C H = C H C O ) ,
S13C (100MHz, CDCl3-d6) 8 (ppm) 24.77, 25.13, 25.24, 26.30, 27.53, 64.53, 65.41, 
81.38, 84.76, 85.36, 95.08, 103.10, 115.12, 126.31, 128.35, 129.69, 137.44, 142.55, 
149.95, 163.10,163.63, 169.95.
6 .6 .2 .11 . P repa r atio n  of 2 ’,3 ’-iso pr o py l id en e -5 ’- 0 - ( ( - 4 ”  S ,5 ” R )-N -a c e t y l -2 ” ,2 ” - 
d im e t h y l -4 ”  -ph e n y l - 1 ” ,3 ”  -o x a z o l id in e -5 ’ ’ -c a r b o x y l a t e )- 
flu o r o u r id in e  102 .
O ^ C O ,H
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Oxazolidene 101 (0.130g, 0.49mmol) and dicyclohexylcarboiimide (0.113g, 0.55mmol) 
were stirred in toluene (1ml) for 5mins. The 5-fluoro-2’, 3’-isopropylideneuridine 69 
(0.139g, 0.46mmol) and 4-dimethylaminopyridine (0.069g, 0.056mmol) were added as 
a slurry in toluene (5ml), the mixture was then heated to 80°C for 20 minutes. The 
reaction was cooled to room temperature and saturated sodium bicarbonate (2ml) was 
added. The aqueous layer was extracted with dichloromethane (5x 2.5ml) and the 
combined organics were dried over MgSC>4, gravity filtered and concentrated under 
vacuum. The product 102 was isolated by silica gel chromatography (1:3chloroform 
ethyl acetate) as a white wax (0.065g, 25%).
TLC, Rf 0.42 (chloroform-ethyl acetate, 1:3, v/v)
[a] d 20 = -39.5° (0.06, chloroform)
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81H (400MHz, CDCI3 -de) 5 (ppm) 1.29 (s, 3H, acetonide), 1.51 (s, 3H, acetonide), 1.64 
(s, 3H, CH3CO N), 1.71 (s, 3H, oxazolidine) 1.76 (s, 3H, oxazolidine) 4.34-4.38 (m, 1H, 
H-5’), 4.42-4.4.43 (m, 2H, H -4\ H-5’) 4.44-4.48 (d,lH, J = 4.0Hz, H-2” ), 4.75 (dd,lH, 
J3’-2’ = 6.4 Hz, J3’-4’ = 4.4Hz, H-3’), 4.90 (dd,lH, J2’.3’ = 6.4 Hz, J2M- = 4.4Hz, H-2’), 
5.24 (d,lH, Jr .2» = 4.0Hz, H -l” ), 5.63 (d,lH, Jr .2- = 2.0Hz, H -l’), 7.20-7.35 (m, 5H, 
aromatic), 7.38 (d,lH, J = 7.5 Hz, N C H =C FC O ), 9.01 (s,lH, NH).
§13C (100MHz, CDCI3 -d6) 5 (ppm) 23.82, 24.25, 24.67, 24.96, 26.11, 63.14, 63.79,
79.76, 80.74, 83.12, 83.37, 93.08, 97.51, 125.12 (d, J= 27Hz), 127.44, 128.29, 138.66,
147.52, 155.63, 167.69, 168.76, 170.18.
819F (CDCI3 -d6) -  164.81 (d, J=-6.7Hz)
ES-MS m/z 548.2 (M+ + H), C26H30N3O9 requires M = 547
6 .6 .2 .12 . P r e p a r a t io n  o f  u r id in e  67 f r o m  2 ’,3 ’- is o p r o p y lid e n e u r id in e  68.175
68 67
To a solution of 2’, 3’-isopropylideneuridine 68 (0.284g, lmmol) in acetonitrile (5ml) 
was added Zn(N03)2.H20 (0.95g, 5.0mmol) and the reaction mixture was stirred at 
50°C overnight. After which time it was analysed by TLC (5:1 ethyl acetate:hexane), a 
spot consistent with uridine 67 was evident. The solvent was evaporated under vacuum, 
the residue diluted with dichloromethane (15ml), dried (MgS0 4) gravity filtered and
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solvent removed via rotary evaporation. Recrystallised from water to obtain (67) 
(0.144g, 60%)
6.6.2.13. Preparation of isopropyl-(2R,3S)-3-(acetyl)amino-2-hydroxy-3-
phenylpropinonat c from isopropyl-(4S,5R)-N-acetyl-2,2-dimethyl-4phenyl-
l,3-oxazolidin-5-yl carboxylic acid 89.
To a solution of 101 (0.263g, lmmol) in acetonitrile (5ml) was added Zn(N03)2.H20 
(0.95g, 5.0mmol) and the reaction was stirred at 50°C overnight. TLC analysis (5:1 
ethyl acetate:hexane), showed a spot consistent with (95). The solvent was then 
removed by evaporation, the residue diluted with dichloromethane (15ml), washed with 
water (10ml) and dried over M gS04 and gravity filtered. The solvent was removed 
under vacuum. The recovered residue was recrystallised from ethyl acetate to obtain 89 
(0.13g, 49%).
O
101 89
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The main objective of this body of work was to design and prepare a reductase activated 
phthalocyanine conjugate prodrug. We were also interested in exploring the potential 
use of an isoserine side chain as a potential carrier for 5-fluorouracil. To achieve both 
goals a large body of synthesis was carried out, and many new prodrug derivatives of 
fluorouracil were both synthesised and evaluated for bioactivity. This work led to the 
following:
1. The successful synthesis of an axial nucleotide -  silicon phthalocyanine 
conjugate.
2. Synthesis of new 5-FU derivatives that demonstrate both enhanced bioactivity 
against cancer cell lines and potential anti-invasion activity.
3. The development of new 5-FU prodrugs, which possess no bioactivty under 
normal cellular conditions, but are activated under reductase rich hypoxic 
conditions.
4. The total synthesis of a novel 5-FU prodrug conjugated to an isoserine side 
chain. Unfortunately, this new derivative possesses no bioactivity against 
cancer lines and cannot be activated to any extent under hypoxic conditions.
5. The synthetic work in Chapter 4 lead to the development of a new cleavage 
technology, which we had hoped to solve a synthetic hurdle with the synthesis 
of the 5-FU isoserine prodrug 102. These new cleavage conditions, although 
unsuccessful in the selective cleavage of 102, have been successfully applied in 
the selective cleavage of trityl groups in the presence of acetonide protection 
groups 82.
The next stage of this research program is the biological evaluation of the new 
‘reductase activated’ prodrug 79. If light therapy does indeed activate the prodrugs to 
yield 5-FU and quinone methides then a new third generation photosensitizer is bom. If
7.0. Conclusion
177
failure occurs with light therapy, that is human reductases cannot convert prodrug 79 
into 5-FU and quinone methides, then the genetherapy route which incorporates the 
gene for nitroreductase becomes the next necessary step for the application o f  these new 
and novel photosensitiser prodrugs. This will be also tested on prodrugs 80A, B and C. 
A SAR study should also be undertaken in the future to determine why prodrugs 58 and 
59 are showing such excellent biological activity, once determined then perhaps better 
leads can be developed to replace 5-FU.
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